

The International Society for Heart and Lung Transplantation
(a forum that includes basic science, the failing heart, and advanced lung disease)
Twenty-Fourth Annual Meeting and Scientific Sessions
April 21 – 24, 2004
Convening at the Hilton San Francisco
San Francisco, CA
Final Program

Board of Directors

President

Jon Kobashigawa, MD, Los Angeles, CA

President-Elect

Alec Patterson, MD, St. Louis, MO

Past President

Stephan Schueler, MD, Newcastle, United Kingdom

Secretary/Treasurer

Robert C. Bourge, MD, Birmingham, AL

Directors

Paul A. Corris, MB, FRCP, Newcastle, United Kingdom

F. Jay Fricker, MD, Gainesville, FL

Katherine Hoercher, RN, Cleveland, OH

Luigi Martinelli, MD, Genova, Italy

Keith McNeil, MD, FRACP, Brisbane, Australia

Mandeep R. Mehra, MD, New Orleans, LA

Soon J. Park, MD, San Francisco, CA

Hermann Reichenspurner, MD, PhD, Hamburg, Germany

Bruce Rosengard, MD, FRCS, FACS, Cambridge, United Kingdom

Heather J. Ross, MD, Toronto, Canada

Adriana Zeevi, PhD, Pittsburgh, PA

JHLT Editor

James K. Kirklin, MD, Birmingham, AL

Heart and Lung Transplant Registry Medical Director

Marshall I. Hertz, MD, Minneapolis, MN

Mechanical Circulatory Support Device Database Medical Director

Mario C. Deng, MD, New York, NY

Staff

Amanda W. Rowe

Executive Director

Phyllis Glenn

Assistant Executive Director

Director of Membership Services

Lisa Edwards

Director of Meetings

LeeAnn Mills

Director of Operations

14673 Midway Road, Suite 200

Addison, TX 75001

Phone: 972-490-9495

Fax: 972-490-9499

www.ishlt.org

ishlt@ishlt.org

PAST PRESIDENTS

1981-1982	Michael Hess, MD
1982-1984	Jack Copeland, MD
1984-1986	Terence English, FRCS
1986-1988	Stuart Jamieson, MD
1988-1990	Bruno Reichart, MD
1990-1991	Margaret Billingham, MD
1991-1992	Christian Cabrol, MD
1992-1993	John O'Connell, MD
1993-1994	Eric Rose, MD
1994-1995	John Wallwork, FRCS
1995-1996	Sharon Hunt, MD
1996-1997	William Baumgartner, MD
1997-1998	Leslie Miller, MD
1998-1999	Alan Menkis, MD, FRCS(C)
1999-2000	Robert L. Kormos, MD
2000-2001	Anne Keogh, MBBS, MD
2001-2002	James B. Young, MD
2002-2003	Stephan Schuler, MD

AWARD RECIPIENTS

LIFETIME SERVICE AWARD

1996 Michael Kaye
1997 Jacques Losman

LIFETIME ACHIEVEMENT AWARD

2004 Sir Magdi Yacoub, MD
1999 Keith Reemtsma, MD
1996 Norman Shumway, MD

ISHLT/ROCHE TRANSPLANT CAREER DEVELOPMENT AWARD

2002 Anthony Azakie, MD
2000 Gordon D. Wu, MD

ISHLT/ROCHE TRANSPLANT RESEARCH FELLOWSHIP GRANT

2003 Felix Fernandez, MD
2002 Ruediger Hoebelt, MD
2001 Matteo Vatta, PhD
2001 Arnar Geirsson, MD
2000 Christopher H. Wigfield, FRCS
1999 Donald Wong, PhD
Sivasai Krovvidi, PhD
1998 Kelly S.A. Blair, MD
A.M. El Gamel, MD
1997 Jonathen Chen, MD
Anne K. Raisanen-Sokolowski, MD
1996 Tuija S. Ikonen, MD

ISHLT/NOVARTIS TRANSPLANT RESEARCH FELLOWSHIP GRANT

2000 Richard S. Lee, MD
1999 George Juang, MD
Satoshi Saito, MD
1998 Margaret L. Schwarze, MD

ISHLT TRANSPLANT RESEARCH FELLOWSHIP GRANT

1998 Scott D. Ross, MD

ISHLT/WYETH-AYERST TRANSPLANT RESEARCH FELLOWSHIP GRANT

1998 Christine L. Lau, MD

ISHLT/ORTHO BIOTECH TRANSPLANT RESEARCH FELLOWSHIP GRANT

1997 Owen T. Lawrence, MD
1996 Andrew F. Pierre, MD
1995 Frances L. Johnson, MD

ISHLT/FUJISAWA TRANSPLANT RESEARCH FELLOWSHIP GRANT

2003 Ewout J. van den Bos, MD
1997 Alyssa M. Krasinskas, MD

ISHLT NURSING RESEARCH GRANT

2003 Diane H. Leloudis, RN, MSN
2003 Janet E. Madill, PhD
2002 Annette J. De Vito Dabbs, RN, MN, PhD
2001 Lynn Doering, RN, DNSc
2000 Nancy M. Albert, MSN, RN
1999 Jeanne Salyer, PhD
1998 Katherine St. Clair, RN, MSN
1997 Eileen Collins, RN, PhD

CAVES AWARD

2003 Sigrid Sandner, MD
2002 Peter Blaha, MD
2001 Alexander S. Krupnick, MD
2000 Michael P. Fischbein, MD
1999 Joerg Koglin, MD
1998 Carla C. Baan, MD
1997 Simon D. Eiref, MD
1996 Moninder S. Bhabra, MD
1995 Elizabeth A. Davis, MD
1994 Jobst Winter, MD
1994 Alain Chapelier, MD
1993 David Marshman, MD
1992 David P. Kapelanski, MD
1991 A. Jiminez, MD
1990 Andres J. Duncan, MD
1989 A.M. Wood, MD
1988 Charles D. Fraser, Jr., MD
1987 Wim Van Der Bij, MD
1986 Stuart J. Knechtle, MD
1985 Michael A. Breda, MD
1984 Hermann Reichensperner, MD
1983 Robbin G. Cohen, MD

SCIENTIFIC PROGRAM COMMITTEE

Program Committee

Mandeep R. Mehra, MD, New Orleans, LA, Chair
Jon Kobashigawa, MD, Los Angeles, CA, President
Abbas Ardehali, MD, Los Angeles, CA
Mark L. Barr, MD, Los Angeles, CA
Robert C. Bourge, MD, Birmingham AL
Maryanne R. Chrisant, MD, Philadelphia, PA
Paul A. Corris, MB FRCP, Newcastle Upon Tyne, United Kingdom
Sandra A. Cupples, DNSc, Potomac, MD
Debi H. Dumas-Hicks, RN, Metairie, LA
Michael C. Fishbein, MD, Los Angeles CA
Kate Gould, MB, BS, Newcastle Upon Tyne, United Kingdom
Edoardo G. Gronda, MD, Milan, Italy
Jeffrey D. Hosenpud, MD, Milwaukee, WI
Manfred Hummel, MD, PhD, Berlin, Germany
Sharon Hunt, MD, Palo Alto, CA
Valluvan Jeevanandam, MD, Chicago, IL
Shaf Keshavjee, MD, FRCSC, Toronto, ON, Canada
James K. Kirklin, MD, Birmingham, AL
Keith McNeil, FRACP, Brisbane, Australia
Robert E. Michler, MD, Columbus, OH
Paul Josef Mohacsi, MD, Berne, Switzerland
Francesco Parisi, MD, Rome, Italy
Alec Patterson, MD, St. Louis MO
Branislav Radovancevic, MD, Houston, TX
Bruce R. Rosengard, MD, Cambridge, United Kingdom
Susan Stewart, FRCPath, Cambridge, United Kingdom
Patricia A. Uber, Pharm.D, New Orleans, LA
Clifford Van Meter, Jr., MD, New Orleans, LA
George M. Wieselthaler, MD, Vienna, Austria
James B. Young, MD, Cleveland, OH

Reviewers

William T. Abraham, MD, FACP, FACC, Columbus, OH
Michael A. Acker, MD, Philadelphia, PA
Maria C. Albanese, MD, Udine, Italy
Annalisa Angelini, MD, Padova, Italy
Carl Atkinson, MD, Cambridge, United Kingdom
Nicholas R. Banner, FRCP, Harefield, Middlesex, United Kingdom
William A. Baumgartner, MD, Baltimore, MD
Raymond L. Benza, MD, Birmingham, AL
Claes-Hakan Bergh, MD, PhD, Vastra Frolunda, Sweden
Geetha Bhat, MD, Louisville, KY
Annette Boehler, MD, Zurich, Switzerland
Heidi Boettcher, MD, Berlin, Germany
Caron Burch, RN, MSN, FNP, Manhatlan Beach, CA
Carlo Campana, MD, Pavia, Italy
Cecilia Chaparro, MD, Toronto, ON, Canada
John V. Conte, MD, Baltimore, MD
Maria Rosa Costanzo, MD, Naperville, IL
Maria G. Crespo-Leiro, MD, La Coruna, Spain
Teresa DeMarco, MD, FACC, San Fancisco, CA 94143

Mario C. Deng, MD, New York, NY
Thomas J. Dengler, MD, Heidelberg, Germany
Marc DePerrot, MD, Toronto, ON, Canada
Fabienne Dobbels, MSc, Leuven, Belgium
Jonathan J. Drummond-Webb, MD, Little Rock, AR
Daniel Duveau, MD, Nantes, Cedex, France
Niloo M. Edwards, MD, Madison, WI
Thomas M. Egan, MD, MSC, Chapel Hill, NC
Howard J. Eisen, MD, Philadelphia, PA
Aly El-Banayosy, MD, Bad Oeynhausen, Germany
David S. Feldman, MD, PhD, Columbus OH
Roberto Fiocchi, MD, PhD, Bergamo, Italy
Stefan Fischer, MD, Hannover, Germany
James F. George, PhD, Birmingham, AL
Allan R. Glanville, MD, FRACP, Sydney, Australia
Daniel J. Goldstein, MD, Newark, NJ
Axel Haverich, MD, Hannover, Germany
Denise D. Hermann, MD, San Diego, CA
Marshall I. Hertz, MD, Minneapolis, MN
James A. Hill, MD, Gainesville, FL
Mariell Jessup, MD, Philadelphia, PA
Maryl R. Johnson, MD, Madison, WI
Annemarie Kaan, RN, Vancouver, BC, Canada
Tom R. Karl, MD, San Francisco, CA
Anne Keogh, MBBS, MD, Sydney, Australia
Walter Klepetko, MD, Vienna, Austria
Christiane Kugler, MSN, RN, Hannover, Germany
Carlos A. Labarrere, MD, Indianapolis, IN
Stephen R. Large, MS, MRFP, FRCS, Cambridge, United Kingdom
Karl B. Lemstrom, MD, PhD, Helsinki, Finland
Matthias Loebe, MD, PhD, Houston, TX
James W. Long, MD, PhD, Salt Lake City, UT
Robert B. Love, MD, Madison, WI
Joren C. Madsen, MD, Boston, MA
Donna M. Mancini, MD, New York, NY
Jan Manzetti, RN, PhD, Pittsburgh, PA
Lena Mared, MD, Lund, Sweden
Bruno, M. Meiser, MD, Munich, Germany
Bryan F. Meyers, MD, St. Louis, MO
Peter H. Michelson, MD, Pittsburgh, PA
Leslie W. Miller, MD, Minneapolis, MN 55455
Aaron P. Milstone, MD, Nashville, TN
Thalachallour Mohanakumar, PhD, St. Louis, MO
Michael S. Mulligan, MD, Seattle, WA
Srinivas Murali, MD, Pittsburgh, PA
Linda Ohler, RN, MSN, FAAN, Arlington, VA
Charles G. Orosz, PhD, Columbus, OH
Jayan Parameshwar, FRCP, Cambridge, United Kingdom
Wayne D. Paris, MSW, Oklahoma City, OK
Myung H. Park, MD, New Orleans, LA
Alain J. Pavie, MD, Paris, France
Si M. Pham, MD, Miami, FL
Richard N. Pierson, III, MD, Baltimore, MD
Barry K. Rayburn, MD, Birmingham, AL
Herman Reichensperner, MD, PhD, Hamburg, Germany
Robert C. Robbins, MD, Stanford, CA

Alan G. Rose, MD, FRCPATH, Minneapolis, MN
Robert L. Scott, MD, New Orleans, LA
Nicholas G. Smedira, MD, Cleveland, OH
Keld Sorensen, MD, Aarhus, Denmark
Randall C. Starling, MD, Cleveland, OH
Jacqueline R. Szmuszkovicz, MD, Los Angeles, CA
David O. Taylor, MD, Cleveland, OH
George Tellides, MD, New Haven, CT
Guillermo Torre-Amione, MD, PhD, Houston, TX
Jorge Trainini, MD, Buenos Aires, Argentina
Alfredo Trento, MD, Los Angeles, CA
Walter E. Uber, Pharm.D, Charleston, SC
Hannah A. Valentine, MD, Stanford, CA
Vincent G. Valentine, MD, New Orleans, LA
Andrian B. Van Bakel, MD, PhD, Charleston, SC
Hector Ventura, MD, New Orleans, LA
Erik A.M. Verschuuren, MD, Groningen, The Netherlands
Lynne E. Wagoner, MD, Cincinnati, OH
Lynne Warner Stevenson, MD, Boston, MA
Steven A. Webber, MB, ChB, Pittsburgh, PA
Willem Weimar, MD, Rotterdam, The Netherlands
Lori J. West, MD, D.Phil, Toronto, ON, Canada
Connie White-Williams, MSN, Birmingham, AL
Gayle L. Winters, MD, Boston, MA
Marlyn S. Woo, MD, San Marino, CA
Clyde W. Yancy, Jr., MD, Dallas, TX

CONTINUING MEDICAL EDUCATION INFORMATION

Accreditation

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education. The International Society for Heart and Lung Transplantation is accredited by the ACCME to provide continuing medical education for physicians. ISHLT designates this activity for a maximum of 29 hours in Category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Educational Objectives

The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in heart and lung transplantation. Because of the rapid advances in medicine in general and transplantation medicine specifically, transplant professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in transplant medicine. This meeting is designed to address their need.

Goals

To enable participants to learn about current practices, emerging technologies, and medical advances related to heart and lung transplantation and end-stage heart and lung disease; and to provide a forum for participants to engage in discussion, debate, and examination regarding the efficacy and applicability of these current practices, emerging technologies, and medical advances.

Target Audience

The audience for this program includes physicians, surgeons, scientists, nurses, and transplant coordinators engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields, or specialties which cause them to become involved in the treatment of transplant recipients or patients with end stage heart or lung disease.

Learning Objectives

At the conclusion of this meeting, participants should be able to:

- * identify, prevent, and treat post-transplant complications of immunosuppression including infection, renal dysfunction, and post-transplant malignancy
- * compare and evaluate the relative advantages and disadvantages of various pharmacologic, non-pharmacologic, and biologic immunosuppression techniques
- * understand current and developing organ preservation/reperfusion techniques and the impact of these on the transplanted organ, and use that knowledge to optimize donor selection and extend the donor pool
- * compare and evaluate the advantages and disadvantages of various mechanical circulatory support systems and their associated patient selection criteria
- * describe the state of the art in clinical heart and lung failure treatment and the criteria for the selection of patients for transplant therapy
- * understand current animal models of basic science immunology and their application to the transplant setting
- * evaluate issues of controversy, such as age, prior transplantation, and systemic diseases, in the selection of candidates for heart and lung transplantation
- * understand the pathology of acute and chronic rejection and its application in the formulation of a definitive diagnosis of rejection
- * identify the issues unique to pediatric transplantation, and apply to pediatric transplantation the relevant practices and therapies of adult transplantation
- * evaluate the current and developing alternatives to orthotopic transplantation, including mechanical

circulatory support, xenotransplantation, and a variety of surgical alternatives; assess the future of these therapies; and compare the value of these therapies as alternatives and/or bridges to transplantation

- * evaluate and implement the use of alternative methods of monitoring and treating rejection
- * identify, prevent, and treat donor-transmitted diseases

Disclosure

Current guidelines state that participants in CME activities should be made aware of any affiliation or financial interest that may affect a speaker's presentation. Each speaker has been requested to complete a disclosure statement. The names of the speakers declaring such affiliations are shown below. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

FACULTY/PRESENTATION	COMPANY AFFILIATION	RELATIONSHIP
Nicholas Banner, MD	Roche, Novartis	Clinical Investigator, Advisor
Sangeeta M. Bhorade, MD	Fujisawa, Wyeth	Research Support
Margaret E. Billingham, MD	XDx, Inc.	Consultant
Edimar A. Bocchi, MD	Abbott	Research Support
Aaron S. Blom, MD	Acorn Cardiovascular	Research Support
Ashley Byno, MD	Fujisawa Healthcare	Research Support
Marcelo Cantrovich, MD	Novartis	Consultant
Jason D. Christie, MD, MS	Fujisawa, Enzon, Eli Lilly	Consultant
Jacqueline Cornelissen, BSc	Novartis Pharma UK	Educational Grant
Howard J. Eisen, MD	Novartis, Thoratec	Consultant
Donald S. Esmore, MD	Ventracor, Ltd.	Consultant
David J. Farrar, MD	Thoratec	Employee
Jay A. Fishman, MD	Roche, Fujisawa, Novartis, Pfizer	Grants, Speaker's Bureau, Consultant
Torin P. Fitton, MD	Argon Recovery Systems	Research Funding
Reda E. Girgis, MB, BCh	Actelion	Speaker/Lecturer
Roland Hetzer, MD, PhD	Berlin Heart	Advisory Board
Aldo T. Iacono, MD	Chiron	Commercialization of Product
Anne Keogh, MD	Actelion, Wyeth	Advisory Board
Walter Klepetko, MD	Fujisawa, Roche, Novartis	Consultant
Jon Kobashigawa, MD	Novartis, Roche, Fujisawa	Research Grant
Robert L. Kormos, MD	Thoratec	Medical Advisory Board
Bronwyn Levvey, MD	Novartis	Research Support
Natalia Lobach, MD	Wyeth-Ayerst	Supporting Grant
Charles C. Marboe, MD	XDx, Inc.	Consultant
Mandeep R. Mehra, MD	Pfizer, XDx, Biosite, Novartis	Consultant, Research Grant
Bruno Meiser, MD	Fujisawa, Wyeth Ayerst, Roche	Consultant
Keith McNeil, MD	Actelion, Roche	Clinical Investigator
Tofy Mussicand, MD	World Heart Corp.	Scientific Advisor
Walter E. Pae, Jr., MD	Arrow International	Research Support
Jignesh Patel, MD, PhD	Fujisawa, Novartis, Roche, Scios, XDx	Research Grants
Myung Park, MD	Biosite, United Therapeutics	Consultant, Research Grant
Ulrich Pirro, MD	Actelion,	
Stacey Pollock-BarZiv, PhD	Novartis Pharma AG	Employee
Raymund R. Razonable, MD	Novartis Canada, Fujisawa	Research Support
Filip R. Rega, MD	Roche, Eli Lilly and Co, Pfizer	Honorarium/Advisory Board, Visiting
Eric A. Rose, MD	Zambon	Consultant
Mitchell T. Saltzberg, MD	Thoratec, Micromed, Arrow	Consultant
Heinrich Schima, MD	Scios, Inc.	Speaker's Bureau
Elizabeth Shane, MD	Micromed	Consultant
Gregory Snell, MD	Merck	Medical School Research Grant
Randall C. Starling, MD	Novartis Pharma	Clinical Trial Investigator
Guillermo Torre-Amione, MD	Novartis, Fujisawa, SangStat	Research Support, Consultant
Patricia A. Uber, Pharm D	Argen	Research Support
	Fujisawa	Scientist, Research Support
		Speaker's Bureau

Adrian B. Van Bakel, MD

Cynthia K. Wallace, MD
Steven A. Webber, MD
Clyde W. Yancy, MD

Martin Zamora, MD

Scios, Glaxo Smith Kline,
Medtronic
Merck
XDx, Inc., Fujisawa
Glaxo Smith Kline, Scios,
Novartis, Sanofi-Synthelabo,
Bristol-Meyers-Squibb,
Medtronic, Nitromed,
CardioDynamics
Medimmune, ICN, Roche

Speaker's Bureau

Research Support
Research Support
Consultant, Grant Support,
Speaker's Bureau

Research Support, Consultant

The International Society for Heart and Lung Transplantation is most grateful for the educational grants and the support of

Platinum Partner
NOVARTIS

Gold Partner
FUJISAWA

Silver Partner
ROCHE

Bronze Partner
ACTELION
CHIRON
XDX, INC.

Corporate Partner
WYETH

Friend of the Society
GENZYME TRANSPLANT

toward this

TWENTY FOURTH ANNUAL MEETING AND SCIENTIFIC SESSIONS

THIS PAGE IS FOR HILTON MAP(S)

GROUND LEVEL

PLAZA A/B ROOM

Satellite Symposia
Concurrent Sessions

BALLROOM LEVEL

YOSEMITE

Exhibits
ISHLT Registration
Internet Cafe
Moderated Posters

FRANCISCAN

General Posters

GRAND BALLROOM LEVEL

GRAND BALLROOM A

Exhibits

GRAND BALLROOM B

Satellite Symposia
Concurrent Sessions
Plenary Sessions
Luncheon Symposia

HOLD 2 PAGES FOR MEETING TEMPLATE

SCIENTIFIC PROGRAM

Note: All meetings and activities will take place at the Hilton San Francisco unless otherwise specified. All papers will be presented in English. Speakers and Moderators have been invited but not confirmed as of the date of the printing of this program.

WEDNESDAY, APRIL 21, 2004

7:00 AM-6:30 PM

Speaker Ready Room (Green Room)

7:00 AM-12:30 PM

ISHLT Board of Directors Meeting (Executive Boardroom)

8:00 AM-10:00 AM

Exhibitor Set Up (Yosemite)

8:00 AM-5:00 PM

Exhibitor Set Up (Grand Ballroom A)

10:00 AM-6:30 PM

Registration Desk Open (Yosemite)

10:00 AM-6:30 PM

Exhibits Open (Yosemite)

NOON-6:00 PM

General Poster Display Session 1 Set-Up (Franciscan)

12:30 PM - 1:30 PM

SATELLITE SYMPOSIUM 1

Early Events and Late Outcomes in Heart Transplantation

(Grand Ballroom B)

Supported by an educational grant from Roche

Moderators: Axel Rahmel, MD and Stuart D. Russell, MD

12:30 PM Acute Cellular Rejection and Humoral Rejection Influence Long Term Survival Following Cardiac Transplantation

Evidence For: James K. Kirklin, MD, University of Alabama, Birmingham, AL

Evidence Against: Jeffrey D. Hosenpud, MD, St. Luke's Medical Center, Milwaukee, WI

12:45 PM (1) Further Analysis of the Intravascular Ultrasound Data from the Randomized Mycophenolate Mofetil (MMF) Trial in Heart Transplant Recipients, J.A. Kobashigawa,¹ J. Tobis,¹

R.M. Mentzer,² H.A. Valantine,³ R.C. Bourge,⁴ F.W. Smart,⁵ L.W. Miller,⁶ R.D. Gordon,⁷ M. Mehra,⁸
¹University of California at Los Angeles, Los Angeles, CA; ²University of Kentucky, Lexington, KY;
³Stanford University, Stanford, CA; ⁴University of Alabama at Birmingham, Birmingham, AL; ⁵Texas Heart Institute, Houston, TX; ⁶University of Minnesota, Minneapolis, MN; ⁷Roche Pharmaceuticals, Basel, Switzerland; ⁸Ochsner Medical Institutions, New Orleans, LA

1:15 PM Panel Discussion

12:30 PM – 3:00 PM

SATELLITE SYMPOSIUM 2

Nursing and Social Sciences: Completing the Circle of Care in Thoracic Transplantation

(Plaza A)

Moderators: Sandra A. Cupples, DNSc, RN and Debi H. Dumas-Hicks, RN, BS, CCTc

12:30 PM Welcome

12:35 PM Psychosocial Outcomes in Cardiothoracic Transplantation: Progress Towards Intervention Development, Dorothy Lanuza, PhD, RN, FAAN, FAHA, University of Wisconsin, Madison, WI

12:55 PM LVADs as Life Time Therapy: Psychosocial Issues, Mary Amanda Dew, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA

1:10 PM Post Transplant Education: Does It Ever End? Christiane Kugler, RB, MSN, Hannover Medical School, Hannover, Germany

1:25 PM Post Transplant Palliative Care and End of Life Issues, Linda Wright, MHSc, MSW, RSW, Toronto General Hospital, Toronto, ON, Canada

1:45 PM HIPAA: Is It Hurting or Helping? Caron Burch, RN, MSN, FNP, University of California at Los Angeles, Los Angeles, CA

2:00 PM Transplant Coordinator/Transplant Nurse Practitioner: Blending the Roles, Connie White-Williams, RN, MSN, University of Alabama, Birmingham, AL, and Sharon Augustine, RN, MS, University of Maryland, Baltimore, MD

2:40 PM Questions and Answer Session

12:30 PM – 3:00 PM

SATELLITE SYMPOSIUM 3

Current Trends in Mechanical Assistance: Role of Destination Therapy
(Imperial B)

Moderators: Eric A. Rose, MD and Mariell Jessup, MD

12:30 PM Chairs' Introduction

12:35 PM Limits of Medical Therapy: When Should we Refer for Destination Therapy? Lynne Warner Stevenson, MD, Brigham and Women's Hospital, Boston, MA

1:00 PM Why do People Die with LVAD's, James W. Long, MD, LDS Hospital, Salt Lake City, UT

1:25 PM Emerging Devices for Destination Therapy, Roland Hetzer, MD, German Heart Institute, Berlin, Germany

1:50 PM Real World Challenges to Implementation of Destination Therapy, Robert L. Kormos, MD, University of Pittsburgh, Pittsburgh, PA

2:15 PM Panel Discussion

1:45 PM – 3:00 PM

SATELLITE SYMPOSIUM 4

Enhancing Organ Donation in Thoracic Transplantation: Are We Doing All We Can to Maximize Donors in Heart Transplantation?

(Grand Ballroom B)

Moderators: Bruce R. Rosengard, MD and James F. Burdick, MD

1:45 PM A Perspective From UNOS, Frank W. Smart, MD, FACC, FACP, Texas Heart Institute, Houston, TX

2:05 PM A Perspective From Eurotransplant, Jacqueline M. Smits, MD, PhD, Eurotransplant International Foundation, Leiden, The Netherlands

2:25 PM A Perspective From Spain, Blanca Miranda, National Transplant Organization, Madrid, Spain

2:45 PM Panel Discussion

3:00 PM - 3:30 PM

Coffee Break (Yosemite)

3:30 PM – 6:00 PM

SATELLITE SYMPOSIUM 5

Achieving Equilibrium in Risk and Outcome in Thoracic Transplantation

(Grand Ballroom B)

Supported by an educational grant from Novartis

Moderators: Leslie W. Miller, MD and Howard J. Eisen, MD

3:30 PM Chairman's Introduction: Co-Morbidities in Thoracic Transplantation: Causes and Management Strategies, Leslie W. Miller, MD, University of Minnesota, Minneapolis, MN

3:50 PM New Onset Diabetes in Transplantation, Jaime Davidson, MD, Endocrine & Diabetes Associates of Texas, Dallas, Texas

4:10 PM New Perspectives on Calcineurin Inhibitors: Friend or Foe? Anne Keogh, MD, St. Vincent's Hospital, Sydney, Australia

4:30 PM Metabolic Factors in the Genesis of Cardiac Allograft Vasculopathy, Hannah Valantine, MD, Stanford University School of Medicine, Palo Alto, CA

4:50 PM BOS: Immune Versus Non-immune Strategies, Paul Corris, FRCP, Freeman Hospital, Newcastle upon Tyne, United Kingdom

5:10 PM Panel Discussion

3:30 PM – 6:00 PM

SATELLITE SYMPOSIUM 6

ISHLT/AST Joint Symposium: Infectious Complications in Thoracic Transplantation

(Imperial A)

Moderators: Kate Gould, MB BS (ISHLT) and Jay A. Fishman, MD (AST)

3:30 PM Introduction and Welcome

3:35 PM Fungal Infection in Thoracic Transplantation, Jose G. Montoya, MD, Stanford University School of Medicine, Stanford, CA

3:55 PM Infections of LVADS and Other Devices, Stephen M. Gordon MD, Cleveland Clinic Foundation, Cleveland, OH

4:15 PM Experiences with SARS and West Nile Virus, Atul Humar, MD, University of Toronto, Toronto, ON, Canada

4:35 PM Hepatitis Viruses and Transplantation, D.E. Jones, University of Newcastle, Newcastle upon Tyne, United Kingdom

4:55 PM HIV in Transplantation, Jay A. Fishman, MD, Massachusetts General Hospital, Harvard Medical School, Boston, MA

5:10 PM Panel Discussion

3:30 PM – 6:00 PM

SATELLITE SYMPOSIUM 7

Primary Lung Graft Failure

(Imperial B)

Moderators: Dirk Van Raemdonck, MD, PhD and Jason D. Christie, MD

3:30 PM Introduction, Jonathan B. Orens, MD, Johns Hopkins Hospital, Baltimore, MD

3:35 PM Overview of the Problem, Dirk Van Raemdonck, MD, University Hospital Gasthuisberg, Leuven, Belgium

3:50 PM Definition and Grading of PGF, Jason D. Christie, MD, University of Pennsylvania, Philadelphia, PA

4:10 PM Risk Factors and Markers of PGF (Donor Factors), Marc de Perrot, MD, University of Toronto Hospital, Toronto, ON, Canada

4:30 PM Risk Factors and Markers of PGF (Recipient Factors), Mark L. Barr, MD, University of Southern California, Los Angeles, CA

4:50 PM Predictors of Outcome, Selim M. Arcasoy, MD, Columbia University, New York, NY

5:10 PM Treatment of PGF, Shaf Keshavjee, MD, Toronto General Hospital, Toronto, ON, Canada

5:30 PM Panel Discussion

5:45 PM Future Directions, Jonathan B. Orens, MD, Johns Hopkins Hospital, Baltimore, MD

6:00 PM-7:00 PM

ISHLT Registry Executive Committee Meeting (Executive Board Room)

6:30 PM – 8:00 PM

Satellite Symposium 8

Expanding the Borders – What is Happening on the Other Side of the World?

(Imperial A/B)

Moderators: O. Howard Frazier, MD and Mark L. Barr, MD

6:30 PM Introduction, Branislav Radovancevic, MD, Texas Heart Institute, Houston, TX

6:35 PM Heart and Lung Transplant: The Future World Perspective, Sir Magdi Yacoub, MD, Magdi Yacoub Institute, Heart Science Center, Harefield, Middlesex, United Kingdom

6:50 PM Heart Failure: Are There Regional Differences in Therapeutic Strategies? Jignesh Patel, MD, UCLA University Cardiovascular Medical Group, Los Angeles, CA

7:05 PM Living-related Lung Transplant: What if this is the Only Option? Hiroshi Date, MD, University School of Medicine, Okayama, Japan

7:20 PM Developing a Heart and Device Program in Countries Exceeding One Billion, Valluvan Jeevanandam, MD, University of Chicago, Chicago, IL

7:35 PM Devices as the Only Practical Choice, Hikaru Matsuda, MD, Osaka University Medical School, Osaka, Japan

7:50 PM Questions and Answer Session

8:30 PM-10:00 PM

Moderated Poster Session 1 Set-up (Yosemite)

THURSDAY, APRIL 22, 2004

7:00 AM-8:00 AM

Morning Coffee (Grand Ballroom A)

7:00 AM-10:00 AM

Moderated and General Poster Display Session 1 Set-Up (Franciscan/Yosemite)

7:00 AM-4:30 PM

Exhibits Open (Grand Ballroom A)

7:00 AM-6:30 PM

Speaker Ready Room (Green Room)

7:00 AM-6:30 PM

Registration Desk Open (Yosemite)

7:00 AM – 6:30 PM

Exhibits Open (Yosemite)

7:55 AM-10:00 AM

OPENING PLENARY SESSION

(Grand Ballroom B)

Moderators: Jon Kobashigawa, MD and Mandeep R. Mehra, MD

7:55 AM Welcome, Jon Kobashigawa, MD, ISHLT President, University of California at Los Angeles, Los Angeles, CA

8:00 AM Scientific Program Report, Mandeep R. Mehra, MD, ISHLT Scientific Program Chair, Ochsner Clinic Foundation, New Orleans, LA

8:05 AM Registry Reports, Marshall I. Hertz, MD, Registry Medical Director, University of Minnesota,

Minneapolis, MN, and Mario Deng, MD, MCSD Database Medical Director, Columbia University, New York, NY

8:30 AM President's Address, Jon Kobashigawa, MD, ISHLT President, University of California at Los Angeles, Los Angeles, CA

Featured Abstract

9:00 AM (2) Refining Pathological Classification of Acute Rejection in Cardiac Allograft Recipients: A Multicenter Study Using Peripheral Blood Gene Expression Profiling, C.C. Marboe,¹ M. Billingham,² H.J. Eisen,³ E. Feller,³ M.C. Deng,¹ M.R. Mehra,⁴ S. Hunt,² J.G. Wohlgemuth,⁵ I. Mahmood,⁵ M.S. Morris,⁵ G. Berry,² ¹Columbia University, New York, NY; ²Stanford University, Stanford, CA; ³Temple University, Philadelphia, PA; ⁴Ochsner Clinic, New Orleans, LA; ⁵XDx, Inc., South San Francisco, CA

9:15 AM ISHLT Commentary: Is It Time for a Reappraisal of the Rejection Nomenclature: The ISHLT Initiative, Susan Stewart, FRCPATH, Papworth Hospital, Cambridge, United Kingdom

9:30 AM Invited Lecture: The Pathology of Acute Rejection in Cardiac Allografts: View From the Past and a Journey Beyond, Margaret E. Billingham, MD, Palo Alto, CA

10:00 AM-10:30 AM

Coffee Break (Grand Ballroom A)

10:30 AM-NOON

CONCURRENT SESSION 1

Lung/Heart-Lung Transplantation 1: Risk Factors for BOS: Current Thinking

(Grand Ballroom B)

Moderators: Paul A. Corris, FRCP and Hiroshi Date, MD

10:30 AM (3) Bile Acids in Bronchoalveolar Lavage after Lung Transplantation as a Marker of Pulmonary Aspiration Associated with Alveolar Neutrophilia, F. D'Ovidio,¹ M. Mura,¹ T.K. Waddell,¹ A. Pierre,¹ M. Hutcheon,¹ D. Hadjiliadis,¹ L. Singer,¹ L. Miller,¹ G. Darling,¹ M. de Perrot,¹ Y. Shargall,¹ S. Keshavjee,¹ ¹Toronto Lung Transplant Program, University of Toronto, Toronto, ON, Canada

10:45 AM (4) Non-Alloimmune Injury Mediated by Gastroesophageal Reflux Precipitates Alloimmune Injury in Lung Transplant Patients, M.G. Hartwig,¹ E. Cantu,¹ J.Z. Appel,¹ H. Woreta,¹ S.M. Palmer,² R.D. Davis,¹ ¹Department of Surgery, Duke University Medical Center, Durham, NC; ²Lung Transplant Program, Duke University Medical Center, Durham, NC

11:00 AM (5) CMV Mismatch Is Not a Risk Factor for Survival or Severe Bronchiolitis Obliterans Syndrome after Lung Transplantation, A.R. Glanville,¹ V.G. Valentine,² C.L. Aboyoum,¹ M.A. Malouf,¹ ¹The Lung Transplant Unit, St Vincent's Hospital, Sydney, NSW, Australia; ²Lung Transplantation, Ochsner Clinic Foundation, New Orleans, LA

11:15 AM (6) Impact of Respiratory Syncytial Virus Pneumonia Following Lung Transplantation: A Case-Controlled Study, M.R. Zamora,¹ T. Hodges,² M.R. Nicolls,¹ T.L. Astor,¹ J. Marquesen,¹ D. Weill,¹ ¹Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO; ²Pulmonary Medicine, University of Southern California, Los Angeles, CA

11:30 AM (7) De Novo HLA Antibodies and Lymphocytic Bronchiolitis Are Significantly Correlated with Bronchiolitis Obliterans Syndrome in Lung Transplantation, A.L. Girnita,¹ A.T. Iacono,² T.E. Corcoran,² S.A. Yousem,¹ R. Duquesnoy,¹ B. Johnson,² J.H. Dauber,² K.J. Spichy,¹ B.P. Griffith,³ K.R. McCurry,⁴ A. Zeevi,¹ ¹Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA; ²Medicine; ³Thoracic Surgery, University of Maryland School of Medicine, Baltimore, MD; ⁴Thoracic Surgery

11:45 AM (8) Role of Flow Cytometry To Exclude Unacceptable HLA Antigens in Lung Transplant Recipients with Anti-HLA Antibodies, J.Z. Appel,¹ E. Cantu,¹ M.G. Hartwig,¹ N.L. Reinsmoen,¹ S.M. Palmer,¹ R.D. Davis,¹ ¹Surgery, Duke University Medical Center, Durham, NC

10:30 AM-NOON

CONCURRENT SESSION 2

Immunosuppression 1: State of the Art Immunosuppression: Sustained Benefits

(Imperial)

Moderators: David O. Taylor, MD and Patricia A. Uber, Pharm D

10:30 AM (9) Six Month Data of a 12-Month, Single-Blind, Randomized, Parallel Group, Multicenter Study To Investigate the Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS, Myfortic®) Compared with Mycophenolate Mofetil (MMF) in De Novo Heart Transplant Recipients, J.A. Kobashigawa,¹ S.F. Davis,² D.G. Renlund,³ M. Hummel,⁴ G. Gerosa,⁵ R. Brambilla,⁶ ¹University of California at Los Angeles, Los Angeles, CA; ²Cardiac Transplant Program, Vanderbilt University, Nashville, TN; ³Heart Failure Treatment and Prevention, University of Utah, Salt Lake City, UT; ⁴Deutsches Herzzentrum, Berlin, Germany; ⁵Instito Chirurgia Cardiovascolare, Padova, Italy; ⁶Novartis Pharma AG, Basel, Switzerland

10:45 AM (10) Two-Year Results of an International, Randomized, Double-Blind Study of Everolimus (RAD) vs Azathioprine To Inhibit the Decline of Pulmonary Function in Stable Lung Transplant Recipients, G.I. Snell,¹ V.G. Valentine,² R.B. Love,³ P. Vitulo,⁴ A.R. Glanville,⁵ U. Pirron,⁶ ¹Lung Transplantation Service, Alfred Hospital, Melbourne, Australia; ²Lung Transplantation, Ochsner Clinic Foundation, New Orleans, LA; ³Lung Transplant Unit, University of Wisconsin, Madison, WI; ⁴Division of Pneumology, IRCCS Policlinico San Matteo, Pavia, Italy; ⁵The Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia; ⁶Business Unit Transplantation, Novartis Pharma AG, Basel, Switzerland

11:00 AM (11) 24-Month Safety Results of a Randomized, Multicenter, Double-Blind Study of Everolimus vs Azathioprine in De Novo Heart Transplant Recipients, H. Eisen,¹ J. Kobashigawa,² R.C. Starling,³ N. Cretin,⁴ J.S. Jaffe,⁴ J. Murphy,⁴ ¹Temple University, Philadelphia, PA; ²UCLA, Los Angeles, CA; ³Cleveland Clinic Foundation, Cleveland, OH; ⁴Novartis Pharmaceuticals, E.Hanover, NJ

11:15 AM (12) Risk/Benefit Evaluation of Tacrolimus (TAC) vs. Cyclosporine Microemulsion (CsA) after Cardiac Transplantation: 18-Month Results, M. Rinaldi,¹ M. Grimm,² N.A. Yonan,³ the European Tacrolimus Heart Study Group, ¹Cardiac Surgery Division, Ospedale Policlinico San Matteo, Pavia, Italy; ²Department of Cardiothoracic Surgery, Allgemeines Krankenhaus Wien, Vienna, Austria; ³Cardiac Transplantation Unit, Wythenshawe Hospital, Manchester, United Kingdom

11:30 AM (13) Sirolimus in Combination with Tacrolimus for Primary Immunosuppression after Heart Transplantation, M. Mueller,¹ B. Meiser,¹ J. Groetzner,¹ I. Kaczmarek,¹ B. Reichart,¹ ¹Department of Cardial Surgery, Ludwig-Maximilians-University, Munich, Bavaria, Germany

11:45 AM (14) Five-Year Results of a Randomized Single Center Study of Tacrolimus (TAC) vs. Neoral Cyclosporine (CYA), J.A. Kobashigawa,¹ J.D. Moriguchi,¹ J. Patel,¹ J. Shaw,¹ B.T. Oeser,¹ H. Laks,¹ ¹University of California at Los Angeles, Los Angeles, CA

10:30 AM-NOON

CONCURRENT SESSION 3

Basic Science 1: Alloimmune Responses

(Plaza A)

Moderators: Abbas Ardehali, MD and Richard N. Pierson, III, MD

10:30 AM (15) Donor Specific Cytotoxic Non-Responsiveness Long after Clinical Heart Transplantation, C.C. Baan,¹ A.H.M.M. Balk,² B.J. van der Mast,¹ S. van den Engel,¹ A.P. Maat,² W. Weimar,¹ ¹Internal Medicine; ²Thorax Center, Erasmus Medical Center, Rotterdam, Netherlands

10:45 AM (16) Chemokine MIG/CXCL9 Stimulates CD4 T Lymphocyte Proliferation and IFN- γ Expression, D. Whiting,¹ G. Hsieh,¹ A. Banerji,¹ G.T. Schnickel,¹ J. Yun,¹ B. Bonavida,² A. Ardehali,¹ ¹Division of Cardiothoracic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA

11:00 AM (17) Indirect Allorecognition of MHC Class I Peptides Accelerates Lung Allograft Rejection in Miniature Swine, T. Shoji,¹ D.R. Johnston,¹ R. Hoerbelt,¹ J.C. Wain,² S.L. Houser,¹ L.C. Benjamin,¹ R.S. Lee,¹ R.S. Hasse,¹ L.G. Ledgerwood,¹ D.A. Guenther,¹ A. Muniappan,¹ M.H. Sayegh,⁴

J.C. Madsen,^{1,3} J.S. Allan,^{1,2} ¹Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA; ²Division of Thoracic Surgery, Massachusetts General Hospital, Boston, MA; ³Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA; ⁴Laboratory of Immunogenetics and Transplantation, Brigham and Women's Hospital, Boston, MA

11:15 AM (18) Human Endothelial T Cell Costimulation Is Inhibited by Interleukin 10 (IL-10) through Induction of Suppressor of Cytokine Secretion-3 (SOCS-3) and ILT-3, C.A. Gleissner,¹ A. Zatrow,¹ R. Klingenberg,¹ N. Xia,¹ T.J. Dengler,¹ ¹Cardiology, University of Heidelberg, Heidelberg, Baden-Württemberg, Germany

11:30 AM (19) Inhibition of T-Lymphocyte Stimulation by a Trophoblast Non-Coding RNA Suppressing MHC Class II Expression in Murine B-Cells, A. Geirsson,¹ A.L.M. Bothwell,² G.L. Hammond,¹ ¹Department of Surgery, Yale University School of Medicine, New Haven, CT; ²Section of Immunobiology, Yale University School of Medicine, New Haven, CT

11:45 AM (20) Pre-Transplant Donor-Specific Transfusions Combined with Cyclosporine Induce Tolerance to MLC Class I-Mismatched Cardiac Allografts in Miniature Swine, R. Hoerbelt,¹ D.R. Johnston,¹ T. Shoji,¹ S.L. Houser,¹ L. Ledgerwood,¹ R. Hasse,¹ A. Iribarne,¹ A. Muniappan,¹ D.A. Guenther,¹ J.S. Allan,¹ D.H. Sachs,¹ J.C. Madsen,¹ ¹Department of Surgery, Massachusetts General Hospital, Transplantation Biology Research Center, Boston, MA

10:30 AM-NOON

CONCURRENT SESSION 4

Donor Management, Preservation, and Organ Distribution 1: Plucking More From the Organ Orchard: Better Use of Existing Donors

(Plaza B)

Moderators: Stephen R. Large, MD and Alfredo Trento, MD

10:30 AM (21) Donor Cause of Death Does Not Affect Medium-Term Survival after Heart Transplantation – A UK National Study, J.S. Ganesh,¹ C.A. Rogers,¹ N.R. Banner,¹ R.S. Bonser,¹ ¹On Behalf of the Steering Group, UK Cardiothoracic Transplant Audit, Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom

10:45 AM (22) Donor Tricuspid Annuloplasty Reduces Post-Transplant Tricuspid Regurgitation, E. McGee,¹ P.M. McCarthy,¹ K.J. Hoercher,¹ J. Garnreiter,¹ G.V. Gonzalez-Stawinski,¹ M.K. Banbury,¹ J.L. Navia,¹ J. Feng,¹ E.H. Blackstone,¹ ¹The Kaufman Center for Heart Failure, The Cleveland Clinic, Cleveland, OH

11:00 AM (23) Pre-Implantation Multiple Cytokine mRNA Expression Analysis in Donor Lung Grafts Predicts Survival after Lung Transplantation in Humans, H. Kaneda,¹ C. Gutierrez,¹ M. de Perrot,¹ M. Yamane,¹ S. Quadri,¹ T. Arenovich,¹ T. Waddell,¹ M. Liu,¹ S. Keshavjee,¹ ¹Thoracic Surgery Research Laboratory, Toronto General Hospital Research Institute, Toronto, ON, Canada

11:15 AM (24) The ICU O₂ Challenge Should Not Be Used for Donor Lung Function Decision Making, D.C. McGiffin,¹ G.L. Zorn,¹ K.R. Young,¹ J.K. Kirklín,¹ K.J. Leon,¹ K.M. Wille,¹ R.N. Brown,¹ D.C. Naftel,¹ K.H. Hart,¹ ¹Depts. of Surgery and Pulmonary Medicine, University of Alabama at Birmingham, Birmingham, AL

11:30 AM (25) Use of Marginal Donor Hearts in Paediatric Heart Recipients, S. Neligan,¹ P. Whitmore,¹ M.J. Fenton,¹ M. Elliott,¹ M. Burch,¹ ¹Department of Cardiothoracic Transplant, Great Ormond Street Hospital for Children, London, United Kingdom

11:45 AM (26) INO-1001, a Novel Poly(ADP-Ribose) Polymerase Inhibitor Reduces Myocardial and Endothelial Reperfusion Injury after Orthotopic Heart Transplantation, G. Szabo,¹ N. Stumpf,¹ C. Flechtenmacher,² Z. Zsengeller,³ S. Mandra,¹ U. Heger,¹ C.F. Vahl,¹ C. Szabo,³ S. Hagl,¹ ¹Department of Cardiac Surgery, University of Heidelberg, Heidelberg, BW, Germany; ²Institute of Pathology, University of Heidelberg, Heidelberg, BW, Germany; ³Inotek Pharmaceuticals, Beverly, MA

12:15 PM-1:30 PM

LUNCHEON SYMPOSIUM

IVUS and Cardiac Allograft Vasculopathy: Late Breaking Trials

(Grand Ballroom B)

Supported by an Educational Grant from Novartis

Moderators: Mandeep R. Mehra, MD and Randall C. Starling, MD

12:15 PM (27) Multi-Center Intravascular Ultrasound Validation Study among Heart Transplant Recipients: Outcomes after 5 Years, J.K. Kobashigawa,¹ J.M. Tobis,¹ R.C. Starling,² M. Tuzcu,² M.R. Mehra,³ A. Yeung,⁴ H. Valantine,⁴ A. Smith,⁵ H. Anzai,¹ B.T. Oeser,¹ K. Abeywickrama,⁶ J. Murphy,⁶ N. Cretin,⁶ ¹University of California at Los Angeles, Los Angeles, CA; ²Cleveland Clinic, Cleveland, OH; ³Oschner Clinic, New Orleans, LA; ⁴Stanford University, Stanford, CA; ⁵Emory University, Atlanta, GA; ⁶Novartis Pharma, Basel, Switzerland

12:30 PM (28) Favorable Effect of Everolimus on Cardiac Allograft Vasculopathy Is Maintained through 24 Months, E.M. Tuzcu,¹ J.A. Kobashigawa,² H.J. Eisen,³ R.C. Starling,¹ T. Crowe,¹ K. Abeywickrama,⁴ J.S. Jaffe,⁴ ¹Cleveland Clinic Foundation, Cleveland, OH; ²University of California at Los Angeles, Los Angeles, CA; ³Temple University, Philadelphia, PA; ⁴Novartis Pharmaceuticals, E. Hanover, NJ; ⁵Cleveland Clinic Foundation; ⁶Novartis Pharmaceuticals; ⁷Novartis Pharmaceuticals

12:45 PM (29) Rapastat: Evaluation of the Role of Oral Sirolimus in the Treatment of Established Graft Vessel Disease. A Prospective, Randomized Intravascular Ultrasound Study, J. Segovia, L. Alonso-Pulpón, P. Ortiz, J. Jiménez-Mazuecos, F. Alfonso, J. Escaned, R. Hernández-Antolín, C. Macaya, Cardiac Transplant Unit, Clínica Puerta de Hierro, Madrid, Spain; Interventional Cardiology Dept, Hosp. Clínico, Madrid, Spain

1:00 PM Chairs' Perspectives and Panel Discussion

2:00 PM-3:30 PM

CONCURRENT SESSION 5

Mechanical Circulatory Support 1: Insights to Bridge to Recovery: Is It a Realistic Goal?

(Grand Ballroom B)

Moderators: George M. Wieselthaler, MD and Asghar Khaghani, MD

2:00 PM (30) Low Rate of Cardiac Recovery Despite Cellular Recovery during LVAD Support: Results from the LVAD Working Group, S. Maybaum,¹ O.H. Frazier,² R. Starling,³ L. Miller,⁴ S. Murali,⁵ K. Aaronson,⁶ K. Margulies,⁷ S. Xydas,¹ S. McRee,⁸ G. Torre,⁸ ¹Columbia University, NY, NY; ²Texas Heart Inst, Houston, TX; ³The Cleveland Clin, Cleveland, OH; ⁴University of Minnesota, Minneapolis, MN; ⁵University of Pittsburgh, Pittsburgh, PA; ⁶University of Michigan, Ann Arbor, MI; ⁷Temple University, Philadelphia, PA; ⁸Baylor College of Medicine, Houston, TX

2:15 PM (31) Mechanical Unloading Reverses Alterations in Cytoskeletal Proteins in the Failing Human Heart, L.A. Aguila-Pastir,¹ N.G. Smedira,² P.M. McCarthy,² J.B. Young,¹ C.S. Moravec,¹ ¹Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH; ²Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH

2:30 PM (32) Sustained Reversal of Electrical Remodeling during and after Left Ventricular Assist Device (LVAD) Support, J. Hardy,¹ C. Terracciano,¹ P. Tansley,¹ E. Birks,¹ C. Bowles,¹ A. Khaghani,¹ N. Banner,¹ M. Yacoub,¹ ¹Cardiothoracic Surgery, Harefield Hospital, Harefield, Middlesex, United Kingdom

2:45 PM (33) Mechanical Unloading Leads to Echocardiographic, Electrophysiological, Histological and Serological Recovery, S. Xydas,¹ Y. Naka,¹ D.M. Mancini,¹ C.C. Marboe,¹ J. Cohen,¹ A. Magnano,¹ A.D. Arnold,¹ N.M. Joyce,¹ M.C. Oz,¹ S. Maybaum,¹ ¹Departments of Surgery, Medicine, and Pathology, Columbia University, New York, NY

3:00 PM (34) Selective Upregulation of the Beta1-Adrenergic Receptor, Dephosphorylation of Cardiac Troponin I and Influence of Beta-Blocker Therapy in Patients Suffering from Terminal Heart Failure and Supported by Ventricular Assist Devices, H. Milting,¹ Ch. Scholz,¹ M. Freitag,² K. Jaquet,² O.E. Brodde,³ B. Pieske,⁴ A. Kassner,¹ L. Arusoglu,¹ D. v. Lewinski,⁴ R. Koerfer,¹ A. El Banayosy,¹ ¹Research Laboratory, Ruhr-University, Heart- Diabetescenter NRW, Bad Oeynhausen, NRW, Germany; ²Research Laboratory Molecular Cardiology, Ruhr-University, St. Josef Hospital, Bochum, NRW, Germany; ³Department Pharmacology, University, Essen, NRW, Germany; ⁴Department Pneumology and Cardiology, Georg-August University, Goettingen, NDS, Germany

3:15 PM (35) Morphological and Molecular Effects of Clenbuterol on Cardiac Myocytes - Role of IGF-I, P.J.R. Barton,¹ P.K. Bhavsar,¹ L.E. Felkin,¹ P.H. Sugden,² M.H. Yacoub,¹ ¹Heart Science Centre, Harefield, Middlesex, United Kingdom; ²National Heart and Lung Institute, Imperial College, London, United Kingdom

2:00 PM-3:30 PM

CONCURRENT SESSION 6

Lung/Heart-Lung Transplantation 2: Pulmonary Vascular Disease

(Imperial)

Moderators: Keith McNeil, MD and Jean-Luc Vachiery, MD

2:00 PM (36) TRACLEER® (Bosentan), for the Treatment of Pulmonary Arterial Hypertension (PAH) – 6 Month Quality of Life Data, A. Keogh, P. Macdonald, T. Williams, K. McNeil, E. Gabbay, S. Proudman, P. Steele, J. Wlodarczyk, K. Trimble, St Vincent's Hospital, Sydney, NSW, Australia; Alfred Hospital, Melbourne, VIC, Australia; Prince Charles Hospital, Brisbane, QLD, Australia; Royal Perth Hospital, Perth, WA, Australia; Royal Adelaide Hospital, Adelaide, SA, Australia; JWCS, Sydney, NSW, Australia; Actelion Pharmaceuticals Pty Ltd, Sydney, NSW, Australia

2:15 PM (37) Soluble CD40 Ligand in Pulmonary Arterial Hypertension - Possible Pathogenic Role of Interaction between Platelets and Endothelial Cells, J.K. Damas,^{1,2} K. Otterdal,¹ A. Yndestad,¹ H. Aass,² S.S. Froland,^{1,3} S. Simonsen,² P. Aukrust,^{1,3} A.K. Andreassen,^{2,1} Research Institute for Internal Medicine, University of Oslo, Oslo, Norway; ²Department of Cardiology, Rikshospitalet, Oslo, Norway; ³Section of Clinical Immunology and Infectious Diseases, Rikshospitalet, Oslo, Norway

2:30 PM (38) A Prospective Longitudinal Study of Airway Vasculature in the Pathogenesis of Bronchiolitis Obliterans Syndrome (BOS), S.Y. Langenbach,² L. Zheng,² T. McWilliams,² B. Levvey,¹ B. Orsida,² M. Bailey,² T.J. Williams,^{1,2} G.I. Snell,^{1,2,1} Department of Allergy Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, VIC, Australia; ²Department of Medicine, Monash University, Melbourne, VIC, Australia

2:45 PM (39) Long Term Outcome of Bosentan Treatment in Primary Pulmonary Hypertension (PPH) and Pulmonary Arterial Hypertension Associated with the Scleroderma Spectrum of Diseases (PAH-SSD), R.E. Girgis,¹ S.C. Mathai,¹ J.A. Krishnan,¹ F.M. Wigley,² P.M. Hassoun,¹ Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD; ²Rheumatology, Johns Hopkins University, Baltimore, MD

3:00 PM (40) Alteration in B-Type Natriuretic Peptide Levels with Epoprostenol Therapy in Pulmonary Hypertension: An Important Marker of Clinical Outcome, M.H. Park, R.L. Scott, P.A. Uber, M.L. Franklin, H.O. Ventura, M.R. Mehra, Ochsner Clinic Foundation, New Orleans, LA

3:15 PM (41) Cardiothoracic Transplantation for Congenital Heart Disease in Teenagers and Adults, R. Radley-Smith,¹ N.R. Banner,¹ A. Khaghani,¹ J. Wray,¹ M. Yacoub,¹ Transplant Directorate, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom

2:00 PM-3:30 PM

CONCURRENT SESSION 7

Clinical Heart Failure 1: New Concepts in Assessing Advanced Heart Failure Severity (Plaza A)

Moderators: Carlos Campana, MD and Nicholas R. Banner, MD

4:00 PM (42) Comparison between Gene Expression in Explanted Hearts with Endstage Coronary Artery Disease and in "Hibernating Myocardium", H. Hausmann,¹ R. Pregla,¹ R. Meyer,¹ H. Siniawski,¹ M. Gutberlet,² H. Amthauer,² R. Hetzer,¹ Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; ²Nuclear Medicine and Radiology, Charite, Campus Virchow Clinic Berlin, Berlin, Germany

4:15 PM (43) Effects of Beta-Blockers and Resynchronization Therapy on the Performance of the Heart Failure Survival Score (HFSS), G.D. Distefano,¹ M. Frigerio,¹ F. Oliva,¹ F.M. Turazza,¹ A. Garascia,¹ G. Foti,¹ G. Masciooco,¹ G. Cattafi,¹ G. Magenta,¹ M. Cipriani,¹ "A.DeGasperis" Cardiac Department, Niguarda-Ca' Granda Hospital, Milan, Italy

4:30 PM (44) Utility of Iodine-123 Metaiodobenzylguanidine Scintigraphy on Candidate Selection for Heart Transplantation, Y. Yazaki, Y. Kamiyoshi, Y. Osamu, K. Osamu, M. Hongo, K. Kogashi, H. Kasai, K. Kubo, First Department of Internal Medicine, Shinshu University, Matsumoto, Nagano, Japan

4:45 PM (45) Sudden Death in Patients Evaluated for Heart Transplantation: HFSS Detects Possible Candidates for Prophylactic ICD Implantation, H. Naegele,¹ M.A. Castel,¹ G. Groth,¹ F.M. Wagner,¹ H.H. Reichenspurner,¹ Cardiac Surgery, University Clinic Eppendorf, Hamburg, Germany

5:00 PM (46) B-Type Natriuretic Peptide, a Marker for Selection of Heart Transplant Candidates, M. Rothenburger,¹ J. Stypmann,² A. Hoffmeier,¹ E. Berendes,³ C. Etz,¹ A. Pioux,⁴ A. Rukosujew,¹ A. Löher,¹ H.H. Scheld,¹ C. Schmid,¹ Thoracic- and Cardiovascular Surgery, University Hospital, Muenster, Germany; ²Cardiology and Angiology, University Hospital, Muenster, Germany; ³Anesthesiology and Operative Intensive Care Medicine, University Hospital, Muenster, Germany; ⁴Institute of Clinical Chemistry and Laboratory Medicine, University Hospital, Muenster, Germany

5:15 PM (47) Predictors of Survival in Heart Failure Patients in NYHA Class IV, D. Pini,¹ L. Ardino,¹ L. Genovese,¹ P. Galimberti,² B. Andreuzzi,¹ A. Municino,¹ M. Mangiavacchi,¹ M. Gasparini,² E. Gronda,¹ Heart Failure Service, Istituto Clinico Humanitas, Rozzano, MI, Italy; ²Electrophysiology Service, Istituto Clinico Humanitas, Rozzano, MI, Italy

2:00 PM-3:30 PM

CONCURRENT SESSION 8

Pediatrics 1: Thoracic Transplantation for Congenital Disease

(Plaza B)

Moderators: Tom R. Karl, MD and Marlyn S. Woo, MD

2:00 PM (48) The Impact of Pretransplant Diagnosis and Surgical Palliation on the Long-Term Outcome of Pediatric Cardiac Transplantation, J.M. Eckermann,¹ A.J. Razzouk,¹ L.L. Bailey,¹ R.E. Chinnock,² R.L. Larsen,² J.K. Johnston,² S.L. Robie,² J.A. Fitts,² Surgery, Loma Linda University, Loma Linda, CA; ²Pediatrics, Loma Linda University, Loma Linda, CA

2:15 PM (49) Heart Transplantation to a Physiologic Single Lung in Patients with Congenital Heart Disease, J.M. Lamour,¹ D.T. Hsu,¹ S. Pinney,² S. Mital,¹ J.M. Quaegebeur,³ R. Mosca,³ L.J. Addonizio,¹ Pediatric Cardiology, Columbia University, New York, NY; ²Cardiology, Columbia University, New York, NY; ³Pediatric Cardiothoracic Surgery, Columbia University, New York, NY

2:30 PM (50) Congenital Category Is Not a Risk Factor for Pediatric Heart Transplantation, K.R. Kanter,¹ A.M. Berg,¹ R.N. Vincent,² W.T. Mahle,² J.M. Forbess,¹ P.M. Kirshbom,¹ Division of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, GA; ²Division of Pediatric Cardiology, Emory University School of Medicine, Atlanta, GA

2:45 PM (51) Airway Complications Following Pediatric Lung Transplantation; Incidence, Etiology, Management and Outcome, C.K. Choong,¹ S.C. Sweet,² E.N. Mendeloff,¹ J. Bell,¹ F.J. Haddad,¹ J.S. Huang,¹ P. Schuler,² M. de la Morena,² C.B. Huddleston,¹ Cardiothoracic Surgery, Washington University Medical School, St. Louis, MO; ²Pediatric Pulmonology, Washington University Medical School, St. Louis, MO

3:00 PM (52) 10 and 20-Year Long-Term Survival after Pediatric Orthotopic Heart Transplantation, P. Kouretas,² M. Ross,¹ B. Reitz,² R. Robbins,² N. Shumway,² S. Harbi,¹ J. Miller,² P. Gamberg,² C. Chin,¹ D. Bernstein,¹ Pediatrics, Stanford University, Stanford, CA; ²Cardiothoracic Surgery, Stanford University, Stanford, CA

3:15 PM (53) Role of Open Lung Biopsy for Diagnosis in Pediatric Lung Transplant Recipients: A Twelve-Year Experience, C.K. Choong,¹ C.B. Huddleston,¹ F.J. Haddad,¹ E.N. Mendeloff,¹ J. Bell,¹ A. Froemming,¹ P. Schuler,² M. de la Morena,² S.C. Sweet,² Cardiothoracic Surgery, Washington University Medical School, St. Louis, MO; ²Pediatric Pulmonology, Washington University Medical School, St. Louis, MO

3:30 PM-4:00 PM

Coffee Break (Grand Ballroom A)

4:00 PM-5:30 PM

CONCURRENT SESSION 9

Clinical Heart Transplantation 1: Circulating Anti HLA Antibodies in Heart Transplantation (Grand Ballroom B)

Moderators: Jeffrey D. Hosenpud, MD and Niloo M. Edwards, MD

4:00 PM (54) HLA Class I II Antibodies Post Heart Transplant Are Associated with Poor Allograft Outcome, A.R. Tambur,¹ S. Pamboukian,¹ P. Berikai,¹ D. Delgado,¹ L. Gu,¹ N.D. Herrera,¹ S. Dunlap,¹ M.

Monpetit,¹ A. Heroux,¹ ¹Heart Failure and Cardiac Transplant Program, Rush Med Ctr, Chicago, IL

4:15 PM (55) Significance of Persistent Post-Transplant Antibody after Cardiac Transplantation, S.K. Takemoto,¹ J. Zhang,¹ E. Chang,¹ J. Shaw,² P.A. Ayele,¹ B.T. Oeser,² D.W. Gjertson,¹ M.C. Fishbein,³ E.R. Reed,¹ J.A. Kobashigawa,² ¹Immunogenetics Center; ²Cardiology; ³Surgical Pathology, UCLA David Geffen School of Medicine, Los Angeles, CA

4:30 PM (56) The Highly Sensitized Patient Awaiting Heart Transplantation: Success with Combination Therapy of Plasmapheresis and Intravenous Gamma Globulin, J.A. Kobashigawa,¹ G. Cogert,¹ J.D. Moriguchi,¹ J.K. Patel,¹ H. Laks,² ¹Division of Cardiology, University of California, Los Angeles, Los Angeles, CA; ²Cardiothoracic Surgery, University of California, Los Angeles, Los Angeles, CA

4:45 PM (57) Outcome after Pre-Transplant Plasmapheresis for Sensitized Recipients Awaiting Heart Transplantation, S.K. Takemoto,¹ G. Cogert,² B.T. Oeser,² P.A. Ayele,¹ D.W. Gjertson,¹ M.C. Fishbein,³ E.R. Reed,¹ J.A. Kobashigawa,² ¹Immunogenetics Center, University of California, Los Angeles, Los Angeles, CA; ²Cardiology, University of California, Los Angeles, Los Angeles, CA; ³Surgical Pathology, University of California, Los Angeles, Los Angeles, CA

5:00 PM (58) The Prospective Use of Plasmapheresis and IVIG in Sensitized Patients Prior to Heart Transplantation, M.W. Weston,^{1,2} M.M. Lopez-Cepero,¹ L. DiChiara,² ¹LifeLink Transplant Institute, Tampa, FL; ²Cardiac Transplant, Tampa General Hospital, Tampa, FL

5:15 PM (59) The Relevance of HLA Antibody and a Donor Specific Flow Cytometry Crossmatch to Rejection and Graft Survival in Cardiac Allograft Recipients, P. Przybylowski,² B. Radovanecvic,¹ O.H. Frazier,¹ F. Smart,¹ N. Acorda,² P.V. Juarez,² L.A. Nemeth,¹ B.D. Kahan,² R.H. Kerman,² ¹Surgery, Texas Heart Institute, Houston, TX; ²Surgery, University of Texas Medical School, Houston, TX,

4:00 PM-5:30 PM

CONCURRENT SESSION 10

Cells, Animals, Machines: Are They the Future?

(Imperial)

Moderators: Paul Mohacsi, MD and Robert E. Michler, MD

4:00 PM (60) Combine Autologous Myoblast Intramyocardial Injection with Coronary Revascularization in Patients with Non-Acute Myocardial Infarction, F. Prosper,¹ G. Rabago,¹ A. Perez,¹ J.J. Gavira,¹ M.J. Garcia Velloso,¹ J. Barba,¹ P.L. Sanchez,² C. Cañizo,² J.M. Martí,¹ M. Hernandez,² N. Lopez Holgado,² J.M. Gonzalez,² C. Martin Luengo,² E. Alegria,¹ J. Herreros,¹ ¹Cardiovascular, Clínica Universitaria, Pamplona; ²Hospital Clínico de Salamanca, Salamanca, Spain

4:15 PM (61) Surgical Treatment for Congestive Heart Failure Using Autologous Adult Stem Cell Transplantation: Early Results, A.N. Patel,^{1,2,3} L. Geffner,² R.F. Vina,² H.C. Urschel, Jr.,³ R. Kormos,¹ F. Benetti,² ¹Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA; ²Cardiovascular Surgery, Benetti Foundation, Rosario, Argentina; ³Cardiothoracic Surgery, Baylor University Medical Center, Dallas, TX

4:30 PM (62) Gal α (1,3)-Galactose on Xenogeneic Endothelium Is a Putative Ligand for Human Monocytes, M.D. Peterson,¹ R. Jin,¹ T.K. Waddell,¹ ¹Surgery, University of Toronto, Toronto, ON, Canada

4:45 PM (63) Lack of Porcine Endogenous Retrovirus (PERV) Infection in Pig-to-Baboon Heart Xenotransplantation with Persistent Depletion of Anti-Gal Antibodies Despite the Presence of Xenoquimerism, N. Domenech, M. Hermida, I. Moscoso, T. Diaz, R. Manez, Unidad de Investigacion, Chu Juan Canalejo, La Coruna, Spain

5:00 PM (64) Will Device Change-Out Be Inevitable in Destination Therapy? S.J. Park,¹ L.D. Joyce,¹ K.K. Liao,¹ A.J. Boyle,² M.M. Colvin-Adams,² S. Ormaza,¹ J. Thompson,¹ L.W. Miller,² ¹Cardiovascular Surgery, University of Minnesota, Minneapolis, MN; ²Cardiology, University of Minnesota, Minneapolis, MN,

5:15 PM (65) Early Mechanical Restraint Improves Border Zone Function during Infarction Induced Ventricular Remodeling, J.J. Pilla,¹ A.S. Blom,² J. Affuso,² V.A. Ferrari,³ J.H. Gorman III,² R.C. Gorman,² M.A. Acker,² ¹Radiology, University of Pennsylvania; ²Surgery, University of Pennsylvania; ³Medicine, University of Pennsylvania

4:00 PM-5:30 PM

CONCURRENT SESSION 11

Nursing and Social Sciences: Strategies for Optimizing Pre- and Post-Transplant Function

(Plaza A)

Moderators: Fabienne Doebbels, MsC, PhDc, and Katherine Hoercher, RN

4:00 PM (66) Impact of Adequacy of Transplant Specific Education on Clinical Outcomes after Heart Transplantation, A.J. Bordelon, P.A. Uber, M.R. Mehra, Ochsner Clinic Foundation, New Orleans, LA

4:15 PM (67) Relation between Quality of Life and Functional Variables in Lung Transplant Recipients, C. Sievers,¹ C. Kugler,² J. Niedermeyer,³ M. Strueber,² G. Warnecke,² K. Pethig,³ A. Haverich,² U. Tegtbur,^{1,1} Sportsmedicine, Hannover Medical School, Hannover, Germany; ²Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany; ³Internal Medicine, University of Jena, Jena, Germany

4:30 PM (68) The Impact of Transplantation on the Cognitive Development and Behaviour of Children, J. Wray,¹ R. Radley-Smith,¹ Paediatrics, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom

4:45 PM (69) Evaluation of a Fast-Track Cardiac Rehabilitation Program after Heart Transplantation, A.F. Kaan,¹ C. Imai,¹ A.G. Taylor,¹ A.L. Zutz,¹ S. Barr,¹ Heart Transplant Program, St Paul's Hospital, Vancouver, BC, Canada

5:00 PM (70) Predictors of Physical Functional Disability at 5 - 6 Years after Heart Transplantation, K.L. Grady,¹ D.C. Naftel,² J.K. Kirklin,² C. White-Williams,² J. Kobashigawa,³ J. Chait,³ J.B. Young,⁴ D. Pelegrin,⁴ K. Patton-Schroeder,⁴ B. Rybarczyk,¹ J. Daily,¹ W. Piccione,¹ A. Heroux,¹ Medicine / Cardiology, Rush University Medical Center, Chicago, IL; ²Cardiothoracic Surgery, University of Alabama, Birmingham, AL; ³Cardiology, University of California, Los Angeles, CA; ⁴Cardiology, Cleveland Clinic Foundation, Cleveland, OH

5:15 PM (71) Striving for Normalcy: Symptoms and the Threat of Rejection after Lung Transplant, A.J. DeVito Dabbs,¹ L.A. Hoffman,¹ V. Swigart,¹ M.B. Happ,¹ J.H. Dauber,² A. Iacono,² ¹School of Nursing; ²Department of Pulmonary, Allergy & Critical Care, University of Pittsburgh, Pittsburgh, PA

4:00 PM-5:30 PM

CONCURRENT SESSION 12

Immunosuppression 2: Experimental Immunosuppression

(Plaza B)

Moderators: Karl B. Lemstrom, MD and Howard Eisen, MD

4:00 PM (72) CCR5 Blockade Modulates the Primate Immune Response after Cardiac Allotransplantation, C. Schroeder,¹ R.N. Pierson III,¹ G. Wu,¹ L.B. Peterson,² M.S. Springer,² A.M. Azimzadeh,¹ I.I. Singer,² J.A. DeMartino,² ¹Division of Cardiac Surgery, University of Maryland, Baltimore, MD; ²Research Laboratories, Merck Inc, Rahway, NJ

4:15 PM (73) Peroxisome Proliferator-Activated Receptor- α Activation Ameliorates Acute Rejection in Rat Cardiac Allografts, Y. Tanaka,¹ K. Okada,¹ T. Hasegawa,¹ M. Okada,¹ Y. Okita,¹ ¹Department of Cardiothoracic Surgery, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan

4:30 PM (74) Gene Transfer-Based Blockade of IL-1, IL-17, IL-18, RANTES or MCP-1 Cytokine Activatory Pathways Results in Prolonged Allograft Survival in a Rat Model of Heart Transplantation, J. Li-Zhong,^{1,2,3} S. Fleury,^{1,2} J. Dudler,⁴ L.K. von Segesser,^{2,5} G. Vassalli,^{1,2} ¹Cardiology, CHUV University Hospital, Lausanne, Switzerland; ²Organ Transplantation, CHUV University Hospital, Lausanne, Switzerland; ³Transplantation Research, Novartis Pharma, Basel, Switzerland; ⁴Rheumatology, CHUV University Hospital, Lausanne, Switzerland; ⁵Cardiovascular Surgery, CHUV University Hospital, Lausanne, Switzerland

4:45 PM (75) Tetrahydrobiopterin Prevents Cyclosporine Induced Vasomotor Dysfunction of the Rat Thoracic Aorta, D. Ramzy,¹ L.C. Tumiati,¹ S. Miriuka,² D. Delgado,² H.J. Ross,² V. Rao,¹ ¹Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada; ²Cardiology, Toronto General

Hospital, Toronto, ON, Canada

5:00 PM (76) The Effect of CSA, FK506 and MMF on the Expression of Inducible Cell Adhesion Molecules (iCAMS), Transplant Vasculopathy and Leukocyte Infiltration, M.H.C. Richter,¹ A. Rahmel,¹ H. Bittner,¹ J. Gummert,¹ F.W. Mohr,^{1,1} University of Leipzig, Heart Center of Leipzig, Leipzig, Germany

5:15 PM (77) FK 778 Directly Inhibits Adhesion Molecule Expression after Cardiac Transplantation: In Vivo and In Vitro Studies, T. Deuse,¹ S. Schrepfer,¹ F. Koch-Nolte,² H.J. Schäfer,³ E. Schwedhelm,⁴ R. Böger,⁴ H. Reichenspurner,^{1,1} Cardiovascular Surgery, University Hamburg, Hamburg, Germany; ²Immunology, University Hamburg, Hamburg, Germany; ³Pathology, University Hamburg, Hamburg, Germany; ⁴Pharmacology, University Hamburg, Hamburg, Germany

5:30 PM-6:30 PM

MODERATED POSTER SESSION 1/Wine and Cheese Reception

(Yosemite)

Immunosuppression

Moderator: Clyde W. Yancy, Jr., MD

(78) Chronic Renal Failure Following Lung Transplantation, K.D. Lake,¹ A.O. Ojo,^{1,2} L.L. Christensen,² R.T. Bustami,² R.M. Merion,^{2,3,1} Department of Internal Medicine, University of Michigan, Ann Arbor, MI; ²Scientific Registry of Transplant Recipients, Ann Arbor, MI; ³Department of Surgery, University of Michigan, Ann Arbor, MI

(79) Renal Recovery after Conversion to Mycophenolate Mofetil (MMF) and Sirolimus (Sir) as Calcineurin Inhibitor-Free Immunosuppression in Late Cardiac Transplant Recipients, J. Groetzner,¹ I. Kaczmarek,¹ P. Landwehr,¹ M. Mueller,¹ L. Buehse,¹ M. Vogeser,² P. Ueberfuhr,¹ S. Daebritz,¹ B. Meiser,¹ B. Reichart,^{1,1} Cardiac Surgery, LMU University Hospital Grosshadern, Munich, Germany; ²Clinical Chemistry, LMU Grosshadern, Munich, Germany

(80) Early Experience with Sirolimus Based, Calcineurin Inhibitor Free, Immunosuppression for Lung Transplant Recipients, Y. Shargall,¹ M. de Perrot,¹ T.K. Waddell,¹ L.S. Singer,¹ D. Hadjiliadis,¹ M. Hutcheon,¹ S. Chernenko,¹ A. Pierre,¹ F. D'Ovidio,¹ S. Kheshavjee,^{1,1} Toronto Lung Transplant Program, Toronto General Hospital, Toronto, ON, Canada

(81) RAD Alters the Immune Response in Bronchoalveolar Lavage(BAL) and Endobronchial Biopsy(EBB) Post Lung Transplantation(LTX), G. Snell,¹ B. Levvey,¹ L. Zheng,² M. Bailey,² B. Orsida,² T. Kotsimbos,¹ T. McWilliams,¹ H. Whitford,¹ E.H. Walters,¹ T. Williams,^{1,1} Allergy, Immunology & Respiratory Medicine, The Alfred, Melbourne, Australia; ²Monash University, Melbourne, Australia

(82) Plasmapheresis for Humoral Rejection and Severe Graft Dysfunction after Heart Transplantation, K. Ramasubbu,¹ D.H. Yawn,³ V. Thohan,¹ M. Loebe,² J.A. Lafuente,² G.P. Noon,² G. Torre-Amione,¹ M.M. Koerner,^{1,1} Department of Medicine, Section of Cardiology, Baylor College of Medicine, Methodist DeBakey Heart Center, Houston, TX; ²Department of Surgery, Baylor College of Medicine, Methodist DeBakey Heart Center, Houston, TX; ³Department of Pathology, Baylor College of Medicine, Methodist DeBakey Heart Center, Houston, TX

(83) Successful Treatment of Vascular Rejection with Rituximab in Cardiac Transplants, H.E. Garrett, Jr.,¹ K. Groshart, D. Duvall-Seaman, C. Graves, R. Suggs, B. Helsley,¹ Department of Surgery, University of Tennessee, Memphis, TN

Post Transplant Complications

Moderator: Roberta C. Bogeav, MD

(84) Is Post Heart Transplant Diastolic Dysfunction a Risk Factor for Mortality?, J.A. Tallaj,¹ J.K. Kirklín,² R.N. Brown,² M. Mitchell,² B.K. Rayburn,¹ R.C. Bourge,¹ R.L. Benza,¹ L.J. Pinderski,¹ S.V.

Pamboukian,¹ D.C. McGiffin,² D.C. Naftel,² ¹Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL; ²Cardiovascular Surgery, University of Alabama at Birmingham, Birmingham, AL

(85) Has Newer Therapies Improved the Survival of Cardiac Death Due To Transplant Coronary Artery Disease?, S.-Z. Gao,¹ B. Cantin,¹ M. Perlroth,¹ S. Hunt,¹ J. Schroeder,¹ ¹Cardiology, Stanford University School of Medicine, Stanford, CA

(86) Routine Angiography Post Cardiac Transplantation: What Value?, M.A.J. Rockx,¹ P.W. Pflugfelder,¹ W.J. Kostuk,¹ ¹Cardiology, London Health Sciences Centre - University Campus, London, ON, Canada

(87) Epidemiology and Clinical Implications of Atypical Mycobacterial Infections in Cadaveric Lung Transplants: The Role of Surveillance Bronchoscopy and Bronchoalveolar Lavage Phenotype, C. Hoopes,¹ A.F. Luetkemeyer,¹ D. Jablons,¹ T. Hall,¹ T. Weaver,¹ J. Golden,¹ ¹Thoracic Surgery, University of California San Francisco, San Francisco, CA

(88) Retransplantation - Never Too Old for One?, J.K. Patel,¹ B.T. Oeser,¹ S. Go,¹ B.J. Rivera,¹ M.L. Plesa,¹ J.D. Moriguchi,¹ J.A. Kobashigawa,¹ ¹University of California at Los Angeles, Los Angeles, CA

(89) Intravascular Ultrasound Findings 10 Years after Heart Transplantation, J. Segovia,¹ L. Alonso-Pulpón,¹ J. Jiménez-Mazuecos,¹ B. Fuertes,¹ F. Alfonso,² R.A. Hernández-Antolín,² J. Escaned,² C. Bañuelos,² M. Sabaté,² C. Macaya,² ¹Cardiac Transplant Unit, C. Puerta de Hierro, Madrid, Madrid, Spain; ²Interventional Cardiology Department, Hosp. Clínico, Madrid, Madrid, Spain

Outcomes in Lung and Heart-Lung Transplantation

Moderator: Vincent G. Valentine, MD

(90) Quantifying Health Status and Functional Outcomes Following Lung Transplant, J.M. L'Abbe,¹ M. Loadman Joyce,¹ M.J. Bentley,¹ D.C. Lien,¹ ¹Transplant Services, University of Alberta Hospital, Edmonton, AB, Canada

(91) Survival Following Lung Transplantation (LT) of Cystic Fibrosis (CF) Patients Infected with Burkholderia cepacia Complex (Bcc), B.D. Alexander,¹ E.A. Wills,¹ L.B. Reller,¹ E.S. Yow,² S.M. Palmer,³ R.D. Davis,⁴ C.W. Woods,¹ J.J. LiPuma,⁵ ¹Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, NC; ²Duke Clinical Research Institute, Duke University Medical Center, Durham, NC; ³Division of Pulmonary and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, NC; ⁴Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC; ⁵Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, MI

(92) High Dose Rate Brachytherapy for In-Stent Restenosis of Lung Transplant Bronchi, S.M. Studer,¹ B.A. Johnson,¹ K.R. McCurry,² E. Cano,¹ A.T. Iacono,¹ ¹Division of Pulmonary & Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA; ²Division of Cardiothoracic Surgery, University of Pittsburgh

(93) Successful Transplantation of B. cepacia Complex Infected Cystic Fibrosis Patients; Transplanting B. cenocepacia (Genomovar III) Infected Patients, A. De Soyza,¹ A. McDowell,² J.R.W. Govan,³ K.F. Gould,⁴ P.A. Corris,¹ ¹Transplantation and Immunobiology, University of Newcastle, Newcastle, Tyne and Wear, United Kingdom; ²Biomolecular Sciences Group, School of Pharmacy, Queen's University, Belfast, Northern Ireland, United Kingdom; ³Medical Microbiology, University of Edinburgh, Edinburgh, Lothian, United Kingdom; ⁴Medical Microbiology, Freeman Hospital, Newcastle, Tyne and Wear, United Kingdom

(94) Lung Transplant with Concomitant Cardiac Surgery: Results and Long-Term Survival, K. Parekh,¹ N. Moazami,¹ B.F. Meyers,¹ T.J. Guthrie,¹ E.P. Trulock,² J.D. Cooper,¹ G.A. Patterson,¹ ¹Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO; ²Division of Pulmonary Medicine, Washington University School of Medicine, St. Louis, MO

(95) Heart-Lung Transplantation for Complex Pulmonary Atresia: A Single Centre Experience, R. Radley-Smith,¹ N.R. Banner,¹ A. Khaghani,¹ J. Wray,¹ M. Yacoub,¹ ¹Transplant Directorate, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom

Heart Transplant Follow-Up

Moderator: Hannah A. Valantine, MD

(96) Frequent Surveillance Biopsies Do Not Improve Survival Following Heart Transplant, C.K. Wallace,¹ M. Koerner,^{2,3} V. Thohan,^{2,3} G. Torre-Amione,^{2,3} ¹Baylor College of Medicine, Houston, TX; ²Department of Medicine, Cardiology Section, Baylor College of Medicine, Houston, TX; ³The Methodist DeBakey Heart Center, The Methodist Hospital, Houston, TX

(97) Pre-Operative Diabetes Is Associated with Reduced Survival in the Early and Chronic Phase after Heart Transplantation, T.J. Dengler,¹ R. Klingenberg,¹ C.A. Gleissner,¹ A. Koch,² F.U. Sack,² P.A. Schnabel,³ A. Remppis,¹ ¹Cardiology, University of Heidelberg, Heidelberg, Germany; ²Cardiac Surgery, University of Heidelberg, Heidelberg, Germany; ³Pathology, University of Heidelberg, Heidelberg, Germany

(98) Endothelial Dysfunction in Cardiac Transplant Recipients Is Associated with a Vasoconstrictor Response to L-NMMA and Elevated Endothelin Levels, S.S. Kushwaha,¹ S. Higano,¹ R. Nelson,¹ G. Pumper,¹ A. Lerman,¹ ¹Cardiovascular Diseases, Mayo Clinic, Rochester, MN

(99) Noninvasive Identification of Cardiac Allograft Vasculopathy with Real-Time Myocardial Contrast Echocardiography: Comparison with IVUS, Coronary Angiography and 99mTc Sestamibi Perfusion Imaging, H.-U. Stempfle,¹ C. Übleis,¹ H.-X. Hoyer,¹ R. Schmid,¹ P. Überfuhr,² V. Klauss,¹ K. Theisen,¹ ¹Cardiology, Med. Poliklinik-Innenstadt, LMU, Munich, Germany; ²Cardiac Surgery, Klinikum Grosshadern, LMU, Munich, Germany

(100) Ex Vivo ³¹P Magnetic Resonance Spectroscopy (MRS) of Heart Grafts Provides Metabolic Markers of Early Dysfunction in Operating Room, T.G. Caus,¹ F. Kober,² A. Mouly-Bandini,¹ S. Confort-Gouny,² Y. Le Fur,² M. Izquierdo,² J.P. Ranjeva,² P. Viout,² D. Metras,¹ P.J. Cozzone,² M. Bernard,² ¹Adult's Cardiac Surgery, University Hospital Timone, Marseilles, France, Metropolitan; ²CRMBM, Faculty of Medicine Timone, Marseilles, France, Metropolitan

(101) Benefits of Three Years of Controlled Exercise Rehabilitation on Heart Transplant Recipients, U. Tegtbur,¹ K. Pethig,² M.W. Busse,³ K. Jung,¹ A. Haverich,⁴ ¹Sportsmedicine, Hannover Medical School, Hannover, Germany; ²Internal Medicine, University of Jena, Jena, Germany; ³Sportsmedicine, University of Leipzig, Leipzig, Germany; ⁴Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany

5:30 PM-6:30 PM

GENERAL POSTER SESSION 1

(Franciscan Ballroom)

Pediatrics

(102) Influence of Pre and Post-Transplant ELISA-Detected Anti-HLA Antibodies on Pediatric Heart Transplant Outcome, S. Di Filippo,¹ A. Girnita,¹ S. Tsao,² G.J. Boyle,² S.A. Miller,² S.A. Webber,² S.K. Gandhi,³ A. Zeevi,¹ ¹Transplant Pathology, Biomedical Science Tower, W1550, Pittsburgh, PA; ²Pediatric Cardiology, Children's Hospital UPMC, Pittsburgh, PA; ³Pediatric Cardiothoracic Surgery, Children's

Hospital UPMC, Pittsburgh, PA, US

(103) Basiliximab in Pediatric Heart Transplantation - Initial Experience, K.M. Ward,¹ S.E. Crawford,² S.G. Pophal,¹ S.R. Rodgers,¹ C.L. Backer,³ C. Mavroudis,³ E. Pahl,¹ ¹Pediatric Cardiology, Northwestern Feinberg School of Medicine, Chicago, IL; ²Pathology, Northwestern Feinberg School of Medicine, Chicago, IL; ³Cardiovascular and Thoracic Surgery, Northwestern Feinberg School of Medicine, Chicago, IL

(104) Experience with Sirolimus in Pediatric Cardiac Transplant Recipients, T.M. Shankel,^{#1} D.C. Cutler,^{#1} J.K. Johnston,^{#1} J.A. Fitts,^{#1} R.E. Chinnock,^{#1} ¹Pediatric Heart Transplant Program, Loma Linda University Children's Hospital, Loma Linda, CA

(105) Non-Adherence to Therapy Is a Common Cause of Death in Adolescence Following Heart or Lung Transplantation, T. Lunnnon-Wood,¹ P. Aurora,¹ P. Whitmore,¹ M.J. Fenton,¹ R. Radley-Smith,¹ M. Elliott,¹ ¹Department of Cardiothoracic Transplant, Great Ormond Street Hospital for Children, London, London, United Kingdom

(106) Post-Operative Use of Aerosolized Aztreonam in Cystic Fibrosis Patients Colonized with Burkholderia Cepacia Prior to Lung Transplantation, M.S. Woo,¹ E. Perez,¹ M.V. Horn,¹ V.A. Starnes,¹ ¹Cardiothoracic Transplant Team, Childrens Hospital Los Angeles, Los Angeles, CA

(107) A Randomized Clinical Trial of Tacrolimus [Prograf®] and Cyclosporine [Neoral®] Immunosuppression in Pediatric Heart Recipients, S.M. Pollock-BarZiv,^{1,2} A.I. Dipchand,^{1,2} B.W. McCrindle,^{1,2} L.J. West,^{1,2} ¹Cardiology, The Hospital for Sick Children, Toronto, ON, Canada; ²University of Toronto, Toronto, ON, Canada

(108) Utility of Serial Panel Reactive Antibody Determinations Following Pediatric Heart Transplant, J.M. Lamour,¹ L.J. Addonizio,¹ S. Mital,¹ D.T. Hsu,¹ ¹Pediatric Cardiology, Columbia University, New York, NY

(109) Value of Early Creatinine Clearance To Predict Late Renal Function in Pediatric Heart Transplant Patients, S. Di Filippo,¹ G.J. Boyle,² S.A. Miller,² S.K. Gandhi,² R. English,² S.A. Webber,² ¹Transplant Pathology, Basic Science Tower, W1551, UPMC, Pittsburgh, PA; ²Pediatric Cardiology, Children's Hospital UPMC, Pittsburgh, PA

(110) Ten Year Survival after Paediatric Heart Transplantation: A Single Centre Experience, R. Radley-Smith,¹ J. Wray,¹ A. Khaghani,¹ M. Yacoub,¹ ¹Transplant Directorate, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom

(111) Late Acute Cardiac Rejections in Pediatric Heart Transplantation: Incidence and Impact on Long-Term Outcome, M. Dandel,¹ D. Kemper,¹ H. Lehmkuhl,¹ M. Hummel,¹ C. Knosalla,¹ R. Hetzer,¹ ¹Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

(112) Results of Cardiac Transplantation in Grown-Up Patients with Congenital Heart Disease, J. Groetzner,¹ B. Reichart,¹ P. Ueberfuhr,¹ I. Kaczmarek,¹ M. Mueller,¹ P. Landwehr,¹ J. Sachweh,¹ B. Meiser,¹ M. Naebauer,² H. Netz,³ S. Daebritz,¹ ¹Department of Cardiac Surgery, Ludwig Maximilians University Hospital Grosshadern, Munich, Germany; ²Department of Internal Medicine, Germany; ³Department of Pediatric Cardiology

New Genes and Proteins in Thoracic Transplantation

(113) The TGF- β Signalling Pathway Is Activated in Coronary Artery Vasculopathy, C. Atkinson,¹ M. Southwood,¹ E. Moseley,¹ J. Wallwork,² M. Goddard,¹ ¹Pathology Department, Papworth Hospital NHS Trust, Cambridge, Cambridgeshire, United Kingdom; ²Transplant Department, Papworth Hospital NHS Trust, Cambridge, Cambridgeshire, United Kingdom

(114) Bone Morphogenetic Protein Signalling Is down Regulated in the Intima of Transplant Coronary Artery Vasculopathy Lesions, M. Southwood,¹ M. Goddard,¹ E. Moseley,¹ C. Atkinson,¹
¹Pathology Department, Papworth Hospital NHS Trust, Cambridge, Cambridgeshire, United Kingdom

(115) Bone Morphogenetic Protein (BMP) and SMAD Signalling Is Important in the Development of the Human Pulmonary Vasculature, M.R. Southwood,¹ P.D. Upton,² C. Atkinson,¹ S. Stewart,¹ N.W. Morrell,²
¹Department of Pathology, Papworth and Addenbrookes Hospitals NHS Trusts, Cambridge, United Kingdom; ²Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom

(116) Gene Expression Profiling by Multiplex, Real Time PCR in Bronchoscopic Biopsies and Lavages of Allografts in Lung Transplant Recipients, X. Xu,¹ J.A. Golden,² G. Dolganov,¹ T. Weaver,¹ K.D. Jones,³ S. Donnelly,¹ G.H. Caughey,^{1,2}
¹Cardiovascular Research Institute; ²Department of Medicine; ³Department of Pathology, University of California at San Francisco, San Francisco, CA

Issues and Challenges in Heart Failure Management

(117) The Utility of B-Type Natriuretic Peptide Levels in Demarcating the Distinct Hemodynamic Profiles of Chronic Heart Failure, K. Alaswad, M.B. Richie, P.A. Uber, R.L. Scott, M.H. Park, H.O. Ventura, M.R. Mehra,
Ochsner Clinic Foundation, New Orleans, LA

(118) Inflammatory Parameters as Predictors of Clinical Course in Patients with End-Stage Heart Failure, E.V. Potapov,¹ F.D. Wagner,¹ F. Hennig,¹ H.D. Volk,² S. Ignatenko,¹ H.B. Lehmkuhl,¹ R. Hetzer,¹
¹Thoracic and Cardiovascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; ²Immunology, CharitéHumboldt University Berlin, Berlin, Germany

(119) Should MADIT-II Criteria Apply to Patients Treated in a Heart Failure Specialty Clinic?, M.C. Montpetit,¹ S.H. Dunlap, M. McLeod, L. Gu, A.L. Heroux,
¹Heart Failure and Transplant Program, Rush University Medical Center, Chicago, IL

(120) The Significance of a Low Initial Hematocrit Value as a Prognostic Factor in Patients with Severe Heart Failure, J. Terrovitis,¹ G. Alexopoulos,¹ E. Tsolakis,¹ E. Tsagalou,¹ S. Drakos,¹ P. Papazaglou,¹ G. Karanastasis,¹ P. Gounopoulos,¹ S. Makri,¹ J. Nanas,¹
¹Department of Clinical Therapeutics, University of Athens, Athens, Greece

(121) Chronic Mechanical Left Ventricular Support Improves Pulmonary Vascular Resistance in Patients Bridged to Transplantation, A.V. Kalya,¹ A.J. Tector,¹ F.X. Downey,¹ M.L. McDonald,¹ A.J. Anderson,¹ C.J. Bartoszewski,¹ J.D. Hosenpud,¹
¹Cardiac Transplant Program, St. Luke's Medical Center, Milwaukee, WI

(122) Insurance with Medicare/Medicaid Is Associated with Non-Adherence in Heart Failure Patients, S.V. Pamboukian,¹ I. Nisar,² S. Patel,² L. Gu,² M. McLeod,² S. Dunlap,² M.R. Costanzo,³ L. Hayes,² A. Heroux,²
¹Cardiology, University of Alabama at Birmingham, Birmingham, AL; ²Cardiology, Rush Presbyterian St. Luke's Medical Center, Chicago, IL; ³Cardiology, Edward Hospital, Naperville, IL

(123) Anemia in Advanced Chronic Heart Failure: The Importance of Iron Deficiency, D. Karageorgopoulos,¹ C. Matsouka,¹ E. Tsolakis,¹ J. Terrovitis,¹ A. Ntalianis,¹ G. Alexopoulos,¹ J. Kanakakis,¹ M. Anastasiou-Nana,¹ J. Nanas,¹
¹Department of Clinical Therapeutics, University of Athens, Athens, Greece

(124) Upgrade from Standard Right Sided Pacing to Cardiac Resynchronization Therapy Shows Clinical Benefit as in De Novo Implantation, S.V. Pamboukian,¹ I. Nisar,² S. Patel,² L. Gu,² M. McLeod,² R. Trohman,² S. Dunlap,² M.R. Costanzo,³ A. Heroux,²
¹Cardiology, University of Alabama at Birmingham, Birmingham, AL; ²Cardiology, Rush Presbyterian St. Luke's Medical Center, Chicago, IL;

³Cardiology, Edward Hospital, Naperville, IL

(125) Withdrawn

(126) Prognostication in Advanced Heart Failure with a Modified Heart Failure Survival Score That Takes into Account Beta-Blockers and Cardiac Resynchronization Therapy, G.D. Distefano,¹ M. Frigerio,¹ F. Oliva,¹ F.M. Turazza,¹ G. Foti,¹ A. Garascia,¹ G. Masciocco,¹ M. Lunati,¹ G. Cattafi,¹ ¹"A De Gasperis" Cardiac Department, Niguarda-Ca' Granda Hospital, Milan, Italy

(127) Preoperative Screening Scale Predicts Prolonged ICU Stay after Implantation of Left Ventricular Assist Devices, J.A. Morgan,¹ R. John,¹ B.J. Lee,¹ D.A. Jordan,¹ M.C. Oz,¹ Y. Naka,¹ ¹Surgery, Columbia University, New York, NY

New/Alternative Therapies to Transplantation

(128) VEGF-C Induces Collateral Formation in Ischaemic Porcine Heart Model, T.I. Pätilä,¹ T.S. Ikonen,¹ J. Rutanen,² A. Ahonen,¹ J. Lommi,¹ K. Lappalainen,¹ L. Ihlberg,¹ T.A. Partanen,³ K. Virtanen,¹ K. Alitalo,³ S. Ylä-Herttua,² A. Harjula,¹ ¹Department of Cardiothoracic Surgery, University of Helsinki Meilahti Hospital, Helsinki, Finland; ²Department of Molecular Medicine, A.I. Virtanen Institute, University of Kuopio, Kuopio, Finland; ³Molecular/Cancer Biology Laboratory, Haartman Institute, University of Helsinki, Helsinki, Finland

(129) Autologous Bone-Marrow Stem Cell Transplantation for Ischaemic Cardiomyopathy. First Findings on Procedure Safety in Human, A. Angelini,¹ I. Vendramin,² C. Messina,³ P. De Coppi,⁴ M.V. Gazzola,³ R. Destro,³ L. Zanesco,³ C. Castellani,¹ M. Della Barbera,¹ M. Valente,¹ G. Thiene,¹ D. Casarotto,² G. Gerosa,² ¹Institute of Pathological Anatomy, University of Padua, Padua, Italy; ²Department of Cardiovascular Surgery, University of Padua, Padua, Italy; ³Department of Pediatrics-Clinic of Pediatric Oncology-Haematology, University of Padua, Padua, Italy; ⁴Division of Pediatric Surgery, University of Padua, Padua, Italy

(130) High-Risk Coronary Interventions Involving Percutaneous Left Ventricular Support, B. Kar,¹ A. Civitello,¹ I.D. Gregoric,¹ B. Radovancevic,¹ C. Gemmato,² T.J. Myers,² R.M. Delgado,¹ O.H. Frazier,¹ ¹Cardiopulmonary Transplantation and Cardiovascular Surgical Research, Texas Heart Institute, Houston, TX

(131) Ex-Vivo and In-Vivo Effects of Gas 914 on Pulmonary Xenograft Rejection, K. Wiebe,¹ T. Schuerholz,² M. Oezkur,¹ M. Mengel,³ R. Schwinzer,¹ M. Winkler,¹ A. Haverich,¹ ¹Department of Surgery, Hannover Medical School, Hannover, Germany; ²Department of Anesthesiology, Hannover Medical School, Hannover, Germany; ³Department of Pathology, Hannover Medical School, Hannover, Germany

(132) Degree of Immunologic Injury Is the Strongest Predictor of Heart Weight Increase in the Xenotransplantation Model, K. Oj,¹ J.M. Schirmer,¹ W.R. Davies,¹ B.E. Schmidt,¹ H.D. Tazelaar,¹ J.M. Risdahl,¹ G.W. Byrne,¹ J.S. Logan,¹ C.G.A. McGregor,¹ ¹William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN

133) CD20+ B-Cells Contribute to Natural Xenoreactive Antibody Production While Elicited Responses Are Partially Mediated by CD19-/CD20- B-Cells (G.V. Gonzalez-Stawinski,¹ C.L. Lau,² J.G. Gaca,³ R.D. Davis,³ ¹Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, OH; ²Cardiothoracic Surgery, Barnes Jewish Hospital, St Louis, MO; ³Surgery, Duke University Medical Center, Durham, NC

(134) Withdrawn

Donor Mangement, Organ Preservation, Organ Distribution

(135) Are out Hospital Non Heart Beating Donors (NHBD) Better Than Brain Death Lung Donors?, A. Varela,¹ J.R. Nuñez,¹ A.P. Gamez,¹ F. Rio,² M. Cordoba,¹ J. Calatayud,² P. Ussetti,¹ M.C. Carreño,¹ F. Alfageme,¹ D. Gomez,¹ ¹Lung Transplantation, Hospital Universitario Clinica Puerta de Hierro, Madrid, Spain; ²Transplantation Unit, Hospital Clinico San Carlos, Madrid, Spain

(136) How Long Does It Take To Optimise Donor Haemodynamics?, F. Ozalp,¹ V. Pathi,¹ U. Nkere,¹ A. Kirk,¹ A.J. Murday,¹ ¹Scottish Cardiopulmonary Transplant Unit, Glasgow Royal Infirmary, North Glasgow University Hospitals NHS Trust, Glasgow, United Kingdom

(137) Systemic Neutrophil Activation and Lung Injury in the Brain-Dead Donor Is a Biphasic Phenomenon, V.S. Avlonitis,¹ C.H. Wigfield,¹ C.M. Gilfillan,¹ J.A. Kirby,¹ J.H. Dark,¹ ¹Department of Surgery, University of Newcastle, Newcastle upon Tyne, United Kingdom

(138) Computer Simulation Predictions of the Impact of Broader Allocation within Zone A to Status 1A and 1B Heart Waitlist Patients, R.T. Bustami,¹ S. Murray,² K.P. McCullough,¹ A.M. Rodgers,¹ T.E. Hulbert-Shearon,² R.A. Wolfe,² W.S. Ring,³ R.M. Merion,² ¹SRTR/URREA, Ann Arbor, MI; ²SRTR/University of Michigan, Ann Arbor, MI; ³Southwestern Medical Center, University of Texas, Dallas, TX

(139) Circulating Troponin I Is a Specific Marker of Donor Heart Dysfunction, B. Nyawo,² S.M. Haj-Yahia,^{1,2} E.J. Birks,^{1,2} M. Kemp,³ N.R. Banner,¹ A. Khaghani,¹ M.H. Yacoub,² ¹Transplant Unit, Royal Brompton and Harefield Hospital, Harefield, Middlesex, United Kingdom; ²Heart Science Centre, Royal Brompton and Harefield Hospital, Harefield, Middlesex, United Kingdom; ³Biochemistry, Royal Brompton and Harefield Hospital, Harefield, Middlesex, United Kingdom

(140) Retrograde vs. Antegrade Lung Flush Perfusion for Graft Preservation in Clinical Lung Transplantation, B. Gohrbandt,¹ S. Fischer,¹ S.P. Sommer,¹ G. Warnecke,¹ J. Niedermeyer,¹ A. Haverich,¹ M. Strueber,¹ ¹Hannover Thoracic Transplant Program, Hannover Medical School, Hannover, NS, Germany

(141) Increasing Frequency of Adenosine Monophosphate Deaminase 1 C34T T Allele in Cardiac Donors Is Associated with Reduced Pre Donation Inotrope Requirements, A.B. Taegtmeier,^{1,3} J.B. Breen,¹ J.D. Smith,² N.R. Banner,¹ M.H. Yacoub,³ P.J. Barton,³ ¹Transplant Unit, Harefield Hospital, Harefield, Middlesex, United Kingdom; ²Tissue Typing Laboratory, Harefield Hospital, Harefield, Middlesex, United Kingdom; ³Heart Science Centre, Harefield Hospital, Harefield, Middlesex, United Kingdom

(142) Modified Reperfusion in Non-Standard Donor Lungs, G.T. Schnickel,¹ D. Whiting,¹ D. Ross,² J. Belperio,² M. Levine,² R. Shpiner,² H. Laks,¹ R. Beygui,¹ A. Ardehali,¹ ¹Division of Cardiothoracic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA

Post Transplant Complications

(143) The Use of Thiazolidinedione Agents in Post Cardiac Transplant Diabetic Patients, P. Srikanthan, W.A. Hsueh, J.A. Kobashigawa, Endocrinology, Diabetes and Hypertension, UCLA David Geffen School of Medicine, Los Angeles, CA; Endocrinology, Diabetes and Hypertension, UCLA David Geffen School of Medicine, Los Angeles, CA; Division of Cardiology, UCLA David Geffen School of Medicine, Los Angeles, CA

(144) The Angiotensin Converting Enzyme Insertion Deletion Polymorphism Does Not Influence the Development or Progression of Post-Cardiac Transplant Hypertension, J.E. Fildes,¹ A.H. Walker,² C.G. Densem,¹ A.K. Deiraniya,¹ I.V. Hutchinson,¹ C.T. Leonard,¹ N. Yonan,¹ ¹The Transplant Centre, South Manchester University Hospital Trust, Manchester, Greater Manchester, United Kingdom; ²Cardiothoracic Surgery, Northern General Hospital, Sheffield, South Yorkshire, United Kingdom

(145) Diagnosis of Fungal Infections by Detection of Anti-Candida Manna Antibodies, Candida Mannan Antigen and Aspergillus Galactomannan Antigen in Patients Following Heart and Lung Transplantation, P. Heizmann,¹ H.B. Lehmkuhl,¹ W. Heizmann,² O. Grauhan,¹ R. Hetzer,¹ ¹Deutsches Herzzentrum Berlin, Berlin, Germany; ²Labor Professor Heizmann, Berlin, Germany

(146) Successful Treatment of Relapsed PTLD with Yt-90/Anti-CD20 Radioimmunotherapy, A.C. Patel,¹ H.S. Lin,² S.C. Sweet,¹ ¹Pediatric Allergy and Pulmonary Medicine, Washington University School of Medicine, St. Louis, MO; ²Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO

(147) Multiple Combination Bactericidal Testing for Patients with Cystic Fibrosis Infected with Burkholderia Cepacia before and after Lung Transplantation, A.R. Scott,¹ J.M. Morton,¹ C. Harbour,² B. Rose,² M. Robinson,² M.L. Plit,¹ A.R. Glanville,¹ ¹The Lung Transplant Unit, St. Vincent's Hospital, Sydney, Australia; ²The Infectious Disease Department, Sydney University, Sydney, Australia

(148) Safety and Efficacy of Rosuvastatin Therapy for the Prevention of Hyperlipidemia in Adult Cardiac Transplant Recipients, A.M. Samman,¹ C. Imai,¹ L. Straatman,¹ J. Frohlich,¹ A. Ignaszewski,¹ ¹Cardiology, St. Paul's Hospital, Vancouver, BC, Canada

(149) Increased Incidence of Hypertension after Orthotopic Cardiac Transplantation Compared with Heterotopic Cardiac Transplantation, A.B. Taegtmeier,^{1,3} J.B. Breen,¹ A.M. Crook,² P.J. Barton,³ N.R. Banner,¹ ¹Transplant Unit, Harefield Hospital, Harefield, Middlesex, United Kingdom; ²Department of Public Health Research, Westminster Primary Care Trust, London, United Kingdom; ³Heart Science Centre, Harefield Hospital, Harefield, Middlesex, United Kingdom

(150) Post-Operative Atrial Dysrhythmias after Lung Transplantation, C.L. Lau,² E.P. Trulock,¹ T.J. Guthrie,² A.A. Aloush,² B.F. Meyers,² R. Hachem,¹ G.A. Patterson,² M.M. Chakinala,¹ ¹Internal Medicine, Washington University School of Medicine, St. Louis, MO; ²Surgery, Washington University School of Medicine, St. Louis, MO

Clinical Lung/Heart-Lung Transplantation

(151) Predictive Value of the 6-Minute Walk Test in Lung Transplant Outcomes, J. L'Abbe,¹ M. Loadman Joyce,¹ S. Lau,¹ M. Bentley,¹ D. Lien,¹ ¹Transplant Services, University of Alberta Hospital, Edmonton, AB, Canada

(152) Single Centre Prognostic Modelling of Cystic Fibrosis Patients Referred for Lung Transplantation, A. De Soya, J.H. Dark, P.A. Corris, Transplantation and Immunobiology Group, University of Newcastle, Newcastle, Tyne and Wear, United Kingdom; Cardiothoracic Surgery, Freeman Hospital, Newcastle, Tyne and Wear, United Kingdom

(153) Impact of Cystic Fibrosis-Related Diabetes (CFRD) on Lung Transplant Outcomes, M.R. Zamora,¹ L.B. Edwards,² D. Weill,¹ T.L. Astor,¹ M.R. Nicolls,¹ ¹Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO; ²The United Network for Organ Sharing, Richmond, VA

(154) Anaemia in Lung Transplant Recipients. Effect on Health Related Quality of Life, D. Swarbrick,¹ P.A. Corris,^{1,2} ¹Immunobiology and Transplantation Research Group, University of Newcastle, Newcastle upon Tyne, United Kingdom; ²Cardiopulmonary Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom

(155) Cardiopulmonary Bypass, Controlled Reperfusion and C-1 Esterase Inhibitor Prevent Reperfusion Injury in Clinical Lung Transplantation, M. Kamler,¹ U. Herold,¹ A. Krapivski,¹ I. Aleksic,¹ R. Ragette,² S. Hagl,³ H. Jakob,¹ ¹Thoracic and Cardiovascular Surgery, University of Essen, Essen,

Germany; ²Pneumology, University of Essen, Essen, Germany; ³Cardiac Surgery, University of Heidelberg, Heidelberg, Germany

(156) Long-Term Use of Inhaled Iloprost in Candidates Awaiting Heart- Heart-Lung- and Lung-Transplantation: Clinical Improvement and Reduced Pulmonary Pressure and Resistance, U. Schulz, ¹G. Tenderich, ¹S. Schulte-Eistrup, ¹R. Koerfer, ¹K. Minami, ¹Thoracic and CardioVascular Surgery, Heart Center NRW, Bad Oeynhausen, NRW, Germany

(157) Long Term Outcome after Single and Bilateral Lung Transplantation for End-Stage Pulmonary Hypertension, M. de Perrot, ¹Y. Shargall, ¹T.K. Waddell, ¹J. Granton, ¹K. McRae, ¹A.F. Pierre, ¹F. D'Ovidio, ¹S. Chernenko, ¹L.G. Singer, ¹M. Hutcheon, ¹S. Keshavjee, ¹Toronto Lung Transplant Program, Toronto General Hospital, Toronto, ON, Canada

(158) Hypogammaglobulinemia after Lung Transplantation, L. Shah, ¹S.M. Kawut, ¹J.S. Wilt, ¹M.K. O'Shea, ²J.R. Sonett, ²S.M. Arcasoy, ¹Lung Transplant Program, Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University College of Physicians and Surgeons, New York, NY; ²Lung Transplant Program, Department of Surgery, Columbia University College of Physicians and Surgeons, New York, NY

(159) Initial Experience with Oral Valgancyclovir for Pre-Emptive Cytomegalovirus Therapy after Lung Transplantation, C. Aigner, ¹P. Jaksch, ¹G. Winkler, ¹C. Czebe, ¹E. Devyatko, ¹S. Taghavi, ¹W. Wisser, ¹W. Klepetko, ¹Department of Cardiothoracic Surgery, Vienna University, Vienna, Austria

(160) A Controlled Trial of Exercise Rehabilitation after Lung Transplantation, U. Tegtbur, ¹E. Guetzlaff, ¹J. Niedermeyer, ²K. Pethig, ³G. Warnecke, ⁴C. Kugler, ⁴M. Strueber, ⁴M.W. Busse, ⁵A. Haverich, ⁴Sportsmedicine, Hannover Medical School, Hannover, Germany; ²Respiratory Medicine, Hannover Medical School, Hannover, Germany; ³Internal Medicine, University of Jena, Jena, Germany; ⁴Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany; ⁵Sportsmedicine, University of Leipzig, Leipzig, Germany

(161) A Donor History of Smoking Affects Early but Not Late Outcome from Lung Transplantation (LTx): A 7-Year Single Centre Experience, T. Oto, ¹A. Griffiths, ¹B. Levvey, ¹D. Pilcher, ¹H. Whitford, ¹M. Rabinov, ¹D. Esmore, ¹T. Williams, ¹G. Snell, ¹Heart & Lung Transplant Unit, The Alfred Hospital, Monash University, Melbourne, VIC, Australia

(162) Function and Bulk of Respiratory and Limb Muscles after Lung Transplantation for Cystic Fibrosis, M. Estenne, ¹C. Pinet, ¹P. Scillia, ²M. Cassart, ²M. Lamotte, ³C. Knoop, ¹C. Mélot, ⁴Chest Service, Erasme University Hospital, Brussels, Belgium; ²Department of Radiology, Erasme University Hospital, Brussels, Belgium; ³Department of Physiotherapy, Erasme University Hospital, Brussels, Belgium; ⁴Department of Intensive Care Medicine, Erasme University Hospital, Brussels, Belgium

Heart Transplantation

(163) Ventilatory Efficiency Is Improved in Cardiac Transplant Recipients Following 12 Weeks of Combined Aerobic and Strength Training, N.D. Eves, ¹M.J. Haykowsky, ¹L. Figgures, ¹W.J. Tymchak, ²Faculty of Rehabilitation Medicine, University of Alberta, Edmonton, AB, Canada; ²Faculty of Medicine, University of Alberta, Edmonton, AB, Canada

(164) Correlation between TGF- β Genotypes and Acute and Chronic Rejection in Cardiac Transplant Recipients, R.L. Benza, ¹J.P. Barchue, ¹H.E. Grenett, ¹C.S. Coffey, ²J.A. Tallaj, ¹B.K. Rayburn, ¹L.J. Pinderski, ¹S.V. Pambokian, ¹D.C. McGiffin, ³J.K. Kirklin, ³R.C. Bourge, ¹Medicine, University of Alabama at Birmingham, Birmingham, AL; ²Biostatistics, University of Alabama at Birmingham, Birmingham, AL; ³Surgery, University of Alabama at Birmingham, Birmingham, AL

(165) The Value of B-Type Natriuretic Peptide in Predicting Allograft Rejection in Cardiac

Transplant Recipients, F.M. Bader,¹ E.M. Gilbert,¹ C.R. Tuttle,² S.S. Schmitz,² B.D. Horne,² S.A. Moore,² D.G. Renlund,² ¹Cardiology- Heart Failure and Transplant, University of Utah School of Medicine, Salt Lake City, UT; ²Cardiology- Heart Failure and Transplant, LDS Hospital, Salt Lake City, UT

(166) N-Terminal Brain Natriuretic Peptide Can Help To Identify Patients with a Poorer Outcome Following Cardiac Transplantation, R.S. Gardner,¹ F. Ozalp,¹ C. Payne,¹ A.J. Murday,¹ T.A. McDonagh,² ¹Scottish Cardiopulmonary Transplant Unit, Glasgow Royal Infirmary, Glasgow, United Kingdom; ²Department of Cardiology, University of Glasgow, Glasgow, United Kingdom

(167) Determinants of B-Type Natriuretic Peptide Plasma Levels in the Chronic Phase after Heart Transplantation, R. Klingenberg,¹ A. Koch,² Ph.A. Schnabel,³ C. Gleissner,¹ A. Remppis,¹ H.A. Katus,¹ T.J. Dengler,¹ ¹Cardiology, University Hospital Heidelberg, Heidelberg, Germany; ²Cardiothoracic Surgery, University Hospital Heidelberg, Heidelberg, Germany; ³Pathology, University Hospital Heidelberg, Heidelberg, Germany

(168) Improvement of Survival and Review of Causes of Death after Heart Transplantation: The Stanford Experience 1980-1997, S.-Z. Gao,¹ B. Cantin,¹ M. Perloth,¹ M. Pham,¹ S. Hunt,¹ P. Oyer,¹ J. Schroeder,¹ ¹Cardiology, Stanford University School of Medicine, Stanford, CA

(169) Etiology of Low Voltage of QRS Complex after Heart Transplantation, G. Cui,¹ J. Kobashigawa,¹ L. Sen,¹ ¹Medicine/Cardiology, UCLA School of Medicine, Los Angeles, CA

(170) Is Oral Treatment of CMV-Infections with Valganciclovir after Heart Transplantation Sufficient?, M. Mueller,¹ B. Meiser,¹ J. Groetzner,¹ I. Kaczmarek,¹ B. Reichart,¹ ¹Department of Cardial Surgery, Ludwig-Maximilians-University, Munich, Bavaria, Germany

Basic Science and Immunobiology

(171) Localized Combinatorial IL-4 and IL-10 Gene Therapy Readjusts the Balance of Endogenous Th1/Th2 Cytokines and Induces the Tolerance of the Cardiac Allografts, H. Furukawa,¹ K. Oshima,¹ T. Tung,¹ H. Russell,¹ G. Cui,^{1&2} H. Laks,¹ L. Sen,^{1&2} ¹Surgery/Cardiothoracic Surgery, UCLA Medical Center/UCLA School of Medicine, Los Angeles, CA; ²Medicine/Cardiology, UCLA Medical Center/UCLA School of Medicine, Los Angeles, CA

(172) The Efficacy of Cardiomyocyte Transplantation Is Enhanced by Epicardial Application of Control-Released Hepatocyte Growth Factor in Infarcted Hearts, K. Tambara,¹ G.U. Premaratne,¹ Y. Sakakibara,¹ H. Nakajima,¹ N. Kanemitsu,¹ M. Yamamoto,² M. Ozeki,² Y. Tabata,² M. Komeda,¹ ¹Department of Cardiovascular Surgery, Kyoto University, Kyoto, Kyoto, Japan; ²Department of Biomaterials, Kyoto University, Kyoto, Kyoto, Japan

(173) Inhibition of NF- κ B by I κ B Super Repressor Gene Transfer Ameliorates Ischemia-Reperfusion Injury after Experimental Lung Transplantation, T. Ishiyama,¹ S. Dharmarajan,¹ M. Hayama,¹ G.A. Patterson,¹ ¹Surgery, Washington University School of Medicine, Saint Louis, MO

(174) The Relative Importance of the Direct and Indirect Allogeneic Presentation Pathways during Early and Late Clinical Cardiac Rejection, N.M. van Besouw,¹ J.M. Zuijderwijk,¹ A.H.M.M. Balk,² L.P.W.M. Maat,³ P.H. van der Meide,⁴ L.M.B. Vaessen,¹ W. Weimar,¹ ¹Internal Medicine - Transplantation, Erasmus Medical Center Rotterdam, Rotterdam, ZH, Netherlands; ²Cardiology, Erasmus Medical Center Rotterdam, Rotterdam, ZH, Netherlands; ³Thoracic Surgery, Erasmus Medical Center Rotterdam, Rotterdam, ZH, Netherlands; ⁴Cytokine Biology Unit - CLAI, Utrecht University, Utrecht, Utrecht, Netherlands

(175) The Role of P38 in Obliterative Airway Disease in Rats; A.S. Farivar,¹ S.M. Woolley,¹ M.S. Mulligan,¹ ¹Cardiothoracic Surgery, University of Washington Medical Center, Seattle, WA

(176) Adenoviral Overexpression of Human BCL-2 in Donor Rodent Lung Allografts Reduces Ischemia/Reperfusion Injury and Improves Post-Transplant Lung Function, D.T. Cooke,¹ J.I. Pearl,¹ M. Tanaka,¹ J. Cole,¹ E.G. Hoyt,¹ R.C. Robbins,¹ ¹Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA

(177) MHC-I Expression on Donor Allogeneic Embryonic Stem Cells Transplanted for Myocardial Repair Correlates with Indices of Differentiation, T. Kofidis,¹ J.L. de Bruin,¹ R.-J. Swijnenburg,¹ D.R. Lebl,¹ D.T. Cooke,¹ M. Tanaka,¹ R.C. Robbins,¹ ¹Cardiothoracic Surgery/Falk Research Center, Stanford University Medical School, Stanford, CA

(178) Stimulation of Paracrine Pathways Enhances Embryonic Stem Cell Engraftment and Differentiation in the Injured Heart, J.L. de Bruin,¹ T. Kofidis,¹ T. Yamane,² M. Tanaka,¹ I.L. Weissman,² R.C. Robbins,¹ ¹Cardiothoracic Surgery/Falk Research Center, Stanford University Medical School, Stanford, CA; ²Department of Immunology, Stanford University Medical School, Stanford, CA

(179) Cytokine Gene Expression Profile in Myocardial Infarction and the Cardioprotective Effect of Des-Aspartate-Angiotensin-I (DAA-I), R.A. Jalil,¹ H.Kh. Haider,² S. Jiang,³ L. Ye,¹ N.M. Idris,¹ P.Z. Ding,³ K.M. Sim,⁴ E.K.W. Sim,¹ ¹Cardiothoracic Surgery, National University of Singapore, Singapore; ²National University Medical Institutes, National University of Singapore, Singapore; ³National Heart Centre, Singapore General Hospital, Singapore; ⁴Department of Pharmacology, National University of Singapore, Singapore

(180) In Vitro Functional Assessment of Human Skeletal Myoblast after Transduction with Adenoviral Bicistronic Vector Carrying Human VEGF₁₆₅ and ANG-1, L. Ye,¹ H.Kh. Haider,² R. Ge,³ P.K. Law,⁴ N.M. Idris,¹ R.A. Jalil,¹ S. Aziz,⁵ E.K.W. Sim,¹ ¹Cardiothoracic Surgery, National University of Singapore, Singapore; ²National University Medical Institutes, National University of Singapore, Singapore; ³Department of Biological Sciences, National University of Singapore, Singapore; ⁴Cell Transplants Inc., Singapore, Singapore; ⁵Washington Adventist Hospital, Washington, DC

Mechanical and Circulatory Support

(181) First Clinical Experience with the Incor LVAD, C. Schmid,¹ T. Tjan,¹ C. Etz,¹ C. Schmidt,² F. Janssen,¹ M. Rothenburger,¹ H.H. Scheld,¹ ¹Thoracic and Cardiovascular Surgery, University Hospital Muenster, Muenster, NRW, Germany; ²Anesthesia and Operative Intensive Care, University Hospital Muenster, Muenster, NRW, Germany

(182) Recent Trends in Biventricular Mechanical Circulatory Support, D.J. Farrar,¹ R.L. Kormos,² S.H. Reichenbach,¹ J.D. Hill,³ ¹Research and Development, Thoratec Corporation, Pleasanton, CA; ²Surgery, University of Pittsburgh, Pittsburgh, PA; ³Surgery, University of California, San Francisco, San Francisco, CA

(183) Improved Heart Transplant Survival in Patients Bridged with Ventricular Assist Device, M.C.Y. Chan,¹ S. Moffatt,² E.S. Shao,¹ B. Cantin,¹ M. Pelletier,² P. Oyer,² R.C. Robbins,² S.A. Hunt,¹ ¹Cardiovascular Medicine, Stanford University, Stanford, CA; ²Cardiothoracic Surgery, Stanford University, Stanford, CA

(184) Short and Long Term LVAD Use Decreases Pulmonary Vascular Resistance, D.B. Dyke,¹ E. Batts,³ A. Wu,¹ T. Koelling,¹ S. Wright,¹ F.D. Pagani,² ¹Division of Cardiology, University of Michigan Health System, Ann Arbor, MI; ²Department of Cardiac Surgery, University of Michigan Health System, Ann Arbor, MI; ³Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI

(185) Body Mass Index and Outcomes after Left Ventricular Assist Device Placement, J. Butler,¹ R.L. Howser,² P.M. Portner,³ R.N. Pierson III,⁴ ¹Division of Cardiology, Vanderbilt University Medical Center, Nashville, TN; ²World Heart Inc., Oakland, CA; ³Department of Cardiothoracic Surgery, Stanford University, Stanford, CA; ⁴Division of Cardiac Surgery, University of Maryland Medical Center, Baltimore,

MD

(186) Aortic Valve Insufficiency Prior to LVAD Reduces Survival To Transplant: The Temple University Experience, E.D. Feller,¹ D. Gupta,² A.A. Bove,¹ H.J. Eisen,¹ M. Macha,² S. Furukawa,² G.O. Berman,¹ ¹Department of Cardiology, Temple University, Philadelphia, Pennsylvania; ²Department of Cardiothoracic Surgery, Temple University, Philadelphia, Pennsylvania

(187) Incidence and Clinical Management of Life-Threatening Left Ventricular Assist Device (LVAD) Failure, E.J. Birks, C.T. Bowles, M. Hipkin, J. Hardy, N.R. Banner, M.H. Yacoub, A. Khaghani, Transplant Unit, Royal Brompton and Harefield Hospital, Harefield, Middlesex, United Kingdom

(188) Changes in Collagen Fractions of the Myocardium Induced by Mechanical Unloading of the Left Ventricle, J. Mueller, H. Liang, G. Wallukat, Y. Weng, R. Hetzer, Cardiac Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

(189) Left Ventricular Recovery Following Support with Left Ventricular Assist Device, M.M. Colvin-Adams,¹ S. Park,² J. Thompson,² A. Boyle,¹ S. Ormaza,² K. Liao,² L.W. Miller,¹ ¹Cardiology, University of Minnesota, Minneapolis, MN; ²Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN

(190) Total Artificial Heart CardioWest in Small Patients, P. Leprince,¹ A. Pavie,¹ Ph. Leger,¹ N. Bonnet,¹ E. Vaissier,¹ J.P. Levasseur,¹ V. Bors,¹ I. Gandjbakhch,¹ ¹CT Surgery, Pitie Salpetriere Hospital, Paris, France

6:00 PM – 7:00 PM

Nursing and Social Sciences Scientific Council Meeting (Grand Ballroom B)

Pathology and Basic Science Scientific Council Meeting (Plaza A)

Pediatric Scientific Council Meeting (Union Square 21)

Pulmonary Hypertension Scientific Council Meeting (Plaza B)

6:30 PM-7:30 PM

Poster Display Session 1 Tear-Down (Franciscan/Yosemite)

7:00 PM-8:00 PM

Corporate Council Reception (President's Suite)

6:30 PM-9:00 PM

SATELLITE SYMPOSIUM 9 (Imperial)

Challenges and Solutions for Improving Outcomes in Lung Transplant

Supported by an educational grant from Chiron

Moderators: Hermann Reichenspurner, MD and Duane Davis, MD

6:30 PM Dinner Reception

7:15 PM Welcoming Remarks

7:20 PM A Historical Odyssey of Lung Transplantation: Challenges Overcome and Challenges To Come, Hermann Reichenspurner, MD, University Hospital Eppendorf, Hamburg, Germany

7:40 PM Surgical Issues in Lung Transplantation, Duane Davis, MD, Duke University Medical Center, Durham, NC

8:00 PM Current Issues in Lung Transplantation: Immunological Basis of Rejection, Adrianna Zeevi, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA

8:20 PM Emerging Strategies in Lung Transplantation, Marshall I. Hertz, MD, University of Minnesota, Minneapolis, MN

8:35 PM Panel Discussion

FRIDAY, APRIL 23, 2004

7:00 AM-8:00 AM

Transplant Registry Meeting (Imperial)

7:00 AM-8:00 AM

Morning Coffee (Grand Ballroom A)

7:00 AM-10:00 AM

Poster Display Session 2 Set-Up (Franciscan/Yosemite)

7:00 AM-4:30 PM

Exhibits Open (Grand Ballroom A)

7:00 AM-5:30 PM

Speaker Ready Room (Green Room)

7:00 AM-6:30 PM

Registration Desk Open (Yosemite)

7:00 AM – 6:30 PM

Exhibits Open (Yosemite)

7:55 AM-10:00 AM

PLENARY SESSION: Late Breaking Clinical Trials in Heart Transplantation

(Grand Ballroom B)

Moderators: Sharon Hunt, MD and Robert C. Bourge, MD

7:55 AM Welcome and Introductions

8:00 AM (191) A Randomized, Prospective, Multi-Center Comparison of Tacrolimus, Mycophenolate Mofetil (MMF) and Steroids vs. Cyclosporine (Modified USP), MMF and Steroids vs Tacrolimus, Sirolimus and Steroids in De Novo Cardiac Transplant Recipients - 6 Month Report.

J.A. Kobashigawa,¹ L. Miller,² S. Russell,³ G. Ewald,⁴ M. Zucker,⁵ L. Goldberg,⁶ H. Eisen,⁷ D. Toltzman,⁸ W.E. Fitzsimmons,⁸ ¹University of California at Los Angeles, Los Angeles, CA; ²University of Minnesota, Minneapolis, MN; ³Duke University, Durham, NC; ⁴Washington University, St. Louis, MO; ⁵Beth Israel Hospital, Newark, NJ; ⁶University of Pennsylvania, Philadelphia, PA; ⁷Temple University, Philadelphia, PA; ⁸Fujisawa Healthcare, Inc., Deerfield, IL

8:15 AM (192) Molecular Testing and Prediction of Clinical Outcome in Heart Transplantation: A Prospective Multicenter Trial.

M.R. Mehra,¹ J. Kobashigawa,² S. Hunt,⁴ H.J. Eisen,³ R. Starling,⁵ F.L.¹⁰ Johnson,⁶ S. Murali,⁷ A. Zeevi,⁷ D. Pauly,⁸ J.G. Wohlgemuth,⁹ M.S. Morris,⁹ R. Woodward,⁹ M.C. Deng,¹⁰ ¹Cardiovascular Diseases, Ochsner Clinic, New Orleans, LA; ²UCLA, Los Angeles, CA; ³Temple University, Philadelphia, PA; ⁴Stanford University, Stanford, CA; ⁵Cleveland Clinic, Cleveland, OH; ⁶Veterans Administration Medical Center, Palo Alto, CA; ⁷University of Pittsburgh, Pittsburgh, PA; ⁸University of Florida, Gainesville, FL; ⁹XDx, Inc., South San Francisco, CA; ¹⁰Columbia University, New York, NY,

8:30 AM (193) Sirolimus from the Time of Heart Transplantation - Persistent Protection from Graft Vasculopathy at 2 Years.

A. Keogh, D. Muller, S. Faddy, P. Ruygrok, M. Richardson, A. Galbraith, St Vincent's Hospital, Sydney, Australia; Green Lane Hospital, Auckland, New Zealand; The Alfred Hospital, Melbourne, Australia; Prince Charles Hospital, Brisbane, Australia

8:45 AM (194) The Effect of Etanercept on Cardiac Transplants.

G. Torre-Amione,^{1,2} J.B. Young,³ B. Radovancevic,⁴ M. Koerner,^{1,2} V. Thohan,^{1,2} R. Bogev,⁵ ¹Department of Medicine, Cardiology Section, Baylor College of Medicine, Houston, TX; ²The Methodist DeBakey Heart Center, The Methodist Hospital, Houston, TX; ³Kaufman Center for Heart Failure, The Cleveland Clinic Foundation, Cleveland, OH; ⁴Texas Heart Institute, St. Luke's Episcopal Hospital, Houston, TX; ⁵Transplant Section, Texas Transplant Institute, San Antonio, TX

9:00 AM (195) A 12-Month, Multicenter, Randomized, Adaptive Design, Open-Label Study To Evaluate the Benefit of C2 Hour Monitoring of Neoral on Safety and Efficacy Outcomes in De Novo Cardiac Transplant Recipients Receiving Basiliximab Induction.

M. Cantarovich,¹ H. Ross, J. Arizon,

J. Orus, L. Straatman, J. Howlett, E. Lage, M. Crespo, S. Wang, H. Haddad, L. Pulpon, I. Andres, W. Hauck, the Motown Study Group, ¹McGill University Health Center, Montreal, Qc, Canada

9:15 AM (196) Randomised Controlled Trial of C₀ Versus C₂ Guided Therapeutic Drug Monitoring of Cyclosporin-A in Stable Heart-Transplant Patients. F. Ozalp,¹ M.B. Will,¹ A.J. McLennan,¹ R.S. Gardner,¹ W. Borland,² T.A. McDonagh,¹ A.J. Murday,¹ ¹Scottish Cardiopulmonary Transplant Unit, Glasgow Royal Infirmary, North Glasgow University Hospitals NHS Trust, Glasgow, United Kingdom; ²Department of Biochemistry, Gartnavel General Hospital, North Glasgow University Hospitals NHS Trust, Glasgow, United Kingdom

9:30 AM ISHLT Lifetime Achievement Award Recipient Invited Lecture: From Transplantation to Regeneration and Back, Sir Magdi Yacoub, MD, Magdi Yacoub Institute, Heart Science Center, Harefield, Middlesex, United Kingdom

10:00 AM-10:30 AM

Coffee Break (Grand Ballroom A)

10:30 AM-NOON

CONCURRENT SESSION 13

Mechanical Circulatory Support 2: Issues of Extended Use of MCS: Preparing for the New Era of Destination Therapy

(Grand Ballroom B)

Moderators: Clifford H. Van Meter, Jr., MD and Aly El-Banayosy, MD

10:30 AM (197) Outpatients on Mechanical Circulatory Support: Experience with over 80 Patients; T.N.H. Drews,¹ M. Jurmann,¹ D. Kemper,¹ M. Pasic,¹ Y. Weng,¹ R. Hetzer,¹ ¹German Heart Institute Berlin, Augustenburger Platz 1, Berlin, Germany

10:45 AM (198) An Automatic Speed Adaptation System for Implantable Rotary Blood Pumps and Its Clinical Evaluation. H. Schima,^{1,2} M. Vollkron,¹ B. Benkowski,⁵ G. Morello,⁵ M. Quittan,³ M. Hiesmayr,⁴ E. Wolner,¹ G. Wieselthaler,¹ ¹Department of Cardiothoracic Surgery and LBI, University of Vienna, Austria; ²Department of Biomed. Eng., University of Vienna, Austria; ³Department of Physical Medicine, University of Vienna, Austria; ⁴Department of cardiovasc Anaesthesia, University of Vienna, Austria; ⁵Micromed Technology Inc, Houston, TX

11:00 AM (199) Right Ventricular Stroke Work Index (RVSWI) Predicts Duration of Inotropic Support after Left Ventricular Assist Device Implantation. S. Schenk,¹ P.M. McCarthy,¹ J. Feng,¹ K.J. Hoercher,¹ R.C. Starling,¹ J.B. Young,¹ L. Zhou,¹ J.L. Navia,¹ E.H. Blackstone,¹ K. Fukamachi,¹ ¹Biomedical Engineering, Cleveland Clinic Foundation, Cleveland, OH

11:15 AM (200) Development of Panel Reactive Antibodies Following Continuous Flow MicroMedeBakey VAD Implantation and Subsequent Effects on Allograft Rejection. W.K. Roethy,¹ C. Oezpeker,¹ H. Schima,¹ M. Grimm,¹ E. Wolner,¹ G. Wieselthaler,¹ ¹Department of Cardiothoracic Surgery & LBI, University of Vienna, Vienna, Austria

11:30 AM (201) Withdrawn

11:45 AM (202) Predictors of Survival with a Totally Implantable Left Ventricular Assist System (LVAS): The European Lionheart Clinical Utility Baseline Study (CUBS). W.E. Pae,¹ J.P. Boehmer,¹ R. Koerfer,² A. El-Banayosy,² R. Hetzer,³ M. Viganò,⁴ A. Pavie,⁵ for the CUBS Study Group, ¹Cardiothoracic Surgery and Cardiology, Penn State Milton S. Hershey Medical Center, Hershey, PA; ²Cardiothoracic Surgery and Cardiology, Penn State Milton S. Hershey Medical Center, Hershey, PA; ³Cardiothoracic Surgery, Bad Oeynhausen Heart Center, Bad Oeynhausen, Germany; ⁴Cardiothoracic Surgery, Bad Oeynhausen Heart Center, Bad Oeynhausen, Germany

10:30 AM-NOON

CONCURRENT SESSIONS 14

Post Transplant Complications 1: A Potpourri

(Imperial)

Moderators: Kate Gould, MB BS and Thomas Dengler, MD

10:30 AM (203) Mycophenolate Mofetil and the Risk of Developing Malignancy Following Orthotopic Heart Transplantation, J.O. O'Neill,¹ L.B. Edwards,¹ D.O. Taylor,¹ Registry of the International Society for Heart and Lung Transplantation

10:45 AM (204) Two Year Pre-Emptive Approach of Post Transplant Lymphoproliferative Disease after Lung Transplantation, E.A.M. Verschuuren,^{1,4} A. de Haan,² M. Erasmus,³ T.H. The,⁴ W. van der Bij,¹ Pulmonology, University Hospital Groningen, Groningen, Netherlands; ²Medical Biology, University Hospital Groningen, Groningen, Netherlands; ³Cardio-Thoracic Surgery, University Hospital Groningen, Groningen, Netherlands; ⁴Clinical Immunology, University Hospital Groningen, Groningen, Netherlands

11:00 AM (205) Role of Voriconazole Prophylaxis for the Prevention of Invasive Aspergillosis (IA) at Six Months in Lung Transplant Recipients, S. Husain,¹ D.B. Zaldonis,² E.J. Kwak,¹ K.R. McCurry,² ¹Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA; ²Division of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA

11:15 AM (206) Caspofungin (CSF) for Invasive Aspergillosis after Thoracic Organ Transplantation: First Experience in 10 Patients, J. Groetzner,¹ P. Landwehr,¹ I. Kaczmarek,¹ M. Mueller,¹ I. Adamidis,¹ M. Weis,¹ P. Ueberfuhr,¹ P. Lamm,¹ S. Daebritz,¹ B. Meiser,¹ B. Reichart,¹ ¹Department of Cardiac Surgery, Ludwig Maximilians University Hospital Grosshadern, Munich, Germany

11:30 AM (207) The Role of Hypogonadism on Bone Loss after Cardiac Transplantation: Is a Testosterone Replacement Therapy Necessary?, H.-U. Stempfle,¹ J. Stief,¹ P. Uberfuhr,² K. Theisen,¹ H.-Y. Sohn,¹ ¹Cardiology, Med.Poliklinik-Innenstadt, LMU, Munich, Germany; ²Cardiac Surgery, Klinikum Grosshadern, LMU, Munich, Germany

11:45 AM (208) Therapy To Prevent Osteoporosis May Be Discontinued One Year after Heart Transplantation in Patients with Normal Bone Density, V. Addesso,¹ A. Cohen,¹ D.J. McMahon,¹ S. Maybaum,¹ D. Mancini,¹ P.B. Namerow,¹ E. Shane,¹ ¹Medicine, Columbia University, New York, NY

10:30 AM-NOON

CONCURRENT SESSION 15

Evolution of Immunosuppressive Strategies

(Plaza)

Moderators: Michael Schmoeckel, MD and Richard N. Pierson, III, MD

10:30 AM (209) Results of a Tolerance-Enhancing Protocol in Human Lung Transplantation, K.R. McCurry,¹ A. Zeevi,^{1,2} D.B. Zaldonis,¹ A. Bertani,¹ K. Spichy,² K. McDade,² A. Jacono,³ S.A. Yousem,² T.E. Starzl,¹ ¹Department of Surgery, University of Pittsburgh, Pittsburgh, PA; ²Department of Pathology, University of Pittsburgh, Pittsburgh, PA; ³Division of Pulmonary, University of Pittsburgh, Pittsburgh, PA

10:45 AM (210) Final Results of the Study of Safety and Tolerability of Simulect® (Basiliximab) Versus OKT3 in Heart Transplantation, J.L. Rodríguez Lambert,¹ M.G. Crespo Leiro,² J. Segovia,³ L. Almenar,⁴ E. Roig,⁵ M.A. Gómez Sánchez,⁶ E. Lage,⁷ N. Manito,⁸ L.A. Pulpón,³ ¹Cardiology. Heart Transplantation, H. Central de Asturias, Oviedo, Spain; ²Cardiology. Heart Transplantation, H. Juan Canalejo, La Coruña, Spain; ³Cardiology. Heart Transplantation, H. Clínica Puerta de Hierro, Madrid, Spain; ⁴Cardiology. Heart Transplantation, H. La Fe, Valencia, Spain; ⁵Cardiology. Heart Transplantation, H. Clínica Provincial, Barcelona, Spain; ⁶Cardiology. Heart Transplantation, H. 12 de Octubre, Madrid, Spain; ⁷Cardiology. Heart Transplantation, H. Virgen del Rocío, Sevilla, Spain; ⁸Cardiology. Heart Transplantation, H. de Bellvitge, L'Hospitalet del Llobregat, Barcelona, Spain

11:00 AM (211) Comparison of Basiliximab and Antithymocyte Globulin as Induction Agents after Lung Transplantation, R.R. Hachem,¹ G.A. Patterson,² E.P. Trulock,¹ ¹Pulmonary Division, Washington University School of Medicine, St. Louis, MO; ²Thoracic Surgery, Washington University School of Medicine, St. Louis, MO

11:15 AM (212) Comparison of Sirolimus Versus Azathioprine in a Tacrolimus Based Immunosuppressive Regimen in Lung Transplantation, S.M. Bhorade,¹ V. Ahya,² R. Kotloff,² M. Baz,³ V. Valentine,⁴ S. Arcasoy,⁵ R. Love,⁶ R. Young,⁷ W.T. Vigneswaran,¹ E.R. Garrity,¹ ¹Medicine, Loyola University Medical Center, Maywood, IL; ²Medicine, University of Pennsylvania Medical Center, Philadelphia, PA; ³Medicine, University of Florida, Gainesville, FL; ⁴Medicine, Ochsner Transplant Center, New Orleans, LA; ⁵Medicine, Columbia University, New York, NY; ⁶Thoracic/ Cardiovascular Surgery, University of Wisconsin, Madison, WI; ⁷Medicine, University of Alabama, Birmingham, AL

11:30 AM (213) Conversion to Sirolimus Lessens Renal Dysfunction in Heart Transplant (HTx)

Patients, J. Hunt,¹ M. Lerman,¹ T. Dewey,¹ M. Magee,¹ M. Mack,¹ ¹Transplant Center, Medical City Dallas Hospital, Dallas, TX

11:45 AM (214) Cyclosporin C2 Levels Determine Rejection Rates after Lung Transplantation; A.R. Glanville,¹ C.L. Aboyou,¹ J. Morton,¹ M. Plit,¹ M.A. Malouf,¹ ¹The Lung Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia

NOON-12:15 PM

ANNUAL BUSINESS MEETING (Members only) (Grand Ballroom B)

NOON – 1:30 PM

ISHLT Editorial Board Meeting (Union Square 23/24)

12:30 PM-2:00 PM

LUNCHEON SYMPOSIUM: Immunosuppression in the Young and Old: More Similar Than Different?

(Imperial)

Supported by an educational grant from Fujisawa

Moderators: Bruno M. Meiser, MD and Linda J. Addonizio, MD

12:30 PM Long Term Outcomes with Calcineurin Inhibitor Immunotherapy in Adult Heart Transplantation, Jon Kobashigawa, MD, University of California at Los Angeles, Los Angeles, CA

12:50 PM Long Term Outcomes with Calcineurin Inhibitors in Pediatric Heart Transplantation,

Steven A. Webber, MD, Children's Hospital of Pittsburgh, Pittsburgh, PA

1:10 PM Modified Immunosuppression in the Elderly Lung Transplant Recipient, Andreas

Zuckerman, MD, University of Vienna, Vienna, Austria

1:30 pm Panel Discussion

2:00 PM-3:30 PM

CONCURRENT SESSION 16

Clinical Heart Transplantation 2: Miscellaneous

(Grand Ballroom B)

Moderators: Jayan Parameshwar, MD and Myung Park, MD

2:00 PM (215) Preferential Depletion of Myeloid Type Peripheral Blood Dendritic Cells during Acute Rejection of Human Heart Allografts, P. Athanassopoulos,¹ L.M.B. Vaessen,² A.H.M.M. Balk,³ A.P.W.M. Maat,¹ A.J.J.C. Bogers,¹ W. Weimar,² ¹Cardiothoracic Surgery; ²Internal Medicine; ³Cardiology, Erasmus MC, Rotterdam, Netherlands

2:15 PM (216) Prophylactic Suture Annuloplasty of the Tricuspid Valve During Orthotopic Heart Transplantation (OHT) – Intermediate Results of a Randomized Clinical Trial, V. Jeevanandam, P. Mather,² H. Russell,¹ S. Furokawa,² J. Raman,¹ ¹Cardiac & Thoracic Surgery, University of Chicago Medical Center, Chicago, IL; ²Cardiac & Thoracic Surgery, Temple University, Philadelphia, PA

2:30 PM (217) Simvastatin Decreases Myocardial Tumor Necrosis Factor- α Content in Heart Transplant Recipients, C.K. Wallace,⁶ S.J. Stetson,^{1,3,4,5} S.A. Kucuker,² K.A. Becker,^{1,3,4,5} J.A. Farmer,^{1,3} S.C. McRee,^{1,3,4,5} M.M. Koerner,^{1,3,4,5} G.P. Noon,² G. Torre-Amione,^{1,3,4,5} ¹The Methodist DeBakey Heart Center, The Methodist Hospital, Houston, TX; ²The M.E. DeBakey Department of Surgery, Division of Transplantation and Assist Devices, The Methodist Hospital, Houston, TX; ³Medicine (Section of Cardiology), Baylor College of Medicine, Houston, TX; ⁴The Gene and Judy Campbell Lab for Cardiac Transplantation, The Methodist Hospital, Houston, TX; ⁵The Winters Center for Heart Failure Research, The Methodist Hospital, Houston, TX; ⁶Baylor College of Medicine, Houston, TX

2:45 PM (218) 10-Year Results of the Pravastatin Randomized Trial in Heart Transplant Recipients, J.A. Kobashigawa,¹ J.D. Moriguchi,¹ G. Cogert,¹ A. Hage,¹ M.A. Hamilton,¹ M.E. Vassilakis,¹ A. Marquez,¹ L. Yeatman,¹ J. Patel,¹ H. Laks,¹ ¹Division of Cardiology, University of California at Los Angeles, Los Angeles, CA

3:00 PM (219) Negative Association between Blood Transfusions and Acute Cardiac Allograft Rejection, F.G. Fernandez,¹ A. Jaramillo,¹ G. Ewald,² J. Rogers,² M.K. Pasque,¹ T. Mohanakumar,¹ N.

Moazami,¹ ¹Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO;
²Cardiology, Washington University School of Medicine, St. Louis, MO

3:15 PM (220) The Success of the Urgent Heart Offering Schemes in the UK, F.M. Seeney,¹ J.H. Dark,² R.L. Potter,¹ J.C. Hussey,¹ C.J. Rudge,¹ ¹UK Transplant, Bristol, United Kingdom;
²Cardiopulmonary Transplantation, Freeman Hospital, Newcastle, United Kingdom

2:00 PM-3:30 PM

CONCURRENT SESSION 17

Lung/Heart-Lung Transplantation 3: Modifying Outcomes in Lung and Heart-Lung Transplantation (Imperial)

Moderators: John Dark, MD and Lianne G. Singer, MD

2:00 PM (221) Highly Efficient Reduction of Waiting List Mortality in Lung Transplantation, M. Strueber,¹ A.R. Simon,¹ G. Warnecke,¹ B. Gohrbandt,¹ S. Fischer,¹ J. Niedermeyer,² A. Haverich,¹ ¹Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Hannover, Germany; ²Department of Respiratory Medicine, Hannover Medical School, Hannover, Hannover, Germany

2:15 PM (222) Impact of Pulmonary Artery Pressure on Survival Following Lung Transplantation for Idiopathic Pulmonary Fibrosis, T.M. Whelan,² R.F. Kelly,¹ M.I. Hertz,² L.B. Edwards,³ P.S. Dahlberg,¹ ¹Cardiovascular and Thoracic Surgery, University of Minnesota, Minneapolis, MN; ²Pulmonary Medicine, University of Minnesota, Minneapolis, MN; ³Research, ISHLT, Addison, TX

2:30 PM (223) Procalcitonin and Modified SOFA Score: The Best Predictors of Mortality after Heart and Lung Transplantation, N. Qedra,¹ F.D. Wagner,¹ B. Jonitz,¹ K. Wegscheider,² S. Buz,¹ M. Loebe,³ R. Hetzer,¹ ¹Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Berlin, Germany; ²Department of Biometrics and Statistics, Department of Biometrics and Statistics, Hamburg, Hamburg, Germany; ³Michael E. DeBakey Department of Surgery, Division of Transplantation and Assist Devices, Baylor College of Medicine, Houston, TX

2:45 PM (224) Primary Graft Failure Is Associated with Increased Long-Term Mortality Following Lung Transplantation Independent of Development of BOS, J.D. Christie,^{1,3} V.N. Ahya,¹ A. Pochettino,² C. Gaughan,³ S.E. Kimmel,³ R.M. Kotloff,¹ ¹Pulmonary and Critical Care Medicine; ²Thoracic Surgery; ³Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA

3:00 PM (225) Effect of Renal Replacement Therapy on Pulmonary Mechanics in Lung Transplantation, V.G. Valentine,¹ L. Seoane,¹ D.M. Fuchs,¹ M.T. Knowler,¹ G.S. Dhillon,¹ D.E. Taylor,¹ ¹Lung Transplantation, Ochsner Clinic Foundation, New Orleans, LA

3:15 PM (226) Outcome of Heart-Lung and Bilateral-Sequential Single Lung Transplantation for Cystic Fibrosis: A UK National Study, J.S. Ganesh,¹ C.A. Rogers,¹ R.S. Bonser,¹ N.R. Banner,¹ ¹On Behalf of the Steering Group, UK Cardiothoracic Transplant Audit, Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom

2:00 PM-3:30 PM

CONCURRENT SESSION 18

Clinical Heart Failure 2: Advanced Heart Failure Management, Prognostication and Heart Transplant Outcome

(Plaza)

Moderators: William T. Abraham, MD and Adrian B. VanBakel, MD, PhD

2:00 PM (227) Development and Validation of a Model To Predict Perioperative Mortality Following Heart Transplantation in the UK; J.S. Ganesh,¹ C.A. Rogers,¹ N.R. Banner,¹ R.S. Bonser,¹ ¹On Behalf of the Steering Group, UK Cardiothoracic Transplant Audit, Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom

2:15 PM (228) Renal Dysfunction Is More Likely in Recipients Bridged to Heart Transplantation with Inotropes Than with Left Ventricular Assist Devices: An Analysis of Pre-Transplant Characteristics in the Modern Era; S.G. Drakos,¹ E.M. Gilbert,¹ S.A. Moore,¹ J.C. Stringham,¹ E.H. Hammond,¹ J.W. Long,¹ T.C. Fuller,¹ J.W. Kent,¹ D.A. Bull,¹ S.S. Schmitz,¹ M.E. Hagan,¹ B.A. Campbell,¹ J.W. Folsom,¹ L.A. Stamos,¹ B.D. Horne,¹ D.G. Renlund,¹ ¹Utah Transplantation Affiliated Hospitals (UTAH) Cardiac Transplant Program, LDS Hospital, University of Utah School of Medicine and Veterans

Affairs Medical Center, Salt Lake City, UT

2:30 PM (229) Impact of Body Mass Index on Survival Following Heart Transplantation, J. Jimenez,¹ L. Edwards,³ J. Jara,¹ B. Bednard,¹ S. Pham,² S. Mallon,¹ Medicine, University of Miami, Jackson Memorial Med. Ctr., Miami, FL; ²Surgery, University of Miami, Jackson Memorial Med. Ctr., Miami, FL; ³Research, United Network Organ Sharing, Richmond, VA

2:45 PM (230) Sildenafil Is Effective and Safe in Reversing Pulmonary Hypertension in Advanced Heart Failure, J. Alaeddini, P.A. Uber, M.H. Park, R.L. Scott, H.O. Ventura, M.R. Mehra, Ochsner Clinic Foundation, New Orleans, LA

3:00 PM (231) Nesiritide Serial Outpatient Infusions over 12 Weeks Show Trends towards Improved Left Ventricular Systolic Function Compared to "Standard" Therapy, M.T. Saltzberg,¹ A.J. Neumann,¹ D.P. Horton,² ¹Midwest Heart Foundation, Downers Grove, IL; ²Scios, Inc, Sunnyvale, CA

3:15 PM (232) Waiting List Survival and Cardiac Transplant Outcome of Patients Supported on Left Ventricular Assist Device vs. Inotropic Support: Comparison of Two Eras, A. Zuckermann,¹ A. Bodhjaljan,¹ D. Dunkler,¹ G. Wieselthaler,¹ A. Mühlbauer,¹ W. Röthy,¹ R. Pacher,² M. Hülsmann,² E. Wolner,¹ M. Grimm,¹ ¹Department of Cardiothoracic Surgery, University of Vienna, Vienna, Vienna, Austria; ²Department of Cardiology, University of Vienna, Vienna, Vienna, Austria

3:30 PM-4:00 PM

Coffee Break (Grand Ballroom A)

4:00 PM-5:30 PM

CONCURRENT SESSION 19

Aristotle's Corner

(Grand Ballroom B)

Moderators: John Wallwork, FRCP and Mandeep R. Mehra, MD

4:05 PM (233) Clinton Redux: It's the Malignancy, Stupid!, P.J. Hauptman,¹ ¹Division of Cardiology, Saint Louis University School of Medicine, St. Louis, MO

4:23 PM (234) Xenotransplantation: A New Darwinian Advantage?, Z.I. Khalpey,¹ J.L. Platt,¹ ¹Transplant Biology and the Depts of Surgery, Immunology & Pediatrics, Mayo Clinic, Rochester, MN

4:41 PM (235) The Lazarus Syndrome and the Cult of the Superman, A.R. Glanville,¹ ¹The Lung Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia

4:54 PM (236) Transplant Rejection: Vertebrate Animals' Programmed Maintenance of Internal Dynamic Molecular Architecture, O.E. Pajaro,¹ ¹Cardiothoracic Surgery, Mayo Clinic, Jacksonville, FL

5:12 PM (237) Why Left Ventricular Assist Devices Are Not yet a Product That Has Matured to the Tornado Phase of the Market: Or Why Aren't We Using More LVAD's?, R.L. Kormos,¹ ¹Cardiothoracic Transplant Surgery, University of Pittsburgh, Pittsburgh, PA

4:00 PM-5:30 PM

CONCURRENT SESSION 20

Pathology: New Developments in Heart Transplant Pathology

(Imperial)

Moderators: Susan Stewart, FRCPath and Michael C. Fishbein, MD

4:00 PM (238) C4d Staining of Cardiac Allografts Correlates with Alloantibody, R.N. Smith,¹ N. Brousades,¹ S. Saidman,¹ A.B. Collins,¹ ¹Pathology, Massachusetts General Hospital, Boston, MA

4:15 PM (239) Detection of Vimentin Specific Autoreactive CD8+T Cells in Cardiac Transplant Patients, L.D. Barber,¹ A. Whitelegg,¹ J.A. Madrigal,¹ N.R. Banner,² M.L. Rose,³ ¹Royal Free Hospital, Anthony Nolan Research Institute, London, United Kingdom; ²Transplant Medicine, Harefield Hospital, Harefield, Middlesex, United Kingdom; ³National Heart and Lung Institute, Imperial College, Harefield, Middlesex, United Kingdom

4:30 PM (240) C-Reactive Protein and Development of a Prothrombogenic Microvasculature in Heart Transplant Recipients, C.A. Labarrere, H.L. DiCarlo, M.A. Ortiz, C. Terry, D.E. Pitts, D.A. Hormuth, Methodist Research Institute, Clarian Health Transplant Center, Clarian Health Partners, Inc., Indianapolis, IN

4:45 PM (241) Acute Cellular Rejection after Human Heart Transplantation Is Associated with ICOS+ Graft-Infiltrating T Lymphocytes and Increased Endothelial Expression of Inducible Costimulator Ligand (ICOSL), R. Klingenberg,¹ F. Autschbach,² C. Gleissner,¹ A. Koch,³ Ph.A. Schnabel,² G. Richter,⁴ H.A. Katus,¹ T.J. Dengler,¹ ¹Cardiology, University Hospital Heidelberg, Heidelberg, Germany; ²Pathology, University Hospital Heidelberg, Heidelberg, Germany; ³Cardiothoracic Surgery, University Hospital Heidelberg, Heidelberg, Germany; ⁴Pediatrics, University Hospital Halle, Halle, Germany

5:00 PM (242) Recipient Origin Cardiomyocytes in Endomyocardial Biopsies of Human Transplanted Hearts, A. Angelini,¹ C. Castellani,¹ M. Della Barbera,¹ M. Valente,¹ A. Gambino,² A.L. Caforio,³ G. Gerosa,² G. Thiene,¹ ¹Institute of Pathological Anatomy, University of Padua, Padua, Italy; ²Department of Cardiovascular Surgery, University of Padua, Padua, Italy; ³Department of Cardiology, University of Padua, Padua, Italy

5:15 PM (243) The Effect of Immunosuppression on Bone Marrow-Derived Recipient Cells in Murine Cardiac Allografts, N. Rezaei,¹ A. Kerjner,¹ S. Corbel,² F.M.V. Rossi,² B.M. McManus,¹ T.J. Podor,¹ ¹Pathology and Laboratory Medicine, The iCAPTURE Centre, St. Paul's Hospital-University of British Columbia, Vancouver, B.C., Canada; ²Medical Genetics, Biomedical Research Centre/UBC, Vancouver, B.C., Canada

4:00 PM-5:30 PM

CONCURRENT SESSION 21

Basic Science and Immunobiology 2: Chronic Rejection: Basic Mechanisms

(Plaza)

Moderators: Bruce R. Rosengard, MD and George Tellides, MD

4:00 PM (244) Inhibition of the Receptor Kinase Activity of VEGF and PDGF Protects Against the Development of Cardiac Allograft Arteriosclerosis, A.I. Nykänen,¹ J.M. Tikkanen,¹ P.K. Koskinen,¹ K.B. Lemström,¹ ¹Cardiopulmonary Research Group of the Transplantation Laboratory, Helsinki University Central Hospital, Helsinki, Finland

4:15 PM (245) Intracoronary Interferon- α Promotes Cardiac Allograft Vasculopathy in Miniature Swine, R. Hoerbelt,¹ L.C. Benjamin,¹ D.R. Johnston,¹ S.L. Houser,¹ T. Shoji,¹ J.S. Allan,¹ L.G. Ledgerwood,¹ R.S. Hasse,¹ D.H. Sachs,¹ J.C. Madsen,¹ ¹Department of Surgery, Mass. General Hospital, Transplantation Biology Research Center, Boston, MA

4:30 PM (246) Targeting STAT-1 and AP-1 Transcription Factors by Decoy-Oligodeoxynucleotides Prevents Graft Vasculopathy in a Chronic Rat Cardiac Transplantation Model, T.H.W. Stadlbauer,¹ S. Fiedel,¹ H. Fingerhuth,¹ A.H. Wagner,² M. Hecker,² H. Hölschermann,¹ ¹Department of Cardiology, University Hospital Giessen, Giessen, Germany; ²Department of Cardiovascular Physiology, University of Goettingen, Goettingen, Germany

4:45 PM (247) P53 Plays a Significant Role in the Pathogenesis of Allograft Vasculopathy, M. Thanikachalam,¹ S. Li,¹ A. Simmonds,¹ M. Cheung,¹ R. Vazquez-Padron,¹ C.A. Liotta,¹ A. Gambotto,² A. Aitouche,¹ S.M. Pham,¹ ¹Surgery, University of Miami, Miami, FL; ²Surgery, University of Pittsburgh, Pittsburgh, PA

5:00 PM (248) Combined Treatment with Epsilon Protein Kinase C Activator and Delta Protein Kinase C Inhibitor Ameliorates Ischemia Reperfusion Injury and Graft Coronary Artery Disease in Murine Cardiac Allografts, M. Tanaka,¹ R.D. Terry,¹ T. Koyanagi,² K. Inagaki,² T. Kofidis,¹ D. Mochly-Rosen,² R.C. Robbins,¹ ¹Department of Cardiothoracic Surgery; ²Department of Molecular Pharmacology, Stanford University, Stanford, CA

5:15 PM (249) The Profibrotic Cytokine Transforming Growth Factor Beta (TGF β) Is Elevated Early in the Development of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant Recipients (LTR), T.J. McWilliams,¹ L. Zheng,² B.E. Orsida,² B.J. Levvey,¹ E.H. Walters,² H.M. Whitford,¹ G.I. Snell,¹ T.J. Williams,¹ ¹Allergy, Clinical Immunology and Respiratory Medicine, The Alfred Hospital, Melbourne, VIC, Australia; ²Allergy, Clinical Immunology and Respiratory Medicine, Monash University, Melbourne, VIC, Australia

5:30 PM-6:30 PM

Moderated Poster Session 2/Wine and Cheese Reception (Yosemite)

Pediatric Menagerie

Moderators: Walter Uber, PharmD

(250) Cytomegalovirus (CMV) Prophylaxis and Infection in Pediatric Heart Transplant Recipients, K.R. Kanter,¹ D.C. Naftel,² E. Pahl,³ C.E. Canter,⁴ S.A. Webber,⁵ R.N. Vincent,¹ J.K. Kirklin,² W.R. Morrow,⁶ Pediatric Heart Transplant Study Group, ¹Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, GA; ²Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL; ³Pediatric Cardiology, Northwestern School of Medicine, Chicago, IL; ⁴Pediatric Cardiology, Washington University, St. Louis, MO; ⁵Pediatric Cardiology, Childrens Hospital of Pittsburgh, Pittsburgh, PA; ⁶Pediatric Cardiology, Arkansas Children's Hospital, Little Rock, AR

(251) Basiliximab in Critically Ill Children Undergoing Heart Transplantation: Initial Data, K.A. Ford,¹ C.M. Cale,² P.G. Rees,³ M.J. Elliott,³ M. Burch,³ ¹Pharmacy Department, Great Ormond Street Hospital for Children, London, United Kingdom; ²Immunology Department, Great Ormond Street Hospital for Children, London, United Kingdom; ³Cardiology Department, Great Ormond Street Hospital for Children, London, United Kingdom

(252) Association of Growth Hormone Therapy with the Development of Bronchiolitis Obliterans Syndrome in Pediatric Lung Transplant Recipients, S.C. Sweet,¹ M.T. de la Morena,¹ P.M. Schuler,¹ C.B. Huddleston,² E.N. Mendeloff,² ¹Department of Pediatrics, Washington University, St. Louis, MO; ²Department of Cardiothoracic Surgery, Washington University, St. Louis, MO

(253) Renal Insufficiency Is Associated with Early Mortality in Pediatric Lung Re-Transplantation, M.T. de la Morena,¹ S.C. Sweet,¹ K. Schechtman,³ P.M. Schuler,¹ E.N. Mendeloff,² C.B. Huddleston,² ¹Pediatrics, Washington University School of Medicine, St. Louis, MO; ²Cardio-Thoracic Surgery, Washington University School of Medicine, St. Louis, MO; ³Biostatistics, Washington University School of Medicine, St. Louis, MO

(254) Pediatric Lung Transplant: Do Primary Pulmonary Hypertension Patients Have Worse Outcome?, S. Koulouri,¹ M.S. Woo,¹ M.V. Horn,¹ E. Perez,¹ V.A. Starnes,¹ J.R. Szmuszkowicz,¹ ¹Cardiothoracic Transplant Program, Childrens Hospital Los Angeles, Los Angeles, CA

(255) Impact of Sirolimus on Lipid Profiles in Pediatric Thoracic Organ Recipients, A. Byno,¹ Y. Law,¹ G. Boyle,¹ S. Miller,¹ P. Fitzgerald,¹ S. Gandhi,¹ R. Sindhi,¹ S. Webber,¹ ¹Cardiology and Transplantation, Children's Hospital, Pittsburgh, PA

New Tools in Advanced Heart Failure Assessment and Management

Moderators: Edoardo G. Gronda, MD

(256) Preponderance and Implications of Etiological Misclassification in Advanced Heart Failure: A Clinical-Pathological Investigation, P.A. Uber, Z.M. N'Dandu, M.H. Park, R.L. Scott, H.O. Ventura, M.R. Mehra, Ochsner Clinic Foundation, New Orleans, LA

(257) Neurohumoral and Immune Markers as Predictors of Acute Deterioration in Patients with End Stage Heart Failure Requiring Ventricular Assist Device or Heart Transplantation, E.V. Potapov,¹ F.D. Wagner,¹ F. Hennig,¹ H.D. Volk,² S. Ignatenko,¹ H.B. Lehmkuhl,¹ R. Hetzer,¹ ¹Thoracic and Cardiovascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; ²Immunology, CharitéHumboldt University Berlin, Berlin, Germany

(258) The Munich Score - A Clinical Index To Predict Survival in Patients with Chronic Heart Failure in the Era of New Medical Therapies, H.-U. Stempfle,¹ A. Alt,¹ J. Stief,¹ K. Theisen,¹ U.

Siebert,² ¹Cardiology, Med.Poliklinik-Innenstadt, LMU, Munich, Germany; ²Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, MA

(259) The Effects of Levosimendan in Refractory Congestive Heart Failure Needing IV Inotropic Drugs: A Logistic Regression Analysis of the Believe Study Comparing Responders Versus Non Responders, E.A. Bocchi,¹ F. Villas-Boas,² on Behalf of the BELIEVE Investigators,² ¹Heart Failure Clinics, Heart Institute (InCor), University of São Paulo Medical School, São Paulo, SP, Brazil; ²Heart Failure Working Group, Brazilian Society of Cardiology, Rio de Janeiro, RJ, Brazil

(260) Decrease of Waiting List Mortality in Cardiac Transplantation Though Transplant Numbers Are Dropping. The Impact of Optimal Bridging, A. Mühlbauer,¹ A. Zuckermann,¹ A. Bohdjalian,¹ G. Wieselthaler,¹ E. Wolner,¹ M. Grimm,¹ ¹Department of Cardio-Thoracic Surgery, University of Vienna, Vienna, Vienna, Austria

(261) Role of Left Ventricular Assist Device for Patients in Acute Myocardial Infarction Complicated by Cardiogenic Shock, S.J. Park,¹ M. Colvin-Adams,² S. Ormaza,³ K.K. Liao,³ R. Segurola,³ A. Boyle,² L.W. Miller,² ¹Joint Cardiac Program, California Pacific Medical Center, San Francisco, CA; ²Medicine, University of Minnesota, Minneapolis, MN; ³Surgery, University of Minnesota, Minneapolis, MN

Outcomes in Lung and Heart-Lung Transplantation II

Moderators: Brian F. Meyers, MD

(262) Expanding the Donor Pool: Successful Use of Marginal Donor Lungs with a History of Smoking, J.C. Mullen,¹ D.C. Lien,¹ M.J. Bentley,¹ K.B. Jackson,¹ K.C. Stewart,¹ P.J. Brown,¹ H.A. Taskinen,¹ D.L. Modry,¹ ¹Lung Transplant Program, University of Alberta, Edmonton, AB, Canada

(263) Multi-Frequency Forced Oscillation Technique [FOT] for Assessment of Lung Allograft Function: A Pilot Study, D.J. Ross,¹ M.D. Goldman,² R.M. Strieter,¹ J.A. Belperio,¹ A. Ardehali,³ ¹Medicine, UCLA, Los Angeles, CA; ²Medicine, King Drew/UCLA, Los Angeles, CA; ³Surgery, UCLA, Los Angeles, CA

(264) Differential Gene Expression Profiling in Lung Transplant Recipients with Chronic Rejection, B.S. Lu,¹ A.D. Yu,¹ G.C. Cao,² E.R. Garrity,¹ W.T. Vigneswaran,³ S.M. Bhorade,¹ ¹Pulmonary and Critical Care Medicine, Loyola University Medical Center, Maywood, IL; ²Preventive Medicine and Epidemiology, Loyola University Medical Center, Maywood, IL; ³Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL

(265) Donor Cause of Death Does Not Influence Mid-Term Survival in Lung Transplant Recipients, J.S. Ganesh,¹ C.A. Rogers,¹ N.R. Banner,¹ R.S. Bonser,¹ ¹On Behalf of the Steering Group, UK Cardiothoracic Transplant Audit, Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom

(266) A Cost-Effectiveness and Cost-Utility Study of Lung Transplantation, H.M. Vasiliadis,¹ J.P. Collet,¹ J. Penrod,² M. Abrahamowicz,³ P. Ferraro,⁴ C. Poirier,⁴ ¹Department of Epidemiology and Biostatistics, McGill University, Montreal, QC, Canada; ²Centre for the Analysis of Cost-Effective Care, Montreal General Hospital, Montreal, QC, Canada; ³Division of Clinical Epidemiology, Montreal General Hospital, Montreal, QC, Canada; ⁴Heart-Lung and Lung Transplant Program, Hopital Notre Dame, Montreal, QC, Canada

(267) MRSA Infection Is the Most Important Risk Factor for the Development of Bronchial Anastomotic Complications after Lung Transplantation, M.A. Malouf,¹ L. Singleton,¹ M. Plit,¹ A.R. Glanville,¹ ¹The Lung Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia

Basic Science and Immunobiology

Moderator: Michael S. Mulligan, MD

(268) Immunisation with Vimentin Causes Rejection of Syngeneic Cardiac Grafts, S. Nair,¹ A. McCormack,¹ A. Holder,¹ A. de Sousa,¹ M. Burke,² E. Lidington,¹ M. Rose,¹ ¹National Heart and Lung Institute, Imperial College, Harefield, Middlesex, United Kingdom; ²Pathology Department, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom

(269) Host Cells Contribute to Myocardium Early, Rather Than Late, after Allogeneic and Syngeneic Murine Heart Transplantation, L.B. Balsam,¹ M. Tanaka,¹ A.J. Wagers,² I.L. Weissman,² R.C. Robbins,¹ ¹Cardiothoracic Surgery, Stanford University, Stanford, CA; ²Pathology, Stanford University, Stanford, CA

(270) Acceptance of Third-Party Cardiac Allografts in Neonatally-Tolerized Mice Is Transferable by Regulatory CD4⁺ T Cells, B. Hofmann,¹ L. Mai,¹ K. Tao,¹ L.J. West,¹ ¹Paediatric Transplant Service, Hospital for Sick Children, Toronto, ON, Canada. This work was supported by the Canadian Institutes for Health Research, Heart and Stroke Foundation of Ontario and Physicians' Services Inc. Foundation.

(271) Alterations in Gene Expression of Toll-Like Receptors in Human Lung Transplantation, C.F. Andrade,¹ H. Kaneda,¹ S. Der,² M. Tsang,¹ C.C. Santos,¹ S. Keshavjee,¹ M. Liu,¹ ¹Department of Surgery - Thoracic Surgery Research Laboratory, Toronto General Hospital, University Health Network, Toronto, ON, Canada; ²Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada

(272) Biochanin-A Attenuates Acute Cardiac Allograft Rejection without Affecting the Reproductive System – In Vivo and In Vitro Studies, S. Schrepfer,¹ T. Deuse,¹ F. Koch-Nolte,² H.J. Schäfer,³ H. Reichenspurner,¹ ¹Cardiovascular Surgery, University Hamburg, Hamburg, Germany; ²Immunology, University Hamburg, Hamburg, Germany; ³Pathology, University Hamburg, Hamburg, Germany

(273) PAI-1 and Allograft Vasculopathy: Insight from a Murine Model of Transplantation, R.L. Benza,¹ G.S. Mohanty,¹ C.S. Coffey,² P.G. Anderson,³ K. Lyle,¹ J.F. George,⁴ ¹Medicine, University of Alabama at Birmingham, Birmingham, AL; ²Biostatistics, University of Alabama at Birmingham, Birmingham, AL; ³Pathology, University of Alabama at Birmingham, Birmingham, AL; ⁴Surgery, University of Alabama at Birmingham, Birmingham, AL

5:30 PM-6:30 PM

General Poster Session 2 (Franciscan Ballroom)

Nursing/Social Sciences/Health Care

(274) Quality of Life after Heart Transplantation in Japanese Patients, K. Shitakura,¹ S. Nunoda,¹ G. Yamanaka,¹ Y. Kubo,¹ M. Shinagawa,¹ K. Ohtsuka,¹ S. Ohkawa,¹ ¹Department of Medicine, Tokyo Women's Medical University, Daini Hospital, Tokyo, Japan

(275) A Randomized Evaluation of a Telehealth Intervention To Improve Well-Being, Mood States, and Social Intimacy in Wait-Listed Lung Transplant Patients, J.R. Rodrigue,¹ M.A. Baz,² M.R. Widows,¹ S.L. Ehlers,¹ ¹Clinical and Health Psychology, University of Florida, Gainesville, FL; ²Medicine, University of Florida, Gainesville, FL

(276) Development of the VAD-QoL: A VAD Specific Quality of Life Questionnaire, C.N. Hallas,¹ J. Wray,¹ C. Bowles,² N.R. Banner,¹ ¹Transplant Unit, Harefield Hospital, Harefield, Middlesex, United Kingdom; ²Artificial Heart Programme Co-ordinator, Harefield Hospital, Harefield, Middlesex, United Kingdom

(277) Two-Year Follow-Up of Psychological State in Patients Referred for Heart Transplant, L.S. Evangelista,¹ K. Dracup,² C. Westlake,³ V. Erickson,¹ M.A. Hamilton,⁴ G.C. Fonarow,⁴ ¹School of Nursing, University of California, Los Angeles, Los Angeles, CA; ²School of Nursing, University of California, San

Francisco, San Francisco, CA; ³School of Nursing, California State University, Fullerton, Fullerton, CA; ⁴School of Medicine, University of California, Los Angeles, Los Angeles, CA

(278) Psychosocial Determinants and Consequences of Subclinical Non-Compliance in Lung Transplant Recipients, A. Cassano-Bailey,¹ A. Szabo,¹ P. Wightman,¹ L. Tan,¹ H. Unruh,¹ ¹Manitoba Lung Transplant Program, University of Manitoba, Winnipeg, MB, Canada

(279) Health-Related Quality of Life in Adolescents after Heart Transplantation, K. Uzark,¹ L. Griffin,² P. Murphy,³ S. Hallowell,⁴ M. Kostyk,⁵ J. Dupuis,⁶ K. Jones,¹ ¹Cardiology, Cincinnati Children's Hospital, Cincinnati, OH; ²Cardiac Transplant, Loma Linda University Medical Ctr, Loma Linda, CA; ³Cardiology, St. Louis Children's Hospital, St. Louis, MO; ⁴Pediatric Cardiology, Cleveland Clinic Foundation, Cleveland, OH; ⁵Heart Transplant, Children's Memorial Hospital, Chicago, IL; ⁶Cardiology, Children's Hospital of Michigan, Detroit, MI

(280) The Relationship between Self Perception and Adherence in Adolescents and Young Adults, J. Wray,¹ S. Waters,² T. Sensky,² R. Radley-Smith,¹ ¹Paediatrics, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom; ²Faculty of Medicine, Imperial College, London, United Kingdom

(281) Pediatric Heart Transplantation: Quality of Life (QOL) Outcomes in Adolescents, S.J. Anthony,^{2,3} S.M. Pollock-Barziv,^{1,3} R. Niedra,^{2,3} A.I. Dipchand,^{1,3} L.J. West,^{1,3} ¹Division of Cardiology, Hospital for Sick Children, Toronto, ON, Canada; ²Department of Social Work, Hospital for Sick Children, Toronto, ON, Canada; ³Pediatric Academic Multi-Organ Transplant Program, Hospital for Sick Children, Toronto, ON, Canada

(282) Psychosocial Variables and Quality of Life after Lung Transplantation, Ch. Kugler,¹ U. Tegtbur,² M. Strueber,¹ J. Niedermeyer,³ A. Haverich,¹ ¹Thoracic Surgery, Medical School Hannover, Hannover, Niedersachsen, Germany; ²Sportsmedicine, Medical School Hannover, Hannover, Niedersachsen, Germany; ³Pulmology, Medical School Hannover, Hannover, Niedersachsen, Germany

Immunosuppression - Animal

(283) CD 154 Blockade Spares Secondary Immunity to Influenza in Primates, C. Schroeder,¹ J.E. Crowe,² G. Wu,¹ S. Pfeiffer,¹ E.C. Sannella,² G.G. Miller,² A.M. Azimzadeh,¹ R.N. Pierson III,¹ ¹Division of Cardiac Surgery, University of Maryland, Baltimore, MD; ²Departments of Pediatrics and Medicine, Vanderbilt University, Nashville, TN

(284) Combination Regimens of FK778 with Tacrolimus and Mycophenolate Mofetil in Experimental Cardiac Transplantation, T. Deuse,¹ S. Schrepfer,¹ H. Reichenspurner,¹ ¹Cardiovascular Surgery, University Hamburg, Hamburg, Germany

Immunosuppression: Clinical

(285) Rapamycin Conversion for Immunosuppressive Therapy in the Setting of Renal Insufficiency in Patients with Heart Transplantation: Pilot Observations, W. H. W. Tang,¹ R.C. Starling,¹ R. Fatica,¹ M. Yamani,¹ J.B. Young,¹ D.O. Taylor,¹ ¹Kaufman Center for Heart Failure, Cleveland Clinic Foundation, Cleveland, OH

(286) Risk Factors for Acute Rejection and Vasculopathy among 634 Patients Treated with Everolimus or Azathioprine, R.C. Starling,¹ J. Kobashigawa,² H. Eisen,³ J. Jaffe,⁴ Y. Li,⁴ ¹Cleveland Clinic Foundation, Cleveland, OH; ²UCLA, LA, CA; ³Temple University, Philadelphia, PA; ⁴Novartis Pharmaceuticals, E.Hanover, NJ; ⁵Novartis Pharmaceuticals, E.Hanover, NJ

(287) Difficulty in Managing Cyclosporin C₂ Monitoring in De Novo Lung Transplant Recipients, J. Cornelissen,¹ A.K. Trull,¹ J. Parameshwar,² S.E. Bellm,¹ S.C. Charman,³ J. Wallwork,² ¹Clinical

Pharmacology, Papworth Hospital NHS Trust, Cambridge, United Kingdom; ²Transplant Unit, Papworth Hospital NHS Trust, Cambridge, United Kingdom; ³MRC Biostatistics Unit, Cambridge, United Kingdom

(288) Caveats of Cyclosporine Dosing Based on C2 Monitoring, J. Thekkudan,¹ J.E. Fildes,¹ R. Sivaprakasam,¹ N. Khasati,¹ S. Datta,¹ R. Martyszczuck,¹ A.A. Maachal,¹ B. Keevil,² C.T. Leonard,¹ N. Yonan,¹ ¹The Transplant Centre, South Manchester University Hospitals Trust, Wythenshawe, Manchester, United Kingdom; ²Department of Biochemistry, South Manchester University Hospitals Trust, Wythenshawe, Manchester, United Kingdom

(289) Efficacy of Thymoglobulin® for the Treatment of BOS after Lung Transplantation and Predictors of a Therapeutic Response, R.R. Hachem,¹ G.A. Patterson,² E.P. Trulock,¹ ¹Pulmonary; ²Thoracic Surgery, Washington University School of Medicine, St Louis, MO

(290) Initial Benefit of Mycophenolate Mofetil (MMF) in Heart Transplant Recipients with Renal Impairment Is Maintained at Two-Year Follow Up, M.J. Matuszewski,¹ T.J. Locke,¹ D.N. Hopkinson,¹ P.C. Bradley,¹ ¹Heart and Lung Transplant Unit, Northern General Hospital, Sheffield, South Yorkshire, United Kingdom

(291) Renal Function Is Preserved Following Heart Transplantation Using IL-2 Receptor Blockade, G. Wheatley,¹ C.W. Yancy,² M.A. Wait,¹ D.M. Meyer,¹ M.E. Jessen,¹ M.C. Paul,¹ P. Kaiser,¹ R.A. Bhojani,¹ M. Drazner,² W.S. Ring,¹ J.M. DiMaio,¹ ¹Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX; ²Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX

(292) Impact of Sirolimus on Gonadal Function in Heart Transplant Recipients, I. Adamidis,¹ I. Kaczmarek,¹ B. Meiser,¹ P. Landwehr,¹ M. Mueller,¹ J. Groetzner,¹ P. Ueberfuhr,¹ B. Reichart,¹ ¹Cardiac Surgery, Ludwig-Maximilians-University, Grosshadern University Hospital, Munich, Bavaria, Germany

(293) Optimal Time Point To Predict Cyclosporine, Tacrolimus and Mycophenoic Acid Area-Under-the-Curve (AUC)_{0-12 hr} in Long-Term Heart/Heart-Lung Transplant Patients, M. Cantarovich,¹ N. Giannetti,¹ R. Cecere,² G. Fontaine,³ J.-G. Besner,⁴ ¹Medicine; ²Cardiovascular and Thoracic Surgery; ³Nursing, Transplant Program, McGill University Health Center, Montreal, QC, Canada; ⁴Faculte de Pharmacie, Universite de Montreal, Montreal, QC, Canada

(294) Sirolimus(SRL) in Heart Transplantation: Preliminary Results of a Multicenter Registry in Spain, M.G. Crespo,¹ N. Manito,² G. Rábago,³ J.F. Delgado,⁴ J.M. Arizón,⁵ E. Lage,⁶ J. Palomo,⁷ ¹Cardiología, H.Juan Canalejo; ²H.Bellvitge; ³C.U.Navarra; ⁴H.Doce Octubre; ⁵H.Reina Sofia; ⁶H.Virgen Rocío; ⁷H.Gregorio Marañón

(295) Therapeutic Drug Monitoring of Everolimus (RAD) May Be Beneficial in Stable Lung Transplant Recipients, U. Pirron,¹ H. Mayer,¹ J. Kovarik,¹ H. Schmidli,¹ ¹Business Unit Transplantation, Novartis Pharma AG, Basel, Switzerland

Clinical Lung/Heart-Lung Transplantation

(296) Cytolytic Induction Therapy Is a Risk Factor for Bronchiolitis Obliterans Syndrome after Lung Transplantation, A.R. Glanville,¹ V.G. Valentine,² C.L. Aboyoun,¹ M.A. Malouf,¹ ¹The Lung Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia; ²Lung Transplantation, Ochsner Clinic Foundation, New Orleans, LA

(297) Effect of Antithymocyte Globulin Induction, Rabbit vs Horse, on BOS and Survival in Lung Recipients, V.G. Valentine,¹ L. Seoane,¹ C.E. Thompson,¹ D.M. Fuchs,¹ G.S. Dhillon,¹ D.E. Taylor,¹ ¹Lung Transplantation, Ochsner Clinic Foundation, New Orleans, LA

(298) Unilateral Acute and Chronic Rejection after Living-Donor Lobar Lung Transplantation, H.

Date,¹ M. Aoe,¹ Y. Sano,¹ I. Nagahiro,¹ K. Goto,² N. Shimizu,¹ ¹Department of Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine, Okayama, Okayama, Japan; ²Department of Anesthesiology and Resuscitology, Okayama University Graduate School of Medicine, Okayama, Okayama, Japan

(299) Comparison and Validation of Three Quality of Life Instruments for the Functional Assessment of Pulmonary Arterial Hypertension, R. Chua,¹ A. O'Loughlin,¹ A.M. Keogh,¹ K. Brown,¹ C. Corrigan,¹ ¹Heart Lung Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia

(300) The Interaction of Underlying Etiology of Pulmonary Hypertension and Response to Bosentan, M.H. Park, C.C. Tannehill, P.A. Uber, R.L. Scott, H.O. Ventura, M.R. Mehra, Ochsner Clinic Foundation, New Orleans, LA

(301) Sustained Long Term Improvement after Transition from I.V. Epoprostenol to S.C. Treprostinil Therapy in Patients with Pulmonary Arterial Hypertension, J.-L. Vachery,¹ S. Huez,¹ K. Retailleau,¹ R. Naeije,¹ ¹Cardiology, ULB Erasme, Brussels, Belgium

(302) Experimental Pulmonary Hypertension Markedly Induces Pulmonary Artery Transient Receptor Potential Protein Expression, P.E. Wolkowicz,¹ H.E. Grenett,¹ M.A. Garces,¹ R. Benza,¹ S. Kim-Park,² ¹Medicine/ Cardiology, University of Alabama at Birmingham, Birmingham, AL; ²Medicine/Human Gene Therapy, University of Alabama at Birmingham, Birmingham, AL

(303) Silent Symptomatic Gastro-Oesophageal Reflux (GOR) in Cystic Fibrosis (CF) Pre Post Lung Transplantation- Are They a Problem?, B. Button,¹ S. Roberts,² G. Snell,¹ B. Levvey,¹ T. Williams,¹ T. Kotsimbos,¹ J. Wilson,¹ ¹Allergy, Immunology & Respiratory Medicine, The Alfred, Melbourne, Australia; ²Gastroenterology, The Alfred, Melbourne, Australia

(304) Skin Diseases after Lung Transplantation, Ch. Eich,¹ R. Speich,¹ E.W. Russi,¹ W. Weder,¹ A. Boehler,¹ ¹Lung Transplant Program, University Hospital, Zurich, Switzerland

(305) Pulmonary Hemodynamics Can Predict Mortality on the Waiting List for Lung Transplantation in Patients with Cystic Fibrosis, F. Venuta,¹ S. Quattrucci,¹ T. De Giacomo,¹ G. Cimmino,¹ M. Anile,¹ C. Andreotti,¹ D. Diso,¹ F. Ruberto,¹ E.A. Rendina,¹ G.F. Coloni,¹ ¹Thoracic Surgery, University of Rome "La Sapienza, Rome, Italy

(306) Impact of Secondary Pulmonary Hypertension of Lung Transplantation Outcome, T. Fitton,¹ T. Kosowski,¹ C.J. Barreiro,¹ V. Chan,¹ B.T. Bethea,¹ M. Borja,¹ J. Orens,¹ J.V. Conte,¹ ¹Cardiac Surgery, Johns Hopkins Hospital, Baltimore, MD

(307) Withdrawn

Mechanical and Circulatory Support

(308) Low-Dose Prophylactic Intravenous Immunoglobulin Does Not Prevent HLA Allosensitization in LVAD Recipients, S.G. Drakos,¹ J.W. Long,¹ J.C. Stringham,¹ T.C. Fuller,¹ B.A. Campbell,¹ S.S. Schmitz,¹ K.E. Nelson,¹ S.A. Moore,¹ E.M. Gilbert,¹ D.G. Renlund,¹ ¹Utah Transplantation Affiliated Hospitals (UTAH) Cardiac Transplant Program, LDS Hospital, University of Utah School of Medicine and Veterans Affairs Medical Center, Salt Lake City, UT

(309) Impact of Diabetes on Outcomes after Left Ventricular Assist Device Placement, J. Butler,¹ R.L. Howser,² P.M. Portner,³ R.N. Pierson III,⁴ ¹Division of Cardiology, Vanderbilt University Medical Center, Nashville, TN; ²World Heart Inc, Oakland, CA; ³Department of Cardiothoracic Surgery, Stanford University, Stanford, CA; ⁴Division of Cardiac Surgery, University of Maryland Medical Center, Baltimore, MD

(310) Left Ventricular Assist System: Clinical Freedom from Device Replacement, T. Mussivand,¹ D.A. Hasle,¹ K.S. Holmes,¹ ¹Cardiovascular Devices Division, University of Ottawa Heart Institute, Ottawa, ON, Canada

(311) Preclinical Animal Trial and Initial Clinical Experience with the Ventrassist-LVAS, D.S. Esmore,¹ F.L. Rosenfeldt,¹ G.A. Edwards,² J.C. Negri,¹ R.F. Salamonson,¹ D.M. Kaye,¹ M.R. Buckland,¹ P.J. Ayre,³ N.L. James,³ J.D. Begg,³ J.C. Woodard,³ ¹Cardiothoracic Surgery, Alfred Hospital, Melbourne, VIC, Australia; ²Veterinary Science, University of Melbourne, Melbourne, VIC, Australia; ³Ventracor Pty Ltd., Sydney, NSW, Australia

(312) Clinical Application of a Wear-Resistant Axial Flow Pump with an Intelligent Control Algorithm as Left Ventricular Assist Device (LVAD), J. Mueller, Y. Weng, T. Drews, D. Kemper, E. Potapov, M. Jurmann, R. Hetzer, Cardiac Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

(313) Morbidity Reduction with the Thoratec Ventricular Assist Device (TVAD) for CHF Using Improved Management Strategies: A 12 Year Experience, A.N. Patel,¹ L. Carroza,¹ J. Ristich,¹ L. Shears,¹ S. Winowich,¹ E. Stanford,¹ P. Anagnostopoulos,¹ R. Kormos,¹ ¹Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA

(314) Effect of Mechanical Circulatory Support on Outcomes after Heart Transplantation in the Modern Era, S.G. Drakos,¹ J.W. Long,¹ J.C. Stringham,¹ E.M. Gilbert,¹ S.A. Moore,¹ B.D. Horne,¹ B.A. Campbell,¹ K.E. Nelson,¹ D.G. Renlund,¹ ¹Utah Transplantation Affiliated Hospitals (UTAH) Cardiac Transplant Program, LDS Hospital, University of Utah School of Medicine and Veterans Affairs Medical Center, Salt Lake City, UT

(315) The Thoratec IVAD: A New Implantable Ventricular Assist Device, M.S. Slaughter,¹ S.S.L. Tsui,² A. El-Banayosy,³ R.L. Kormos,⁴ T.B. Icenogle,⁵ J.D. Hill,⁶ ¹Surgery, Cardiothoracic Division, Advocate Christ Medical Center, Oak Lawn, IL; ²Surgery, Papworth Hospital, Cambridge, United Kingdom; ³Surgery, Heart Center NRW, Bad Oeynhausen, Germany; ⁴Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; ⁵Surgery, Sacred Heart Medical Center, Spokane, WA; ⁶Surgery, California Pacific Medical Center, San Francisco, CA

(316) Left Ventricular Assistance with Axial Flow Pumps: Can We Control Right Ventricular Function?, M.E.W. Kirsch,¹ E. Vermes,¹ S. Nakashima,¹ T. Farrokhi,¹ D.Y. Loisanche,¹ ¹Cardiothoracic Surgery, Henri Mondor Hospital, Créteil, France

(317) Comparison of Novacor and Heartmate Vented Electric Left Ventricular Assist Devices in a Single Institution, A.V. Kalya,¹ A.J. Tector,¹ J.D. Crouch,¹ F.X. Downey,¹ M.L. McDonald,¹ D.P. O'Hair,¹ A.J. Anderson,¹ C.J. Bartoszewski,¹ J.D. Hosenpud,¹ ¹Cardiac Transplant Program, St. Luke's Medical Center, Milwaukee, WI

(318) Reduced Infection with Use of Left Ventricular Assist Device (LVAD) as an Alternative to Transplantation, L.W. Miller,¹ S.J. Park,² J.W. Long,³ D.E. Renlund,³ A.J. Boyle,¹ M.M. Colvin-Adams,¹ ¹Cardiology, University of Minnesota, Minneapolis, MN; ²Surgery, University of Minnesota, Minneapolis, MN; ³Surgery, LDS Hospital, Salt Lake City, UT

(319) First German Experience with the CardioWest TAH - Report from a Single Center, A. El-Banayosy,¹ L. Arusoglu,¹ M. Morshuis,¹ L. Kizner,¹ P. Sarnowski,¹ R. Koerfer,¹ ¹Department of Cardiothoracic Surgery, Heart and Diabetescenter NRW, Bad Oeynhausen, Germany

Donor Management, Organ Preservation, Organ Distribution

(320) Lung Transplantation Using Lungs from Donors 50 Years of Age and Older, S. Fischer,¹ P. Struckmeier,¹ R. Tessmann,¹ A.R. Simon,¹ J. Niedermeyer,¹ B. Gohrbandt,¹ G. Warnecke,¹ A. Haverich,¹ M. Strueber,¹ ¹Hannover Thoracic Transplant Program, Hannover Medical School, Hannover, NS,

Germany

(321) Beneficial Effects of Tumor Necrosis Factor Converting Enzyme Inhibitor on Reimplantation Lung Injury, T. Goto,¹ A. Ishizaka,² M. Kohno,¹ M. Sawafuji,¹ K. Kobayashi,¹ ¹Department of Surgery, Keio University, Tokyo, Japan; ²Department of Medicine, Keio University, Tokyo, Japan

(322) Long-Term Preservation Using a New Apparatus Combined with Suppression of Proinflammatory Cytokines Improves Donor Heart Function Following Transplantation in a Canine Model, K. Oshima,¹ I. Takeyoshi,¹ J. Mohara,¹ H. Tsutsumi,¹ S. Ishikawa,¹ K. Matsumoto,² Y. Morishita,¹ ¹Second Department of Surgery, Gunma University Faculty of Medicine, Maebashi, Gunma, Japan; ²Department of Pathology, Nippon Medical School Second Hospital, Kawasaki, Kanagawa, Japan

(323) Does Donor Catecholamine Administration Affect Early Lung Function Post-Transplantation?, M.E. Mukadam,¹ D.K. Harrington,¹ I.C. Wilson,¹ S.J. Rooney,¹ D.P. Pagano,¹ R.D. Thompson,¹ R.S. Bonser,¹ ¹Cardiothoracic Transplantation Unit, University Hospital, Birmingham, West Midlands, United Kingdom

(324) Effect on Cardioplegic Solution with Poly(ADP-Ribose) Synthetase (PARS) Inhibitors, on Myocardial Ischemia-Reperfusion Injury in Rat Hearts, K. Yamazaki,¹ S. Miwa,¹ K. Ueda,¹ S. Tanaka,¹ S. Toyokuni,¹ O. Unimonh,¹ K. Takaba,¹ T. Ikeda,¹ K. Nishimura,¹ M. Komeda,¹ ¹Department of Cardiovascular Surgery, Kyoto University, Kyoto, Kyoto, Japan

(325) A Heat Shock Protein 70 Inducer, Geranylgeranylacetone, Suppresses Ischemia-Reperfusion Injury after Lung Transplantation in Rats, T. Sugawara,¹ T. Tabata,¹ Y. Matsumura,¹ Y. Okada,¹ Y. Matsuda,¹ T. Kondo,¹ ¹Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan

(326) Comparison of Left Ventricular Tissue and Right Atrial Tissue for Activation of Mitogen-Activated Protein Kinases in Canine Heart Transplantation from Non-Heart-Beating Donors, N. Koike,¹ I. Takeyoshi,¹ S. Ohki,¹ M. Tokumine,¹ Y. Morishita,¹ ¹Second Department of Surgery, Gunma University Faculty of Medicine, Maebashi, Gunma, Japan

(327) Prevention of Severe Ischemic-Reperfusion Injury Utilizing a Multifaceted Approach during Procurement, Storage, and Reperfusion in Lung Transplantation, A. Stewart,¹ S. Arcasoy,¹ S. Kawut,¹ J. Wilt,¹ J. Sonett,¹ ¹Division of Lung Transplantation, Columbia Presbyterian Medical Center, New York, NY

(328) Quantifying the Resuscitation of Hearts Procured from Nonheartbeating Donors with Radiolabeled Annexin V, D. Prastein,¹ J. Gu,¹ A. Wright,¹ M. Kwon,¹ B. Line,¹ B. Griffith,¹ R.N. Pierson,¹ F. Gage,² R. Poston,¹ ¹Division of Cardiothoracic Surgery, University of Maryland School of Medicine, Baltimore, MD; ²Organ Recovery Systems, Inc., Des Plaines, IL

Post Transplant Complications

(329) Transcutaneous Electrical Nerve Stimulation for Severe Gastroparesis after Lung Transplantation, J.G. Weinkauff,¹ R.C. Robbins,² J. Theodore,¹ J.L. Faul,¹ ¹Pulmonary and Critical Care Medicine, Stanford University Medical Center, Stanford, CA; ²Cardiothoracic Surgery, Stanford University Medical Center, Stanford, CA

(330) The Role of Self-Expandable Metallic Stents (SEMS) in Promoting Healing of Post Lung Transplant Bronchial Dehiscence, M.M. Mughal,¹ T.R. Gildea,¹ S. Murthy,² M. DeCamp,² G. Petterson,² A.C. Mehta,¹ ¹Pulmonary & Critical Care, The Cleveland Clinic Foundation, Cleveland, OH; ²Thoracic & Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, OH

(331) Association of Anti-Donor HLA Class I Antibodies with Early Coronary Transplant

Vasculopathy, G.V. Gonzalez-Stawinski,¹ P.M. McCarthy,¹ J.B. Young,¹ R.C. Starling,¹ M.H. Yamani,¹ K. Hoercher,¹ E. Beyer,¹ P.E. Parrino,¹ D.J. Cook,¹ ¹The Cleveland Clinic Transplant Center, The Cleveland Clinic Foundation, Cleveland, OH

(332) Long-Term Results of Angioplasty Versus Stenting in Cardiac Transplant Recipients with Allograft Vasculopathy, L. Simpson,¹ P.K. Mehta,¹ B.J. Hott,¹ J.D. Vega,² W.M. Book,¹ ¹Internal Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA; ²Surgery, Emory University School of Medicine, Atlanta, GA

(333) Comparison of Inflammatory Activation and Restenosis after Percutaneous Coronary Intervention in Heart Transplant Recipients and Patients with Stable Angina Pectoris, A. Hognestad,¹ K. Endresen,¹ R. Wergeland,² J. Mellembakken,³ T.E. Mollnes,⁴ T. Omland,¹ J.K. Kjekshus,¹ P. Aukrust,⁵ A.K. Andreassen,¹ ¹Department of Cardiology, Rikshospitalet, Oslo, Norway; ²Department of Clinical Chemistry, Rikshospitalet, Oslo, Norway; ³Department of Gynaecology, Rikshospitalet, Oslo, Norway; ⁴Department of Immunology, Rikshospitalet, Oslo, Norway; ⁵Section of Clinical Immunology and Infectious Diseases, Rikshospitalet, Oslo, Norway

(334) Incidence and Severity of Rejection and Infection in Patients Bridged to Transplantation with Ventricular Assist Devices; P. Kaul,¹ S. Haj-Yahia,¹ E.J. Birks,¹ C.T. Bowles,¹ J. Hardy,¹ M.L. Rose,¹ N.R. Banner,¹ M.H. Yacoub,¹ A. Khagani,¹ ¹Department of Transplantation, Harefield Hospital, Harefield, Middlesex, United Kingdom

(335) Prophylactic Sternal Plating in the Cardiac Transplant Population; J.P. Agarwal,¹ J. Raman,² V. Jeevanandam,² A.S. Anderson,³ A.Y. Kim,³ D.H. Song,¹ ¹Plastic and Reconstructive Surgery, University of Chicago Hospitals, Chicago, IL; ²Cardiothoracic Surgery, University of Chicago Hospitals, Chicago, IL; ³Cardiology, University of Chicago, Chicago, IL

(336) Posttransplant Lymphoproliferative Disorder (PTLD) May Not Be Associated with Development of Bronchiolitis Obliterans, R.G. Nador,¹ A. Yiannopoulos,¹ J. Theodore,¹ N.R. Henig,¹ ¹Pulmonary and Critical Care Medicine, Stanford University Medical Center, Stanford, CA

(337) TGF β 1 Polymorphisms and Transplant Coronary Artery Disease, S.G. Miriuka,¹ P. Tzakas,² B. Wong,² D. Ramzy,¹ D.H. Delgado,¹ D.E.C. Cole,² H.J. Ross,¹ ¹Division of Heart Transplant, Toronto General Hospital - UHN, Toronto, ON, Canada; ²Departments of Laboratory Medicine and Pathobiology, Medicine and Paediatrics (Genetics), University of Toronto, Toronto, ON, Canada

Heart Transplantation

(338) Impair in Endothelial-Dependent Forearm Vasodilation in Heart Transplantation, A. Cuppoletti,¹ F. Pérez Villa,¹ M. Sitges,¹ M. Llancaqueo,¹ M. Azqueta,¹ C. Pare,¹ J. Orús,¹ M. Roqué,¹ I. Vallejos,¹ J. Magriñà,¹ E. Roig,¹ ¹Cardiovascular Institute, Hospital Clinic. IDIBAPS. University of Barcelona, Barcelona, Barcelona, Spain

(339) Eras of Immunosuppression Change Risk Factors for Long-Term Survival after Cardiac Transplantation, A. Zuckermann,¹ A. Bodhjalian,¹ D. Dunkler,¹ A. Mühlbauer,¹ S. Rödler,¹ J. Ankersmit,¹ E. Wolner,¹ M. Grimm,¹ ¹Department of Cardiothoracic Surgery, University of Vienna, Vienna, Vienna, Austria

(340) The Impact of Cytogam on Cardiac Transplant Recipients with Moderate Hypogammaglobulinemia, M.H. Yamani,¹ R.C. Starling,¹ R. Avery,² S. Mawhorter,² A. McNeil,¹ N.B. Ratliff,³ D. Cook,⁴ D. Pelegrin,¹ P. Colosimo,¹ K. Kiefer,¹ R. Hobbs,¹ D. Taylor,¹ P. McCarthy,⁵ J.B. Young,¹ ¹Cardiovascular Medicine; ²Infectious Disease; ³Anatomic Pathology; ⁴Allogeneic Laboratory; ⁵Cardiothoracic Surgery, Cleveland Clinic Foundation, Cleveland, OH

(341) Donor-Transmitted Coronary Atherosclerosis and Cardiac Allograft Microvasculopathy, O.

Grauhan,¹ R. Meyer,¹ N. Hiemann,¹ C. Knosalla,¹ H. Lehmkühl,¹ M. Dandel,¹ M. Pasic,¹ Y. Weng,¹ R. Hetzer,¹ ¹Thoracic and Cardiovascular Surgery, German Heart Institute, Berlin, Germany

(342) Peripheral Vascular Disease Adversely Affects Survival for Cardiac Transplant Recipients, S. Xydas,¹ C. Mutrie,¹ J.S. Chang,¹ J.K. Yang,¹ D. Vigilance,¹ N.C. Dang,¹ D.M. Mancini,² Y. Naka,¹ M.C. Oz,¹ J.C. Lantis,¹ ¹Departments of Surgery and Medicine, Columbia University, NY, NY

(343) Inhaled Nitric Oxide as Rescue Therapy for Right Ventricular Insufficiency after Orthotopic Heart Transplantation, S. Datta,¹ A. Machaal,¹ J. Thekkudan,¹ R. Sivaprakasan,¹ A.K. Deiraniya,¹ N. Yonan,¹ ¹Transplant Unit, Wythenshawe Hospital, Manchester, Lancashire, United Kingdom

(344) Primary Graft Failure (PGF) in Cardiac Transplantation (OHT) over an 8 Year Period: The Relationship between Donor and Recipient Factors, P. Anagnostopoulos,¹ C. Savopoulou,¹ L. Shears,¹ J. Ristich,¹ A. Patel,¹ R. Kormos,¹ ¹Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA

(345) Impact of Late Post-Transplant Acute Cardiac Rejections on Graft Function and Development of Coronary Arteriopathy, M. Dandel,¹ C. Knosalla,¹ R. Meyer,¹ H. Lehmkühl,¹ R. Hetzer,¹ ¹Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Berlin, Germany

Basic Science and Immunobiology

(346) Tissue Implantation with Autologous Myoblast Sheet Improved Cardiac Performance in the Impaired Myocardium, Y. Sawa,¹ I. Memon,¹ Y. Miyamoto,¹ S. Taketani,¹ S. Miyagawa,¹ H. Kondoh,¹ T. Shimizu,² T. Okano,² H. Matsuda,¹ ¹Department of Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan; ²Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, 8-1 Kawata-chou Shinjyu-ku, Tokyo, Japan

(347) STAT-1 and AP-1 Decoy-Oligodeoxynucleotide Therapy Delays Acute Rejection and Prolongs Cardiac Allograft Survival, T.H.W. Stadlbauer,¹ H. Fingerhuth,¹ A.H. Wagner,² M. Hecker,² H. Hoelschermann,¹ ¹Department of Cardiology, University Hospital Giessen, Giessen, Germany; ²Department of Cardiovascular Physiology, University of Goettingen, Goettingen, Germany

(348) Chemokinereceptor 7 (CCR7) Plays an Important Role in the Development of Transplant Arteriosclerosis, S.M. Ensminger,¹ S. Helm,¹ B.M. Spriewald,¹ M. Manoharan,¹ L. Ohl,² T. Fischlein,¹ M. Weyand,¹ R. Forster,² ¹Department of Cardiac Surgery and Medicine III, Friedrich-Alexander University, Erlangen-Nuremberg, Erlangen, Bavaria, Germany; ²Institute of Clinical Immunology, Hannover Medical School, Hannover, Lower Saxony, Germany

(349) Melatonin and Acute Cardiac Allograft Rejection, F.J. Jung,¹ L. Yang,¹ L. Haerter,² I. Inci,¹ D. Schneiter,¹ D. Lardinois,¹ M. Keel,² W. Weder,¹ S. Korom,¹ ¹Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland; ²Department of Trauma Surgery, University Hospital Zurich, Zurich, Switzerland

(350) Inhibition of Obliterative Airway Disease Development in Murine Tracheal Allografts by Matrix Metalloproteinase-9 Deficiency, F.G. Fernandez,¹ L.G. Campbell,¹ R.M. Senior,² S. Itoharu,³ E.P. Trulock,² G.A. Patterson,¹ T. Mohanakumar,¹ A. Jaramillo,¹ ¹Surgery, Washington University School of Medicine, St. Louis, MO; ²Medicine, Washington University School of Medicine, St. Louis, MO; ³Riken Brain Science Institute, Wako, Saitama, Japan

(351) Vascular Endothelial Growth Factor Gene Polymorphism Are Associated with Allograft Coronary Artery Disease after Clinical Heart Transplantation, S. Datta,¹ J. Fildes,¹ J. Thekkuden,¹ R. Sivaprakashan,¹ N. Yonan,¹ I.V. Hutchinson,² ¹Transplant Unit, Wythenshawe Hospital, Manchester, Lancashire, United Kingdom; ²Department of Immunology, University of Manchester, Manchester, Lancashire, United Kingdom

(352) Embryonic Stem Cell Transplantation Elicits a Primarily Th-1 Host T-Cell Response, T. Kofidis,¹ J.L. de Bruin,¹ M. Zwierchoniewska,¹ R.-J. Swijnenburg,¹ D.T. Cooke,¹ D.R. Lebl,¹ M. Tanaka,¹ E. Fedoseyeva,¹ R.C. Robbins,¹ ¹Cardiothoracic Surgery/Falk Research Center, Stanford University Medical School, Stanford, CA

(353) Myocardial Restoration with Embryonic Stem Cell Bioartificial Tissue Transplantation, T. Kofidis,¹ J.L. de Bruin,¹ G. Hoyt,¹ T. Yamane,² R.-J. Swijnenburg,¹ D.R. Lebl,¹ M. Tanaka,¹ I.L. Weissman,² R.C. Robbins,¹ ¹Cardiothoracic Surgery/Falk Research Center, Stanford University Medical School, Stanford, CA; ²Department of Immunology, Stanford University Medical School, Stanford, CA

(354) Overexpression of Human BCL-2 Attenuates Graft Coronary Artery Disease by Modulating Local Th1 Immune Response but Not Host Immune Response in Murine Cardiac Allografts, M. Tanaka,¹ R.D. Terry,¹ S. Nakae,² D.T. Cooke,¹ T. Kofidis,¹ R.C. Robbins,¹ ¹Department of Cardiothoracic Surgery; ²Department of Pathology, Stanford University, Stanford, CA

(355) Both after Heart and Bone Marrow Transplantation the Heart Harvest Bone Marrow Derived Cardiomyocytes, R.A. De Weger,¹ I. Verbrugge,¹ L.F. Verdonck,³ N. De Jonge,² M. Van Oosterhout,¹ D.F. Van Wichen,¹ Y. De Souza,⁴ F.G. Gmelig Meyling,⁴ ¹Pathology, UMC-U, Utrecht, Utrecht, Netherlands; ²Heart and Lung Institute, UMC-U, Utrecht, Utrecht, Netherlands; ³Hematology, UMC-U, Utrecht, Utrecht, Netherlands; ⁴Immunology, UMC-U, Utrecht, Utrecht, Netherlands

6:00 PM – 7:00 PM

Infectious Disease Council Meeting (Imperial)

Heart Failure and Transplant Medicine Scientific Council Meeting (Grand Ballroom B)

Pulmonary Transplantation Scientific Council Meeting (Plaza)

Cell Transplantation/Tissue Engineering Scientific Council Meeting (Union Square 21)

6:30 PM-MIDNIGHT

Poster Teardown (Franciscan/Yosemite)

4:30 PM-8:30 AM

Exhibit Hall Teardown (Grand Ballroom A)

7:00 PM-8:00 PM

BUS DEPARTURE TO EXPLORATORIUM

7:30 PM-10:00 PM

PRESIDENT'S GALA RECEPTION (Exploratorium Museum)

9:30 PM

BUS RETURN FROM EXPLORATORIUM

SATURDAY APRIL 24, 2004

7:00 AM-8:00 AM

MCSD Database Meeting (Imperial)

7:00 AM-8:00 AM

Morning Coffee (Yosemite)

7:00 AM-10:30 AM

Registration Desk Open (Yosemite)

7:00 AM– 4:30 PM

Exhibits Open (Yosemite)

7:00 AM-5:30 PM

Speaker Ready Room (Green Room)

7:55 AM-10:00 AM

PLENARY SESSION

(Grand Ballroom B)

Moderators: Mark L. Barr, MD and Stephan Schueler, MD

7:55 AM Welcome and Introductions

8:00 AM Caves Award Winner Presentation

8:15 AM Research Grant Awards Presentations

Featured Abstract

8:30 AM (356) Outcome of Listing for Cardiac Transplantation (Tx) for Failed Fontan: A Follow-Up Multi-Institutional Study, D. Bernstein,¹ D. Naftel,⁵ C. Chin,¹ L. Addonizio,² P. Gamberg,¹ D. Hsu,² E. Blume,³ C. Canter,⁶ R. Morrow,⁴ J. Kirklin,⁵ Pediatr Heart Tx Study Group,¹ Pediatrics, Stanford University, Stanford, CA; ²Pediatrics, Columbia University, New York, NY; ³Cardiology, Harvard University, Boston, MA; ⁴Pediatrics, University of Arkansas, Little Rock, AK; ⁵Cardiovascular Surgery, University of Alabama, Birmingham, AL; ⁶Pediatrics, Washington University, St. Louis, MO

8:45 AM Invited Lecture: Thoracic Transplantation for Congenital Heart Disease in Children and Adults, Tom Spray, MD, The Children's Hospital of Philadelphia, Philadelphia, PA

Featured Abstract

9:15 AM (357) The Presence of Non-HLA IgM Antibody Adversely Effects Graft Survival Following Both Heart and Lung Transplantation, R.E. Stanford,^{1,2} J.D. Smith,^{1,2} A.J. Danskin,² H. Newell,² N. Banner,³ M.L. Rose,¹ National Heart and Lung Institute, Imperial College, Harefield, United Kingdom; ²Tissue Typing Laboratory, Harefield and Royal Brompton NHS Trust, Harefield, United Kingdom; ³Department of Transplantation, Harefield and Royal Brompton NHS Trust, Harefield, United Kingdom

9:30 AM Invited Lecture: Implications of Circulating Antibodies After Thoracic Transplantation, Ronald H. Kerman, MD, University of Texas Medical School, Houston, Houston, TX

10:00 AM-10:30 AM

Coffee Break (Yosemite)

10:30 AM-NOON

CONCURRENT SESSION 22

Post Transplant Complications 2: Cardiac Vasculopathy

(Grand Ballroom B)

Moderators: Branislav Radovancevic, MD and Robert L. Scott, MD

10:30 AM (358) Common Chemokine Receptor Single Nucleotide Polymorphisms Are Associated with Transplant Vasculopathy in Heart Transplant Recipients, S.G. Miriuka,¹ D.H. Delgado,¹ B. Wong,² J. Wang,³ V. Rao,¹ D.E.C. Cole,² R.A. Hegele,³ H.J. Ross,¹ Division of Heart Transplant, Toronto General Hospital - UHN, Toronto, ON, Canada; ²Departments of Laboratory Medicine and Pathobiology, Medicine and Paediatrics (Genetics), University of Toronto, Toronto, ON, Canada; ³Blackburn Cardiovascular Genetics Laboratory, Robarts Research Institute, London, ON, Canada

10:45 AM (359) Late Survival after Heart Transplantation: Are We Getting Better at Long-Term Management?, R.J. Rodeheffer, J.K. Kirklin, R.N. Brown, L.W. Stevenson, C.W. Yancy,¹ D. Renlund, K.D. Aaronson, W.G. Dec, P. Henke, R.C. Bourge, Cardiac Transplant Research Database,¹ University of Alabama at Birmingham, Birmingham, AL

11:00 AM (360) Cardiac MR Identifies Transplantarteriopathy by a Reduced Endomyocardial

Perfusion, O.M. Muehling,¹ P. Panse,⁴ M. Jerosch-Herold,³ R.F. Wilson,² N. Wilke,⁴ L.W. Miller,²
¹Department of Medicine, University of Munich, Munich, Germany; ²Department of Medicine, University of Minnesota, Minneapolis, MN; ³Department of Radiology, University of Minnesota, Minneapolis, MN;
⁴Department of Radiology, University of Florida, Jacksonville, FL

11:15 AM (361) Impaired Coronary Flow Reserve by Contrast-Enhanced Transthoracic Echocardiography Predicts Cardiac Allograft Vasculopathy, F. Tona,¹ A.L.P. Caforio,¹ R. Montisci,¹ A. Gambino,² M. Bontorin,¹ M.G. Leone,¹ G. Feltrin,² C. Sarais,¹ R. Carta,¹ A. Portale,¹ G. De Simone,¹ D. Calzolari,¹ A. Angelini,³ G. Thiene,³ G. Gerosa,² S. Iliceto,¹ ¹Cardiology; ²Cardiovascular Surgery; ³Pathology, University of Padova, Padova, Italy

11:30 AM (362) Graft Vasculopathy: Comparison of Cyclosporine and Tacrolimus over 15+ Years, D.A. Baran,¹ S. Kaplan,² S. Lubitz,² I. Galin,² S. Alvi,¹ R. Correa,² M. Courtney,² M. Chan,² D. Spielvogel,² S.L. Lansman,² A.L. Gass,² ¹Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ; ²Cardiovascular Institute, Mt. Sinai Medical Center, New York, NY

11:45 AM (363) Cytomegalovirus Burden and Progressive Severity of Cardiac Allograft Vasculopathy, L. Potena,¹ C. Magelli,² W.F. Fearon,¹ A.C. Yeung,¹ F. Coccolo,² G. Magnani,² F. Grigioni,² P. Ortolani,² H.T. Luikart,¹ S.A. Hunt,¹ E.S. Mocarski,¹ J.P. Cooke,¹ D.B. Lewis,² A. Branzi,² H.A. Valantine,¹ ¹Department of Cardiovascular Medicine, Stanford University, Stanford, CA; ²Institute of Cardiology, University of Bologna, Bologna, BO, Italy

10:30 AM-NOON

CONCURRENT SESSION 23

Lung/Heart-Lung Transplantation 4: Mechanisms of Early Immune and Inflammatory Injury in Lung Transplantation

(Imperial)

Moderators: Annette Boehler, MD and Thomas K. Waddell, MD

10:30 AM (364) Upregulation of IL-17 in Acute Rejection after Lung Transplantation, L.J. Dupont,¹ B. Vanaudenaerde,¹ W. Wuyts,¹ D. Van Raemdonck,² G. Verleden,¹ ¹Department of Respiratory Medicine, Uz Kuleuven, Leuven, Belgium; ²Department of Thoracic Surgery, Uz Kuleuven, Leuven, Belgium

10:45 AM (365) Elevated IL-15 in Acute Lung Allograft Rejection, A.D. Yu,¹ B.S. Lu,¹ W.T. Vigneswaran,² E.R. Garrity,¹ S.M. Bhorade,¹ ¹Pulmonary and Critical Care Medicine, Loyola University Medical Center, Maywood, IL; ²Cardiovascular and Thoracic Surgery, Loyola University Medical Center, Maywood, IL

11:00 AM (366) Impact of Pre-Transplant T Cell Depletion Combined with Tacrolimus Monotherapy on the Immune Responses in Lung Transplant Recipients, A. Zeevi,¹ A.L. Girnita,¹ K.J. Spichty,¹ D. Zaldonis,² K. McDade,¹ A.T. Iacono,³ S.A. Yousem,¹ J. Britz,⁴ R. Kowalski,¹ J. Woodcock,⁴ C. Bentlejewski,¹ K.R. McCurry,² ¹Pathology, University of Pittsburgh, Pittsburgh, PA; ²Thoracic Surgery; ³Pneumology; ⁴Cylex, Baltimore, MD

11:15 AM (367) Exhaled Nitric Oxide (eNO) Correlates with IL-17 in Bronchoalveolar Lavage Fluid (BALF) during Acute Lung Rejection, B.M. Vanaudenaerde,¹ W.A. Wuyts,¹ L.J. Dupont,¹ D.E. Van Raemdonck,² G.M. Verleden,¹ ¹Lab of Pneumology, Lung Transplantation Unit, University Hospital Gasthuisberg, Leuven, Belgium; ²Department Thoracic Surg, Lung Transplantation Unit, University Hospital Gasthuisberg, Leuven, Belgium

11:30 AM (368) Pulmonary Capillaritis in Lung Transplant Recipients: Response to Therapy and Effect on Long-Term Allograft Function, T.L. Astor,¹ D. Weill,¹ M.R. Zamora,¹ ¹Division of Pulmonary and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO

11:45 AM (369) P-Glycoprotein and Outcome Following Lung Transplantation, J.E. Fildes,¹ J. Thekkudan,¹ R. Guntamadugu,¹ A. Owen,² D. Singh,³ N. Yonan,¹ C.T. Leonard,¹ ¹The Transplant Centre, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Wythenshawe, Manchester, United Kingdom; ²Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom; ³North West Lung Research Centre, South Manchester University Hospital Trust, Wythenshawe, Manchester, United Kingdom

10:30 AM-NOON

CONCURRENT SESSION 24

Pediatrics 2: Immunologic Monitoring and Management

(Plaza)

Moderators: Maryanne R. Chrisant, MD and Francesco Parisi, MD

10:30 AM (370) HLA Sensitization but Not Tolerance to Incompatible Donor ABO Antigens Follows Tissue Allograft Placement in Infant Norwood Patients, N.E. Lobach,¹ L. Hornberger,¹ J.F. Smallhorn,¹ A.I. Dipchand,¹ N. denHollander,² G. VanArsdell,¹ S.M. Pollock-BarZiv,¹ L.J. West,¹ ¹Paediatrics, Hospital for Sick Children, Toronto, ON, Canada; ²Regional Histocompatibility Lab, Toronto General Hospital, Toronto, ON, Canada

10:45 AM (371) Discovery and Validation of Molecular Pathways and Diagnostic Testing for Cardiac Rejection in Children: A Multi-Center Study, S. Webber,¹ D. Bernstein,² S. Mital,³ L. Addonizio,³ C. Bentlejewski,¹ A. Byno,¹ G. Boyle,¹ J. Phillips,⁴ J. Wohlgemuth,⁴ A. Zeevi,¹ ¹Pediatrics, Children's Hospital, Pittsburgh, PA; ²Pediatrics, Stanford University, Palo Alto, CA; ³Pediatrics, Columbia University, New York, NY; ⁴XDx, Inc., South San Francisco, CA

11:00 AM (372) Panel-Reactive Antibody Cross-Reactivity and Outcomes in the Pediatric Heart Transplant Study Group, W.T. Mahle,¹ D.C. Naftel,² P. Rusconi,³ R.E. Edens,⁴ R.E. Shaddy,⁵ Pediatric Heart Transplant Study Group, ¹Emory Univ; ²University of Alabama, Birmingham; ³University Miami; ⁴University Iowa; ⁵University Utah

11:15 AM (373) Sirolimus Immunosuppression in Paediatric Heart Transplant Patients: A Single Centre Experience, N.E. Lobach,¹ S.M. Pollock-BarZiv,¹ L.J. West,¹ A.I. Dipchand,¹ ¹Paediatrics, Hospital for Sick Children, Toronto, ON, Canada

11:30 AM (374) Value of Non Invasive Tissue Doppler Derived Tei-Index in Detection of Transplant Vasculopathy in Pediatric Heart Transplant Recipients, H. Abdul-Khalig,¹ M. Abdel-Rhahman,¹ S. Schubert,¹ H.B. Lehmkuhl,¹ E. Wellnhofer,¹ P. Ewert,¹ N. Hiemann,¹ B. Schmitt,¹ P.E. Lange,¹ R. Hetzer,¹ ¹Deutsches Herzzentrum Berlin, Berlin, Germany

11:45 AM (375) Prospective Follow-Up of Panel Reactive Antibodies in Children 5-Years Following Implantation of Cryopreserved Allografts, D.K. Hooper,¹ J.A. Hawkins,² T.C. Fuller,³ T. Profaizer,³ R.E. Shaddy,¹ ¹Pediatrics, University of Utah, Salt Lake City, UT; ²Surgery, University of Utah, Salt Lake City, UT; ³Pathology, University of Utah, Salt Lake City, UT

NOON-2:00 PM

ISHLT Board of Directors Meeting (Executive Boardman)

12:15 PM-1:45 PM

LUNCHEON SYMPOSIUM

Cytomegalovirus in Heart and Lung Transplantation: Issues and Challenges

(Grand Ballroom B)

Supported by an educational grant from Roche

Moderators: Martin Zamora, MD, and Jim J. Egan, MD

12:15 PM Chairmans' Introduction, Martin Zamora, MD, University of Colorado, Denver, CO and Jim J. Egan, MD, Mater Misericordiae Hospital, Dublin, Ireland

12:20 PM Overview of Risks Associated with CMV Infection in Thoracic Transplantation, Raymond R. Razonable, MD, Mayo Clinic and Foundation Rochester, MN

12:45 PM Prevention and Treatment Challenges for CMV in Thoracic Transplantation, Martin Zamora, MD, University of Colorado, Denver, CO

1:10 PM Can the Impact of CMV on Endothelial Function be Prevented in Heart Transplantation?, Karl Lemstrom, MD, PhD, Helsinki University, Helsinki Finland

1:35 PM Questions and Answer Session

2:00 PM-3:30 PM

CONCURRENT SESSION 25

Clinical Heart Transplantation 3: Risk Factors and Outcomes

(Grand Ballroom B)

Moderators: Manfred Hummel, MD and Donna M. Mancini, MD

2:00 PM (376) Late Outcomes after Heart Transplantation in Adults with Congenital Heart Disease: A Multi-Institutional Analysis, B.S. Clemson, J.K. Kirklin, C.E. Canter, D.C. Naftel, J.B. Young, J.A. Hill, R.J. Rodeheffer, B. Radovancevic, S. Faulkner, The Cardiac Transplant Research Database, ¹University of Alabama at Birmingham, Birmingham, AL

2:15 PM (377) Ten Year Follow-Up of the Functional and Morphological Adaptation of Undersized Donor Hearts Following Cardiac Transplantation, P.J. Mather, ¹S. Furukawa, ²V. Jeevanandam, ³¹Internal Medicine, Division of Cardiology, Temple University School of Medicine, Philadelphia, PA; ²Cardiothoracic Surgery, Temple University School of Medicine, Philadelphia, PA; ³Cardiothoracic Surgery, University of Chicago, Chicago, IL

2:30 PM (378) Outcomes of Cardiac Transplantation with Donors 50 Years of Age and Greater, S.R. Meyer, ¹M.J. Bentley, ¹J.C. Mullen, ¹D.L. Modry, ¹A. Koshal, ¹I.M. Rebeyka, ¹D.B. Ross, ¹S. Wang, ¹Surgery, Division of Cardiac Surgery, University of Alberta, Edmonton, AB, Canada

2:45 PM (379) Impact of Recipient Race, Gender, and Pregnancy Status on Mortality Following Heart Transplantation, R.S.D. Higgins, ¹L.B. Edwards, ²R.A. Perez-Tamayo, ¹S.H. Dunlap, ¹A.L. Heroux, ¹E.B. Savage, ¹Cardiovascular-Thoracic Surgery, Rush University Medical Center, Chicago, IL; ²United Network for Organ Sharing, Richmond, VA

3:00 PM (380) Independent Predictors of Develop of Renal Dysfunction after Heart Transplantation in Patients with Previously Normal Renal Function, I.P. Garrido, ¹M.G. Crespo-Leiro, ¹M.J. Paniagua, ¹J. Muniz, ²A. Castro-Beiras, ¹Heart Trasplantation Unit, Hospital Juan Canalejo, A Coruna, A Coruna, Spain; ²Instituto de Ciencias de la Salud, Universidad de A Coruna, A Coruna, A Coruna, Spain

3:15 PM (381) Decreased Survival in Heart Transplant Patients Requiring Chronic Dialysis: A Canadian Experience, M. Cantarovich, ¹F. Ivis, ²K. Badovinac, ²¹Medicine, Transplant Program, McGill University Health Center, Montreal, QC, Canada; ²Canadian Organ Replacement Register, Canadian Institute for Health Information, Toronto, ON, Canada

2:00 PM-3:30 PM

CONCURRENT SESSION 26

Donor Management, Preservation, and Organ Distribution 2: Donor Organ Reanimation: The Future of Organ Preservation

(Imperial)

Moderators: Valluvan Jeevanandam, MD and Martin Struber, MD

2:00 PM (382) Hemorrhagic Shock and Resuscitation in Organ Donors: L-Arginine Improves Impaired Lung Transplant Function, G. Preissler, ¹H.U. Ebersberger, ¹I.V. Huff, ¹M.E. Eichhorn, ¹K. Messmer, ²K.W. Jauch, ¹F. Loehe, ¹¹Department of Surgery, University Hospital Grosshadern, Munich, Germany; ²Institute for Surgical Research, University Hospital Grosshadern, Munich, Germany

2:15 PM (383) Nebulized N-Acetyl Cysteine Protects the Pulmonary Graft from the Non-Heart-Beating Donor inside the Cadaver, F. Rega, ¹W. Wuylts, ²B. Vanaudenaerde, ²N. Jannis, ¹A. Neyrinck, ¹T. Lerut, ³G. Verleden, ²D. Van Raemdonck, ^{1,3,1}¹Center for Experimental Surgery and Anaesthesiology, KU Leuven, Leuven, Belgium; ²Laboratory of Pneumology, KU Leuven, Leuven, Belgium; ³Department of Thoracic Surgery, University Hospital Gasthuisberg, Leuven, Belgium

2:30 PM (384) Improved Viability and Reduced Apoptosis in Subzero 21 Hours Preservation of Transplanted Rat Hearts Using Antifreeze Proteins, G. Amir, ¹B. Rubinsky, ²L. Horovitz, ³B.S. Yousif, ¹J. Leor, ³A.K. Smolinsky, ¹J. Lavee, ¹¹Heart Transplantation Unit, Department of Cardiac Surgery, Sheba Medical Center, Tel Hashomer, Israel; ²Department of Bioengineering and Department of Mechanical Engineering, University of California, Berkeley, CA; ³The Neufeld Cardiac Research Institute, Tel Aviv University, Tel Aviv, Israel

2:45 PM (385) S-Nitroso-Human Serum Albumin Improves Organ Preservation in Orthotopic Heart Transplantation in the Pig, R. Gottardi, ¹T. Szerafin, ¹S. Semsroth, ¹S. Hallstroem, ¹H. Gasser, ¹R. Seitelberger, ²E. Wolner, ²B.K. Podesser, ^{1,1}¹Ludwig Boltzmann Institute for Cardiosurgical Research, University Vienna, Austria; ²Department for Cardiothoracic Surgery, University Vienna, Austria

3:00 PM (386) Impact of 24 Hour Continuous Hypothermic Perfusion on Heart Preservation by Assessment of DNA Damage and Repair, T.P. Fitton,¹ C.J. Barreiro,¹ B.T. Bethea,¹ C. Wei,¹ R. Lin,¹ L. Amado,¹ F. Gage,¹ J. Hare,¹ W.A. Baumgartner,¹ J.V. Conte,¹ Cardiac Surgery, Johns Hopkins Hospital, Baltimore, MD

3:15 PM (387) Ex Vivo Reperfusion of Human Lungs Declined for Transplantation; A Novel Approach To Alleviate Donor Organ Shortage?, A. Neyrinck,¹ F. Rega,¹ N. Jannis,¹ F. Van Gelder,² E. Vandezande,² G.M. Verleden,² W. Coosemans,² P. De Leyn,² Ph. Nafteux,² T. Lerut,² D. Van Raemdonck,^{1,2} Center for Experimental Surgery and Anaesthesiology, K.U.Leuven, Belgium; ²University Hospitals Leuven, Belgium

2:00 PM-3:30 PM

CONCURRENT SESSION 27

Basic Science and Immunobiology 3: Pathobiology of Heart Failure

(Plaza)

Moderators: Robert C. Robbins, MD and David S. Feldman, MD

2:00 PM (388) Antagonists of Stretch-Activated Ion Channels Restore Contractile Function in Hamster Dilated Cardiomyopathy, A.C. Nicolosi,¹ C.S. Kwok,² Z.J. Bosnjak,² Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, WI; ²Anesthesiology, Medical College of Wisconsin, Milwaukee, WI

2:15 PM (389) The Role of Nitric Oxide in Cardiomyogenesis Using Embryonic Stem Cells, L.L. Shears,¹ S. Kanno,¹ R.L. Kormos,¹ K.R. McCurry,¹ T.R. Billiar,¹ Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA

2:30 PM (390) Increased Gene Expression of Inflammatory Cytokines and Endotoxin Receptors in Peripheral Blood Mononuclear Cells of Patients with Chronic Heart Failure, T.J. Dengler,¹ M. Schoels,² R. Klingenberg,¹ C.A. Gleissner,¹ T. Giese,² Cardiology, University of Heidelberg, Heidelberg, Germany; ²Immunology, University of Heidelberg, Heidelberg, Germany

2:45 PM (391) TNF Inhibition at the Time of Myocardial Infarction Attenuates the Subsequent Development of Heart Failure, M.F. Berry,¹ T.J. Pirolli,² L.T. Bish,² M.A. Moise,¹ J.W. Burdick,¹ K.J. Morine,² V. Jayasankar,¹ T.J. Gardner,¹ H.L. Sweeney,² Y.J. Woo,¹ Department of Surgery, Division of Cardiothoracic Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA; ²Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, PA

3:00 PM (392) Bcl-xL Gene Transfer Reduced Apoptosis and Preserved Cardiac Function after Rat Ischemia/Reperfusion Injury, M. Morikawa,¹ Y. Ito,² J. Huang,² K. Takahashi,¹ T. Uzuka,¹ K. Ikeda,¹ Y. Honma,¹ H. Hamada,² T. Abe,¹ Thoracic & Cardiovascular Surgery, Sapporo Medical University, Sapporo, Hokkaido, Japan; ²Molecular Medicine, Sapporo Medical University, Sapporo, Hokkaido, Japan

3:15 PM (393) Peripheral Blood Dendritic Cell Phenotype Indicates Immune Predisposition towards Th-1 Responses in Human End-Stage Heart Failure, P. Athanassopoulos,¹ L.M.B. Vaessen,² A.H.M.M. Balk,³ A.P.W.M. Maat,¹ A.J.J.C. Bogers,¹ W. Weimar,² Cardiothoracic Surgery; ²Internal Medicine; ³Cardiology, Erasmus MC, Rotterdam, Netherlands

3:30 PM-4:00 PM

Coffee Break (Yosemite)

4:30 PM – 8:30 PM

Exhibit Hall Tear down (Yosemite)

4:00 PM-5:45 PM

CLOSING PLENARY SESSION

(Grand Ballroom B)

Moderators: Alec Patterson, MD and Shaf Keshavjee, MD

Late Breaking Clinical Trials in Lung Transplantation

4:00 PM (394) A Randomized Trial of Early Administration of Inhaled Cyclosporine in Lung

Transplant Recipients, A.T. Iacono,¹ B.A. Johnson,¹ T.E. Corcoran,¹ D.A. Smith,¹ W.F. Grgurich,¹ J.H. Dauber,¹ K.R. McCurry,² A. Zeevi,³ G.J. Burckart,⁴ J.G. Youssef,¹ J.L. Vensak,¹ G.C. Smaldone,⁵ J.J. Fung,⁶ B.P. Griffith,⁷ ¹Pulmonary, Allergy, Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA; ²Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA; ³Transplant Pathology, University of Pittsburgh, Pittsburgh, PA; ⁴Department of Pharmacy, University of Southern California, Los Angeles, CA; ⁵Pulmonary/Critical Care Medicine, SUNY Stony Brook, Stony Brook, NY; ⁶Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA; ⁷Cardiac Surgery, University of Maryland, Baltimore, MD

4:15 PM (395) New Treatments for Pulmonary Fibrosis: Is RAD an Answer?, M.A. Malouf,¹ P. Hopkins,¹ G. Snell,¹ A.M. Southcott,¹ L. Singleton,¹ A.R. Glanville,¹ ¹Australian National RAD Trial, St. Vincent's Hospital, Sydney, NSW, Australia

Controversy in Lung Transplantation: Altering the Lung Transplant Allocation System: The Proposed UNOS Change

4:30 PM Advantages of the Proposed System, Thomas M. Egan, MD, University of North Carolina, Chapel Hill, NC

4:45 PM Does the Proposed Change Disadvantage Certain Patient Diagnostic Sub-Groups?, Robert P. Frantz, MD, Mayo Clinic, Rochester, MN

5:00 PM The Eurotransplant Solution to Address High Urgency Patients, Walter Klepetko, MD, University of Vienna, Vienna, Austria

5:15 PM Panel Discussion

5:30 PM ADJOURN

EXHIBIT HOURS

Grand Ballroom A

Thursday	April 22, 2004	7:00am – 4:30pm
Friday	April 23, 2004	7:00am – 4:30pm

Yosemite

Wednesday	April 21, 2004	10:00am – 6:30pm
Thursday	April 22, 2004	7:00am – 6:30pm
Friday	April 23, 2004	7:00am – 6:30pm
Saturday	April 24, 2004	7:00am – 4:30pm

EXHIBIT FLOOR PLANS

EXHIBITING COMPANIES	Booth #
Abiomed, Inc.	217
Actelion Pharmaceuticals US, Inc.	213
Argon Medical Devices, Inc.	315
Arrow International	408
ATC Technologies, Inc.	311
CardioDynamics	419
Caremark Inc.	415
Chase Medical	412
CHF Solutions, Inc.	312
CTI Clinical Trial & Consulting Services	102
Elsevier	603
Fujisawa Healthcare, Inc.	201
Genzyme Transplant	310
ISHLT Registry	601
Medical Insight Research	316
MedImmune, Inc.	314
MicroMed Technology, Inc.	114
Novartis Pharmaceuticals Corporation	701
PharmaCare (formerly CVS ProCare Pharmacy)	417
Roche Pharmaceuticals	301
Saunders/Mosby Medical Books	313
Scanlan International, Inc.	309
Therakos, a Johnson & Johnson Company	308
Thoratec Corporation	209
United Network for Organ Sharing (UNOS)	604
Ventracor Limited	413
ViraCor Laboratories	416
Vitrolife	409
World Heart Corporation	108
XDx	501

EXHIBITORS

ABIOMED, Inc. Booth # 217

Brad Goskowicz
22 Cherry Hill Drive
Danvers, MA 01923
Phone: 978-777-5410
Fax: 978-777-1561
Email: marketing@abiomed.com

ABIOMED is a leading developer, manufacturer and marketer of devices designed to assist or replace the pumping function of the failing heart. Products include the BVS[®] 5000 Bi-ventricular Support System; the most widely used advanced cardiac assist system, and the *new* AB5000[™] Circulatory Support System offering the latest cost-effective solution for cardiac assist. The AB5000 system offers uni-ventricular or bi-ventricular support, patient ambulation and transport, all in the most flexible, simple and effective technology available today. The Company's first generation AbioCor[®] Implantable Replacement Heart is the subject of an initial clinical trial being conducted under an Investigational Device Exemption from the United States Food and Drug Administration.

ACTELION PHARMACEUTICALS Booth # 213

601 Gateway Blvd, Suite 100
South San Francisco, CA 94080
Phone: 650-624-6900
Fax: 650-952-0991
Web site: www.actelion.com

Actelion Pharmaceuticals US, Inc. (located in South San Francisco, CA) is the U.S. affiliate of Actelion Ltd., a bio-pharmaceutical company headquartered in Switzerland. Actelion is the global leader in creative science related to the endothelium-the single layer of cells lining every blood vessel. Actelion's clinical research and drug discovery focuses on : cardiology, pulmonology, rheumatology, oncology, malaria, and Alzheimer's disease. Its flagship drug, Tracleer[®] (bosentan) tablets, is approved for pulmonary arterial hypertension and is the first in a new class of drugs known as endothelin receptor antagonists (ERA). Actelion is also currently developing Veletri[®] (tezosentan), an intravenous ERA. Actelion is quoted on the Swiss Stock Exchange (SWX Main Market: ATLN).

ARGON MEDICAL DEVICES, INC. Booth #315

1445 Flat Creek Road
Athens, TX 75751
Phone: 800-927-4669
Fax: 903-677-9369
Web site: www.argonmedical.com

Argon Medical Devices, Inc. manufactures disposable Vascular Access devices for Cardiology, Radiology and Critical Care markets. Founded in 1972, Argon has focused on designing and delivering quality vascular devices to customers with exceptional service.

In 1991 Argon introduced the Jawz tm Endomyocardial Biopsy Forcep. The Jawz tm Forcep has earned the respect of the transplant community as the premier Heart biopsy device.

Argon also supplies Hydrophilic and Stainless Steel Guide Wires, Standard and Specialty Introducers as well as a myriad of accessories for Vascular Access. Argon Services the market with dedicated domestic sales professionals and several International distributor partnerships.

ARROW INTERNATIONAL Booth # 408

Hill & George Aves
Reading, PA, 19610

Contact: Sue Prutzman
Phone: 1-800-233-3187
Fax: 610-478-3184
Web site: www.intl.com

The world wide technology leader in Cardiac Assist has new technology for Intra-Aortic Balloon pumps and catheters, destination therapy LVAD's, and centrifugal LVAD pumps. Come see our new fiber-optic WAVE™ catheter. The LionHeart™ LVAD, in the clinical trials, is designed for destination therapy of heart failure patients. Learn more about our results with four patients currently living over two years with the Arrow LionHeart™. Our new Arrow CorAide™ centrifugal LVAD has begun clinical trials. The Arrow CorAide™ development, in partnership with the Cleveland Clinic, features only one moving part in a magnetically suspended centrifugal pump design.

ATC TECHNOLOGIES, INC. Booth # 311

80 Cummings Park
Woburn, MA 01801
Company contact: Paul Kierce
Phone:1-781-939-0725
Fax: 1-781-939-0726
Email ATCTEK@aol.com

Sparrowhawk disposable endomyocardial biopsy forceps are designed and manufactured to provide the precision "cutting action" that is expected and required during the biopsy procedure. The Sparrowhawk biopsy forceps are available in a variety of sizes and lengths, and incorporate formable shafts to meet the specific needs of physicians.

CAREMARK INC. Booth # 415

2211 Sanders Road
Northbrook, IL 60062
Phone: 800-237-2767
Fax: 800-323-2445
Web site: www.carmark.com

Caremark has been a national leader in specialty pharmacy for over 25 years. We provide biotech medications and services to participants with chronic or genetic conditions. With Caremark Specialty Pharmacy Services, every individual is assigned a pharmacist-led CareTeam, which reviews dosing and medication schedules, troubleshoots injection-related issues, discusses side effect management, and reinforces physician instructions to ensure that the individual's prescribed medication is administered appropriately. Caremark also handles all insurance benefits investigations. To learn more about how Caremark Specialty Pharmacy Services can help you and your patients, please call 1-800-237-2767, fax 1-800-323-2445, or visit our Web site at www.carmark.com

CARDIODYNAMICS Booth #419

6175 Nancy Ridge Drive
San Diego, CA 92121
Phone:1-800-778-4825
Fax:1-858-535-9622
Web Site: www.cdic.com

BioZ ICG (Impedance Cardiography) provides noninvasive hemodynamic parameters, including cardiac output, systemic vascular resistance, and fluid status, through four dual sensors on the patient's neck and chest. BioZ ICG has been used in over 2.5 million patient applications in a variety of clinical settings because it aids clinicians in the assessment, diagnosis, and treatment of patients including perioperative, critical care, sub-acute, and emergency. Products include the stand-alone BioZ ICG Monitor, BioZ ICG Module for GE Patient Monitors.

CHASE MEDICAL Booth #412

1876 Firman Drive
Richardson, TX 75081
Contact: Cynthia Bock
Tel: 972-783-0644
Fax: 972-235-3446
Email: cbock@chasemedical.com

Chase Medical provides innovative products and programs for the treatment of CHF. Products include TR³ISVR Surgical Ventricular Restoration System featuring the Mannequin Endoventricular Shaper and SIMON 3D Cardiac Analysis System. TR³ISVR enables the surgeon to efficiently and reproducibly restore dilated ventricles to a more normal size, shape and orientation resulting in significantly improved EF, and less risk of post-operative MR. SIMON provides a comprehensive analysis of LV function with more than 50 parameters presented in tabular and 3D format. SIMON provides tools to assess tissue viability and structure of the ventricle, monitor disease state, and help in surgical planning.

CHF SOLUTIONS, INC. Booth #312

7601 Northland Dr.
Suite 170
Brooklyn Park, MN 55428
Phone: 866-709-4030
Fax: 763-463-4663
Web site: www.chfsolutions.com

The System 100 uses a technique called "Ultrafiltration" to simply, safely and precisely remove excess fluid from fluid-overloaded patients. Up to four liters of excess fluid can be removed in up to an eight hour period using the System 100.

CTI CLINICAL TRIAL AND CONSULTING SERVICES Booth # 102

6460 Harrison Avenue
Cincinnati, OH 45247
Contact: Genie Dubuk
Phone: 513-598-9290
Fax: 513-598-3426
Email: info@ctifacts.com
Website: www.CTIFacts.com

CTI Clinical Trial and Consulting Services provides innovative clinical trial services and consulting solutions for the pharmaceutical industry in the specific areas of transplantation, infectious disease and end stage organ disease, including dialysis and liver function.

ELSEVIER Booth #603

Health Sciences Division
170 S. Independence Mall West
Suite 300E
Philadelphia, PA 19106
Phone: 215-238-7800
Fax: 215-238-6462
www.elsevierhealth.com

ELSEVIER, a premier worldwide health science publishing company featuring the SAUNDERS, MOSBY, CHURCHILL LIVINGSTONE, BUTTERWORTH HEINEMANN, and HANLEY-BELFUS imprints, is proud to publish THE JOURNAL OF HEART AND LUNG TRANSPLANTATION, the Official Publication of the International Society for Heart and Lung Transplantation. Visit us at booth # 603 and browse through our complete selection of publications in TRANSPLANTATION, SURGERY, AND CARDIOVASCULAR

MEDICINE including books, periodicals and software

FUJISAWA HEALTHCARE, INC. Booth #201

3 Parkway North
Deerfield, IL 60015
Phone: 847-317-8800
Fax: 847-317-5953
Web site: www.fujisawaHealthcare.com

Fujisawa Healthcare, Inc. manufactures and markets proprietary pharmaceutical products in specialty therapeutic areas where there is an unmet medical need. Fujisawa's global mission to explore the frontiers of human health underscores the company's commitment to the field of immunology, where aggressive research and development initiatives have helped to put Fujisawa at the forefront of transplantation.

Genzyme Transplant Booth #310

500 Kendall Street
Contact: Kevin Campbell
Cambridge, MA 02142
Phone: 617.768.6298
Fax: 617.768.6419

Genzyme is proud to announce that SangStat is now a wholly owned subsidiary, to be recognized in the future as Genzyme Transplant. The Genzyme Transplant group will continue building on its foundation in transplantation to discover, develop and market high value therapeutic products in the transplantation, immunology and hematology/oncology areas. The flagship product of Genzyme Transplant is Thymoglobulin® (Anti-thymocyte [Rabbit]). Thymoglobulin is a polyclonal antibody directed against several epitopes on T-cells, B-cells as well as adhesion molecules on monocytes and macrophages. Additional products marketed by Genzyme Transplant include Gengraf® (Co-Promotion with Abbott)

ISHLT/REGISTRY Booth # 601

1100 Boulders Pkwy, Suite 500
Richmond, VA 23225
Contact: Burkely Keck
Phone: 804-330-8500
Fax: 804-327-1449

The ISHLT Transplant/Mechanical Circulatory Assist Device Database collects worldwide transplant and assist device data. Data are utilized for scientific study to increase the body of knowledge regarding thoracic transplantation and cardiac device management. This year's exhibit will feature online availability of center-specific analysis for review by ISHLT members who represent the center submitting the data. In addition, ISHLT members can view preliminary screens for the device database and receive information on how to provide data to the transplant and device database.

MEDICAL INSIGHT RESEARCH Booth #316

Remco op den Kelder
25 Burlington Mall Road, 6th Floor
Burlington, MA 07803
Phone: 781-273-5480
Fax: 781-273-5484

Medical Insight Research is an economic research and strategy consulting firm specializing in the health care, pharmaceutical, and biotechnology industry.

MEDIMMUNE, INC. Booth # 314

35 W. Watkins Mill Road

Gaithersburgh, MD 20878
Phone: 301-417-0770
Fax: 301-527-4203
Web site: www.medimmune.com

MedImmune, Inc. is a biotechnology company focused on developing and marketing products that address medical needs in areas such as infectious disease, transplantation medicine, autoimmune disorders and cancer. CytoGam® (cytomegalovirus immune globulin intravenous (Human) (CMV-IVIG) is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung liver, pancreas and heart. In transplants of these organs other than kidney from CMV seropositive donors into seronegative recipients, prophylactic CMV-IGIV should be considered in combination with ganciclovir.

MICROMED TECHNOLOGY, INC. Booth # 114

8965 Interchange Dr.
Houston, TX 77054
Contact: Betty S. Russell, Ex. Vice President
Phone: 713-838-9210
Fax: 713-838-9214
Email: brussell@michromedtech.com
Web site: www.micromedtech.com

MicroMed will present the DeBakey VAD®, the most widely used implantable axial-flow VAD. Developed in collaboration with NASA, Drs. Michael DeBakey and George Noon, the C-cell battery size pump is highly durable and designed to provide full left ventricular support. This miniaturized pump is lightweight, is virtually silent and provides flows in excess of 10L/M for use in broad BSA ranges. The system is in multi-center clinical trials in the US for use as both bridge to transplantation and for destination therapy. The DeBakey VAD Child, the first implantable VAD for pediatric use, will also be displayed. The DeBakey VAD is CE approved.

NOVARTIS PHARMACEUTICALS CORPORATION Booth # 701

One Health Plaza
East Hanover, NJ 07936
Phone: 888-NOW-NOVA
Web site: www.Novartis-Transplantation

This year, Novartis, the makers of Neoral® (cyclosporine, USP [Modified]), Sandimmune® (cyclosporine, USP), and Simulect® (basiliximab), marks its 20th year as the leading contributor to the advancement of transplantation. Our focus is to develop meaningful therapeutic advances that improve the quality of life of transplant recipients and enhance the long-term success of transplantation. In partnership with the transplant community, 30 leading research institutions, and with over 300 scientists and clinicians dedicated to transplant research, we maintain the broadest pipeline in the field with three compounds in clinical trials, and more than a dozen projects in preclinical development.

PharmaCare (formerly CVS ProCare Pharmacy) Booth # 417

600 Penn Center Boulevard
Pittsburgh, PA 15235
Contact: Jennifer Maxwell
Phone: 1-800-238-7828
Web: www.cvsprocare.com

PharmaCare (formerly CVS ProCare Pharmacy) is designed to meet the specialized needs of individuals living with organ transplants and other challenging health conditions. PharmaCare provides a full range of quality pharmaceutical care, from dispensing the latest FDA-approved medications, to over-the-counter medications. When you choose PharmaCare as your pharmacy, you can be confident in knowing that your patient's pharmacy care is in the hands of the most advanced pharmacy experts in the country. To learn more about the many specialized services provided by PharmaCare or to enroll your patients,

please call us today toll free at 1-800-238-7828. www.cvsprocare.com

ROCHE Booth # 301

PBC Congresses
Bldg 74/40.409
4070 Basel, Switzerland
Contact: Nils Meyer, International Congress Manager
Phone: 41-61-688-71-26
Fax: 41-61-688-14-09
Email: nils.meyer@Roche.com
Web Site: www.roche.com

Roche is proud to be a sponsor of the 24th Annual Meeting of the International Society for Heart & Lung Transplantation in San Francisco. We invite you to visit our exhibit where our specialists will discuss any questions you may have related to our pharmaceutical products and services. We are also interested in hearing about any issues of interest to you related to the health care industry in general. We look forward to meeting you on the exhibit floor.

SAUNDERS/MOSBY MEDICAL BOOKS

Booth # 313
284 Shearwater
Foster City, CA 94404
Contact: Taum Dell'Armo
Phone: 800-955-0345

Medical Books offered at publisher's discount prices.

SCANLAN INTERNATIONAL, INC. Booth #309

One Scanlan Plaza
St. Paul, MN 55107
Phone: 651-298-0997
Fax: 651-298-0018
Email: info@scanlangroup.com
Web site: www.scanlangroup.com

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Offering a wide array of Titanium Needle Holders, forceps and clamps and stainless steel instrumentation, including Micro surgical instrumentation, Scanlan SUPER CUT™ and ULTRA SHARP® scissor collection, Scanlan DIAMOND DUST™ instrumentation, Heifetz™ temporary occlusion clips. Scanlan offers a wide variety of custom modifications to accommodate surgeons' specific needs. Single-use products include SCANLAN® Surg-I-Loop® PLUS, single use aorta/vein punch, A/C LOCATOR® and RADIOMARK® graft markers, Vascu-Stat® single-use bulldog clamps, as well as SURG-I-PAW® jaw covers and SOFT-GRIP™ fabric clamp covers.

THERAKOS, A JOHNSON & JOHNSON COMPANY Booth # 308

437 Creamery Way
Exton, PA 19341
Phone: 610-280-1014
Fax: 610-280-1087
Web site: www.therakos.com

THERAKOS, a Johnson & Johnson Company, is a worldwide leader in extracorporeal disease management through the establishment of extracorporeal photoimmune therapy as a standard medical practice. Our UVAR® XTS™ System and UVADEX® Methoxsalen Sterile Solution are approved for the palliative treatment of skin manifestations in Cutaneous T-Cell Lymphoma.

THORATEC CORPORATION Booth # 209

6035 Stoneridge Drive
Pleasanton, CA 94588
Phone 925-847-8600
Fax 925-847-8574

Thoratec® Corporation, a world leader in circulatory support, provides a broad range of complementary cardiac assist product offerings for the treatment of congestive heart failure. As a single, trusted source, only Thoratec offers both implantable and paracorporeal ventricular assist devices. Our HeartMate® LVAS and Thoratec VAD Systems are ideally suited for short to long term, left, right or biventricular support in patients of almost any size.

UNITED NETWORK FOR ORGAN SHARING (UNOS) Booth #604

700 N. 4th Street
Richmond, VA 23219
Phone: 804-782-4890
Web site: www.unos.org

UNOS is a 501 (c) 3 non-profit, scientific, educational and charitable organization that oversees the national Organ Procurement and Transplantation Network. Responsibilities include: facilitating organ donation through research, education and advocacy; managing the U.S. transplant waiting list matching donors to recipients; and maintaining a database that monitors U.S. transplant recipients. Through private, charitable funding, UNOS also works to increase organ availability and continuously improve the outcomes and quality of life of transplant candidates and recipients.

VENTRACOR LIMITED Booth # 413

126 Greville Street,
Chatswood, NSW 2067 AUSTRALIA
Contact: Dr John Woodard
Phone: 61 2 9406 3100
Fax: 61 2 9406 3101
Email: john.woodard@ventracor.com

Ventricor Limited's VentrAssist™ left ventricular assist system (LVAS)
The VentrAssist™ is a third generation LVAS with a unique design which features only one moving part, a hydrodynamically suspended impeller.
The VentrAssist™ LVAS provides left heart support and is designed as a permanent alternative to a heart transplant. The titanium alloy pump is implanted below the diaphragm and is connected to the circulatory system using standard fabric tubes known as vascular grafts. The device itself measures 2.5 inches (60 mm) in diameter and weighs just 10oz (298 grams). This allows it to be used in both children and adults.

VIRACOR LABORATORIES Booth # 416

1210 NE Windsor Dr.
Lee's Summit, MO 64086
Phone: 800-305-5198
Fax: 816-347-0143
Website: www.viracor.com

A diagnostic and research laboratory supporting the transplant community. Providing rapid turn-around, quantitative real-time PCR assays for the detection of Adenovirus, BK Virus, EBV, CMV, HHV-6, HHV-7, HHV-8, HSV1 & HSV2, ImmuKnow™, JCV, SV-40, VZV, Parvo B19 and other pathogens.

VITROLIFE Booth # 409

3601 South Inca Street,
Englewood, 80110, CO, USA
Contact: P.J. Stewart

Phone: 1-866-848-7354
Fax: 1-866-848-7632
E-mail: transplantation.us@vitrolife.com

Product Description: Vitrolife develops specialized media and devices for preparation and cultivation of cells, tissues and organs. The products of Vitrolife Transplantation Systems are clinically proven solutions supporting thoracic and cardio-vascular surgery. Vitrolife's Perfadex(R) is optimized for preservation of lungs for transplantation.

WORLDHEART CORPORATION Booth #108

1 Laser Street
Ottawa, Ontario K2E 7V1 Canada
Contact: Jennifer Poulsen
Phone: 613-226-4278
Fax: 613-723-8522
Web site: www.worldheart.com

WorldHeart Corporation, a global medical device company based in Ottawa, Ontario and Oakland, California, is currently focused on the development and commercialization of pulsatile ventricular assist devices. Its Novacor LVAS (left ventricular assist system) is well established in the marketplace and its next-generation technology, HeartSaverVAD™, is a fully implantable assist device intended for long-term support of patients with heart failure.

XDx Booth # 501

750 Gateway Blvd., Suite H
South San Francisco, CA 94080
Gavin Williams
Phone: 650-624-0120
Fax: 650-624-0125
Email: gwilliams@xdxinc.com

XDx is a molecular diagnostics company located in South San Francisco, CA. XDx is finalizing development of AlloMap molecular expression testing, a multi-gene expression test for monitoring acute rejection and immune status in cardiac transplant patients. Using a simple blood sample, AlloMap molecular expression testing aims to translate an individual's immune response into clinically actionable information and improve cardiac transplantation patient management. AlloMap molecular expression testing will be offered by the XDx Reference Laboratory, scheduled to open in late 2004. Multi-center clinical validation studies are currently ongoing.

LINED NOTE PAGES

FUTURE ISHLT MEETINGS

APRIL 6 - 9, 2005
ISHLT 25TH ANNUAL MEETING AND SCIENTIFIC SESSIONS
Philadelphia, PA

December 8-11, 2004
3RD INTERNATIONAL CONGRESS ON IMMUNOSUPPRESSION/ISHLT 6TH FALL EDUCATION MEETING
San Diego, California, USA

APRIL 5 – 8, 2006
ISHLT 26TH ANNUAL MEETING AND SCIENTIFIC SESSIONS
Madrid, Spain